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Callipyge sheep is an excellent model to study genes regulation in muscle growth 
since the up­regulation of DLK1 and/or RTL1 results in extreme postnatal muscle 
hypertrophy in loin and hindquarters. DLK1 and/or RTL1 are the primary inducers of 
muscle hypertrophy due to the inheritance model for the callipyge phenotype. The overall 
aim of this dissertation is to study the physiological pathways responding to the up­
regulation of DLK1 and / or RTL1 in the hypertrophied muscles. Microarray analysis of 
gene expression identified 375 genes that were differentially expressed in callipyge 
semimembranosus. Twenty­five transcripts were further verified by quantitative PCR in 
two hypertrophied muscles (semimembranosus and longissimus dorsi) and one non­
hypertrophied muscle (supraspinatus). In order to identify the genes that are consistently 
co­expressed with DLK1/RTL1, the current study extends the gene expression analysis on 
these 25 genes in 4 hypertrophied muscles (longissimus dorsi, semimembranosus, 
semitendinosus and triceps brachii ) and 3 non­hypertrophied muscles (supraspinatus, 
infraspinatus and heart). The quantitative PCR results showed that DLK1 expression was 
significantly increased in the 4 hypertrophied muscles but not in the 3 non­hypertrophied 
muscles. However, RTL1 was up­regulated in both hypertrophied and non­hypertrophied 
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muscles, which confirmed that RTL1 is not sufficient to induce muscle hypertrophy but it 
may act in concert with DLK1 to increase muscle mass in callipyge lambs. Five other 
genes, including PARK7, DNTTIP1, SLC22A3, METTL21E and PDE4D, were 
consistently co­expressed with DLK1, herein they were the potential transcriptional target 
genes responding to DLK1 signaling. Since the hypertrophied muscles have a fiber type 
shift to a more fast­twitch, glycolytic muscle fibers and less oxidative fibers, DNTTIP1, 
METTL21E and PARK7 were examined for their effects on MYH promoter activity using 
luciferase assays. The results showed that both PARK7 and DNTTIP1 had an effect to 
increase MYH4 and decrease MYH7 luciferase activity, similar to the effects of DLK1. In 
contrast, METTL21E increase MYH7 and decreased MYH4 luciferase activity. In DLK1­
treated myotubes, the mRNA expression of Myh4 and DNTTIP1 were both increased, 
suggesting DLK1 may regulate Myh4 expression through elevated DNTTIP1 expression. 
Though PARK7 was not up­regulated in DLK1­treated cells, its increased levels in 
hypertrophied muscles still indicated its important role in callipyge muscle hypertrophy. 
PARK7 has been shown to positively regulate PI3K/AKT pathway by suppressing the 
phosphatase activity of PTEN in mouse fibroblasts. The aim of the second study is to 
determine whether the elevation of PARK7 was part of the physiological mechanism for 
muscle hypertrophy in callipyge lambs. Primary myoblasts isolated from Park7 (+/+) and 
Park7 (­/­) mice were used to examine the effect of differential expression of Park7. The 
Park7 (+/+) myotubes had significantly larger diameters and more total sacomeric 
myosin expression than Park7 (­/­) myotubes. IGF1 treatment increased the mRNA 
abundance of Myh4, Myh7 and Myh8 between 20­40% in Park7 (+/+) myotubes relative 
to Park7 (-/-).  The activity of PI3K/AKT pathway was determined by examination the 
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level of phosphorylation of AKT. The basal level of AKT phosphorylation (S473) was 
increased in Park7 (+/+) myotubes and this increase was substantially elevated in Park7 
(+/+) myotubes at all levels of IGF1 supplementation. The differential levels of AKT 
phosphorylation were eliminated by the addition of a PTEN inhibitor, suggesting PARK7 
inhibited PTEN activity in myotubes. After removal of IGF1, the Park7 (+/+) myotubes 
could still maintain about 20% higher signal intensity through 12 hours. These combined 
results suggested PARK7 can positively regulate the PI3K/AKT pathway by inhibition of 
PTEN phosphatase activity. The elevated expression of PARK7 in the muscles of 
callipyge lambs would be expected to lead to increased muscle growth in response to the 
normal IGF1 signaling present in young growing lambs. The results presented in this 
thesis unveiled the genes consistently co­expressing with DLK1 in callipyge lambs and 
identified DNTTIP1 as a secondary transcriptional effector gene responding to DLK1 
signaling. Furthermore, this thesis suggested a positive role of PARK7 in callipyge 




CHAPTER 1. INTRODUCTION 
1.1 Objective 
In food animal industry, there is always a need to identify genes that can increase 
meat production. Callipyge sheep is an excellent model for this study since the up­
regulation of DLK1 and / or RTL1 results in the increased muscle mass. The overall aim 
of this dissertation is to study the physiological pathways responding to the up­regulation 
of DLK1 and / or RTL1 in the hypertrophied muscles. The current study is based on the 
results from the previous study, in which twenty­five transcripts were discovered and 
validated with differential expression in hypertrophied muscles. Two projects were 
included in this study. The objective of the first project was to identify the secondary 
transcriptional targets for DLK1 and / or RTL1 signaling (primary effectors) from the 25 
transcripts. The consistent up­regulation of Parkinson Protein 7 (PARK7) expression in 
hypertrophied muscles but not in non­hypertrophied muscles makes it a potential 
secondary target. Therefore, the objective of the second project was to explore the 
functional role of PARK7 in muscle growth and protein accretion. Based on the 
objectives of the two projects, callipyge sheep, DLK1, RTL1, PARK7 and muscle 
hypertrophy pathways will be reviewed in this section to provide a better understanding 
in the follow­up experiments.  
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1.2 Callipyge Phenotype 
The first callipyge sheep was identified in a commercial Dorset flock in Oklahoma in 
1983 when it was referred to as “Solid Gold”. The unexpected superior muscling in the 
hindquarters makes it a unique model for researchers to study muscle development. Some 
of the offspring from the “Solid Gold” inherited the same extreme­muscling phenotype 
and thus were termed callipyge from the Greek –calli for beautiful, and –pyge for 
buttocks (Cockett et al. 1994).  
The callipyge lambs are born normal and carry the same live weights as the normal 
lambs throughout their entire life (Jackson et al. 1997a; Freking et al. 1998b; Duckett et 
al. 2000; Lorenzen et al. 2000). However, depending on location, different degrees of 
increased muscle mass are found when slaughtering (Koohmaraie et al. 1995; Jackson et 
al. 1997b, c; Freking et al. 1998b; Duckett et al. 2000). Specifically, the increase of 
muscle mass in the pelvic limb (42%) and the torso (50%) is much greater than in the 
thoracic limbs (14%) (Jackson et al. 1997c), which is consistent with the visual 
perception that callipyge sheep appear to be more muscular in the hind legs and also 
appear to be wider and deeper through the rack and loin (Jackson et al. 1997c). Notably, 
the supraspinatus and infraspinatus muscles located in thoracic limbs do not undergo 
muscle hypertrophy (Koohmaraie et al. 1995; Jackson et al. 1997c; Lorenzen et al. 2000). 
The “rostro–caudal gradient” is given to describe this special characteristic (Georges et al. 
2003). Furthermore, the selective muscular hypertrophy of callipyge lambs develops 
during the postnatal growth period between birth and weaning (Jackson et al. 1997a; 
Carpenter & Cockett 2000; Duckett et al. 2000; Lorenzen et al. 2000), therefore the 30­
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day old lambs are utilized in the present study when the increase of muscle mass is 
statistically detectable.  
As different from the “double­muscling” cattle (Kambadur et al. 1997), whose 
increased muscle mass is a results of the increase in the fiber number (hyperplasia), the 
muscle hypertrophy in callipyge sheep is due to the increased diameter of muscle fibers 
(hypertrophy). (Koohmaraie et al. 1995; Carpenter et al. 1996; Carpenter & Cockett 2000; 
Lorenzen et al. 2000). In a study of the histology and composition of muscles from 
callipyge lambs, a 34% increase in fiber size was determined in the longissimus, which 
was sufficient to account for the observed 31% increase in the loin eye area (Carpenter et 
al. 1996). A striking muscle fiber change is observed in the hypertrophy­responsive 
muscles with an increase in the proportion and size of type IIB fast­twitch, glycolytic 
muscle fibers (Carpenter et al. 1996; Carpenter & Cockett 2000). These fast­twitch fibers 
increase in diameter by 35% to 75% depending on the age and muscle affected 
(Carpenter et al. 1996; Carpenter & Cockett 2000; Kerth et al. 2003). The muscle fiber 
switch reflects the metabolic change in callipyge muscles, and identifying of the 
regulators in the muscle fiber switch will enrich our knowledge concerning the muscle 
growth in callipyge sheep. The current study investigates the potential genes modulating 
muscle fiber switch using a cell culture model.  
A reduction in the rate of protein degradation, rather than increased protein synthetic 
capacity, was first proposed to account for the higher protein accretion in callipyge sheep 
(Koohmaraie et al. 1995; Lorenzen et al. 2000). Calpains are calcium­dependent 
proteases that degrade myofibers, whereas calpastatin inhibits calpain activity 
maintaining the integrity of myofibers. Increased calpastatin activity was described in 
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callipyge muscles suggesting a reduced protein degradation and increased protein 
accretion (Koohmaraie et al. 1995; Lorenzen et al. 2000). Recently, a higher level of 
PARK7, a positive regulator of the PI3K/AKT pathway (see section 1.5.5), has been 
identified in hypertrophied muscles (Fleming­Waddell et al. 2009). The up­regulation of 
PARK7 is assumed to enhance the downstream targets of AKT, such as p70S6 kinase 
(p70S6K), to increase protein synthesis (see section 1.6.1)(Fleming­Waddell et al. 2009). 
One goal of the current study is to address whether the elevation of PARK7 is part of the 
physiological mechanism for the induced muscle hypertrophy in callipyge lambs.  
Other advantages of callipyge over normal sheep are the superior feed efficiency for 
both male and female animals and the higher dressing percentage (Koohmaraie et al. 
1995; Jackson et al. 1997a; Jackson et al. 1997b). Lambs with the callipyge mutation 
have average daily gains which are similar to that of their half­siblings with a normal 
muscle phenotype but less feed per day (Jackson et al. 1997a). Dressing percentage is 
influenced by the amount of muscle, fat, gut­fill, and wool on the lamb (Jackson et al. 
1997b). A total of 6 to 7% decrease in fat depot is constantly described in callipyge 
animals, and this reduction is not limited to subcutaneous fat, but also is reported in 
internal fat and intramuscular fat. (Koohmaraie et al. 1995; Jackson et al. 1997b; Freking 
et al. 1998b; Goodson et al. 2001). The results of the comparison of internal organs vary. 
The lighter lungs, liver, and kidneys were first demonstrated in callipyge animals, 
(Koohmaraie et al. 1995) but a later comprehensive study showed no statistically 
significant difference in the mean weights for liver, lungs, kidneys, rumen, reticulum, 
omasum, abomasum, small intestine, spleen, and testicles (Jackson et al. 1997b). At the 
same time, a lighter large intestine was indicated in this study. Two other studies 
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confirmed the lighter liver weights in more animals (Freking et al. 1998b; Lorenzen et al. 
2000). Furthermore, the carcasses of callipyge lambs are more compact with a 
significantly shorter length and greater width at the shoulder and rump (Freking et al. 
1998b). In addition, a reduction in fleece weight and staple length is observed for ewes 
with the callipyge phenotype (Freking et al. 1998a). These unique characteristics together 
contribute to the higher dressing percentage in callipyge sheep.  
Despite the advantageous characteristics described above, the meat quality in 
callipyge muscle is not as good as in normal muscle. The higher levels of calpastatin 
activity are detrimental to meat tenderness. Several studies showed the increased Warner­
Bratzler shear force value from callipyge loin chops (Duckett et al. 2000) as a result of 
the reduced rate of calpain­mediated postmortem proteolysis. One study indicated that the 
postmortem proteolysis is delayed by as much as 20 days in callipyge lambs 
(Koohmaraie et al. 1995). Notably, no difference in the tenderness of the SS (non­
hypertrophied muscle) between callipyge and normal lambs was reported (Koohmaraie et 
al. 1995; Shackelford et al. 1997; Duckett et al. 2000). Moreover, the lower marbling 
score also affects the quality, making them less juicy and flavorful (Jackson et al. 1997b; 
Freking et al. 1999; Abdulkhaliq et al. 2002).  
Despite the low meat quality in callipyge lambs, the better feed efficiencies and 
higher muscle yields allow researchers to use them as a model to study muscle growth. In 
addition, the unique inheritance model also attracts attention from the Genetics experts.  
1.3 Genetics in Callipyge Sheep 
The mutation causing muscle hypertrophy in callipyge lambs was first mapped to the 
distal end of ovine chromosome 18 (Cockett et al. 1994). Later, a non­Mendelian mode 
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of inheritance called polar overdominance was described based on the offspring 
production from multiple mating combinations (Cockett et al. 1996). The Callipyge 
sheep is the only animal model that demonstrates the polar overdominance phenomena. 
Only the lambs inherit a paternal mutant allele and a normal maternal allele (+/C) exhibit 
the callipyge phenotype, whereas the lambs inheriting a maternal mutant allele (C/+) or 
both mutant alleles (C/C) possess the same phenotypes as the normal lamb (+/+) (Cockett 
et al. 1996; Freking et al. 1998a). Although the underlying mechanism for polar 
overdominance is complex (Georges et al. 2003) and is still under investigation, studies 
suggests that it relates to the altered genes expression around the callipyge mutation.  
The callipyge mutation was identified in 2002 as a single base change of an A (wild­
type allele) to a G (callipyge allele) between the DLK1 (Delta-Like homolog 1) and 
MEG3 (Maternal Expressed Gene 3) genes in the DLK1­DIO3 (Deiodinase, 
Iodothyronine, type III) imprinted gene cluster (Freking et al. 2002; Smit et al. 2003). No 
evidence showed that the callipyge mutation disrupted protein coding. However, several 
studies have suggested that it acts as a long­range control element to alter the 
transcription of the nearby imprinted genes in cis (Freking et al. 1998a; Bidwell et al. 
2001; Charlier et al. 2001a; Bidwell et al. 2004; Murphy et al. 2006; Takeda et al. 2006; 
Fleming­Waddell et al. 2007; Vuocolo et al. 2007; Fleming­Waddell et al. 2009). These 
imprinted genes include the paternally expressed genes: DLK1 and Retrotransposon-like 
1 (RTL1), and the Maternal Expressed Gene 3 (MEG3), Maternal Expressed Gene 8 
(MEG8) and RTL1 antisense (RTL1AS) (Fahrenkrug et al. 2000; Schmidt et al. 2000; 
Charlier et al. 2001b; Shay et al. 2001; Bidwell et al. 2004). Telomeric to MEG8 is the 
largest known cluster of mammalian miRNA, which are present in the introns of an 
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ncRNA transcript, called MicroRNA-containing Gene (MIRG) (Seitz et al. 2003a; Seitz et 
al. 2004). The existence of these maternally expressed MIRG has been confirmed in the 
skeletal muscle of sheep (Caiment et al. 2010)(see Figure 1.1). The imprinted status of 
DIO3 in sheep has not been determined. Increased expressions of the paternally 
expressed genes (DLK1 and RTL1) are detected in the lambs which inherited the mutation 
from the sire (+/C), and up­regulated levels of maternally expressed genes (MEG3, 
MEG8 and RTL1AS) are identified in the animals which inherited the mutation from the 
dam (C/+) (Bidwell et al. 2001; Charlier et al. 2001a; Bidwell et al. 2004; Perkins et al. 
2006; Takeda et al. 2006; Fleming­Waddell et al. 2007; Fleming­Waddell et al. 2009). 
Notably, only the paternally expressed genes are protein­coded (DLK1 and RTL1), 
whereas all the maternally expressed genes are non­coding RNA. Unlike RTL1, whose 
increased transcript abundance has been detected in all the muscles in callipyge animals, 
the up­regulation of DLK1 has been shown exclusively in the hypertrophy­responsive 
muscles, suggesting DLK1 is the primary effector of muscle hypertrophy but a synergistic 
effect of RTL1 cannot be ruled out (Bidwell et al. 2004). The following section will 




Figure 1.1 The DLK1-DIO3
The relative positions of these imprinted genes are shown above. The protein coding 
genes (DLK1 and RTL1; 
coding RNA (MEG3, RTL1AS
allele (Mat). The genes are shaded with blue or pink on the parent
to indicate their allele­specific expression. The causative mutation (A to G; CLPG) for 
the callipyge phenotype lies in the intergeni
1.4
DLK1, also known as 
(stromal cell­derived protein 1) and 
multiple functions and different discoveries [for review see 
protein that contains six extracellular epidermal growth factor (EGF)
proteolytic cleavage reorganization site, and a short intracellular tail 
Laborda 2000). The cleavage of the EGF
form of DLK1 called FA­
amniotic fluid (Jensen et al.
factor alpha converting enzyme, TACE) is identified as an enzyme to catalyze the 
production of FA­1 (Wang & Sul 2006
the proteolytic cleavage site is found to remain constitutively membrane
 Imprinted Gene Cluster.  
blue) are expressed from the paternal allele (Pat) and the non
, MEG8 and MIRG; pink) are expressed from the maternal 
­of­origin chromosome 
c region between DLK1 and MEG3
 Primary inducers in callipyge sheep 
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form of DLK1 predominates during later fetal and adult life (Davis et al. 2004; White et 
al. 2008). 
The function of DLK1 has been extensively explored in the context of adipogenesis. 
DLK1 is proposed as a marker for pre­adipocytes where it strongly expressed, and its 
expression level is immediately decreased during adipocyte differentiation. Constitutive 
Dlk1 expression inhibits adipose differentiation (Smas & Sul 1993; Smas et al. 1997). 
This result is further confirmed in Dlk1 knockout mice, whose fat deposition is highly 
increased and serum lipid metabolites are altered (Moon et al. 2002). Thus, Dlk1 is 
considered as a negative regulator of adipogenesis, and this anti­adipogenic function of 
Dlk1 could be an explanation for the lean muscle phenotype characteristic of callipyge 
sheep. 
Several studies have illustrated a role of Dlk1 in muscle growth. Transgenic mice 
over­expressing Dlk1 results in a 10 to 15% increase in quadriceps femoris muscle mass 
and a 9 to 10% increase in myofiber diameter (Davis et al. 2004). Conversely, muscle­
specific gene ablation of Dlk1 in the mouse results in reduced body weight and skeletal 
muscle mass due to reductions in myofiber numbers (Waddell et al. 2010). A 
polymorphism in the DLK1 gene in pigs is associated with increased lean muscle mass 
and decreased adiposity similar to callipyge sheep (Kim et al. 2004). Moreover, a marked 
reduction in mRNA levels of myosin heavy chain 4 as well as compromised regenerative 
capacity and elevated inflammatory response to injury are also detected in the Dlk1 
knockout mice (Waddell et al. 2010). These combined transgenic models suggest the 
important role of Dlk1 during postnatal muscle development and regeneration.  
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The expression of Dlk1 is greater during embryonic development and gradually 
decreases after birth. However, increased expression of Dlk1 is discovered in human 
myopathies including Duchenne and Becker muscular dystrophies (Andersen et al. 2009). 
The relationship between Dlk1 and muscle disorders could be explained by the 
involvement of satellite cells. Muscle satellite cells have been characterized as a 
population of muscle­specific committed progenitors that are responsible for the postnatal 
maintenance, growth, repair and regeneration of skeletal muscle [for review, see (Kuang 
& Rudnicki 2008)]. The expression of transcriptional factor Pax7 has been defined as a 
maker of muscle satellite cells (Kuang et al. 2006). A subpopulation of PAX7 positive 
cells is found to be DLK1 positive in muscles of newborn sheep (White et al. 2008). 
Substantial numbers of Dlk1 positive satellite cells were observed in Duchenne muscles. 
Furthermore, myogenic Dlk1 positive cells were identified during muscle regeneration in 
animal models in which the peak expression of Dlk1 mRNA and protein coincided with 
that of myoblast differentiation (Andersen et al. 2009). These combined evidences 
suggest that Dlk1 functions to regulate myogenic progenitor cells to modulate muscle 
growth.  
The mechanism on how Dlk1 regulates muscle growth has been explored and studies 
have shown that Dlk1 acts as an inhibitor for Notch signaling. The structure of DLK1 has 
high homology to the drosophila protein Delta except that DLK1 lacks the critical 
Delta/Serrate/Lag­2 (DSL) domain at its N­terminus (Artavanis­Tsakonas et al. 1999; 
Laborda 2000). However, DLK1 can still interact with Notch­1 and down­regulate its 
activity in mammalian cell lines (Baladron et al. 2005; Bray et al. 2008). The Notch 
signaling is a conserved cell fate regulator and is known to inhibit myogenic regulatory 
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transcription factor MyoD expression and myogenic differentiation, but enhances satellite 
cell proliferation and self­renewal (Nofziger et al. 1999; Wen et al. 2012). Ablation of 
Dlk1 inhibits the expression of MyoD, and facilitates the self­renewal of activated 
satellite cells. Conversely, over­expression of Dlk1 inhibits the proliferation and 
enhanced differentiation of cultured myoblasts. This suggests a model in which Dlk1 
facilitates muscle differentiation through dampening of Notch signaling (Waddell et al. 
2010).  
Extensive studies have shown that Dlk1 is involved in tumorgenesis. Dlk1 is proposed 
as a marker for hepatoblastomas (Dezso et al. 2008) and adrenal gland tumors (Turanyi et 
al. 2009). It is also detected frequently in colon adenocarcinomas, pancreatic islet 
carcinoma, and small cell lung carcinoma (Yanai et al. 2010). The mechanism on how 
Dlk1 regulates oncogenesis is complicated but studies have shown that Dlk1­positive 
fetal liver cells have higher proliferative potential compared to the Dlk1­negative cell 
population. The Dlk1­positive fetal liver cells are able to differentiate into both the 
hepatocyte and cholangiocyte lineages, which implies that Dlk1­positive liver cells are 
still hepatoblasts (Tanimizu et al. 2003; Xu et al. 2012). Interestingly, PARK7, the target 
gene in the present study, is also associated with development of multiple cancers (see 
section 1.5.5), indicating it may function together with Dlk1 to modulate cell fate 
determination.  
1.4.2  Retrotranposon-like 1 
Retrotranposon-like 1 (RTL1), is the other up­regulated gene in callipyge sheep. 
RTL1 belongs to the Ty3­Gypsy retrotransposons gene family and contains a gag­pol­like 
structure common to retroviruses (Charlier et al. 2001b). This highly conserved gene only 
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has one single exon open reading frame and encodes a full length 151 kD protein in 
skeletal muscles (Byrne et al. 2010).  
RTL1 is highly expressed at the late­fetal stage in both the fetus and placenta. 
Paternally knockout RTL1 in mice showed pre­ and postnatal growth retardation in the F1 
and F2 generations, and after the F3 generation, most showed late­fetal or neonatal 
lethality (Sekita et al. 2008). A 40% decrease in passive permeability in placenta is also 
reported in RTL1 deficient mice, indicating that the loss of RTL1 may damage the 
placental physical barrier (Sekita et al. 2008). A 2.5 to 3 times over­expression of RTL1 
leads to 15% retardation in growth after weaning in early generations, and predominant 
neonatal lethality was found after the F6 generation (Sekita et al. 2008). The expansion of 
the inner spaces of the fetal capillaries has also reported in this model. These combined 
evidences indicate an essential function of RTL1 for the development of embryo and 
growth of fetus and adult animals. Recently, RTL1 has been identified as a novel driver of 
hepatocarcinogenesis (Riordan et al. 2013). Mutations resulting in the over­expression of 
RTL1 are found in the mouse model of hepatocarcinogenesis. Over­expression of RTL1 
results in highly penetrant (86%) tumor formation in vivo and the increased growth 
ability of hepatocytes in vitro (Riordan et al. 2013).  
A maternally expressed non­coding RNA transcribed from the opposite direction 
(RTL1-antisense, RTL1AS), containing at least four microRNA, was identified for the 
RISC­mediated degradation of RTL1 transcripts (Seitz et al. 2003b; Bidwell et al. 2004; 
Davis et al. 2005). The identification of RTL1AS provides a new insight into the polar 
overdominance of the callipyge phenotype, in which only the paternal heterozygous (+/C) 
have the increased level of RTL1. The miRNA­mediated degradation of RTL1 transcripts 
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in homozygous animals (C/C) reduces the mRNA abundance of RTL1 (Bidwell et al. 
2004; Davis et al. 2005). However, the role of RTL1 in the callipyge muscle hypertrophy 
is still unclear and needs further investigation.   
1.5 Parkinson Disease 7 
Parkinson Protein 7 (PARK7 / DJ-1) was first identified in 1997 as an oncogene that 
transformed NTH3T3 cells in cooperation with activated Ras (Nagakubo et al. 1997). 
PARK7 encodes a 20­kDa protein comprising 189 amino acid residues ubiquitously 
expressed in various human tissues (Nagakubo et al. 1997). Later, a mutation is found to 
be responsible for a recessive early­onset form of Parkinson’s disease (Bonifati et al. 
2003). Substantial studies implicated that PARK7 plays important roles in male fertility, 
cellular management of oxidative stress, mitochondrial homeostasis, and tumor 
progression.  
1.5.1 Genetics and Structure Biology of Park7  
The PARK7 gene was located in human chromosome 1p36.2­p36.3, in mouse 
chromosome 4 and in sheep chromosome 12. PARK7 genomic DNA comprises seven 
exons, in which the 2­7 exons encode for PARK7 protein. Human PARK7 homomers 
comprise a structure with a six­strand parallel β­sheet sandwiched by α­helical 
arrangements (flavodoxin fold) (Honbou et al. 2003a; Honbou et al. 2003b). The PARK7 
protein is homologous to a number of bacterial enzyme families such as ThiJ, a protein 
involved in thiamine biosynthesis, the Pfp1 protease (Bonifati et al. 2003) as well as the 
YajL redox­sensitive chaperone (Martinat et al. 2004). The three­dimensional structure is 
given below (Figure 1.2.) [for review, see (Trempe & Fon 2013)]. Though the crystal 
structure of PARK7 is similar to the Pfp1 protease, PARK7 does not exhibit protease 
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activity due to the distorted catalytical triad that is essential for protease activity, and the 
occupation of additional C­terminal helix at putative active site of PARK7 (Wilson et al. 
2003; Martinat et al. 2004). PARK7 contains three cysteine residues, C46, C56, and 
C106. Of the three cysteine residues, C106 is highly susceptible to oxidative stress and is 
oxidized as SOH, SO2H, and SO3H. PARK7 at C106 with SO3H is thought to be an 
inactive form of PARK7 (Figure 1.3.) and the mutation of C106 results in loss of PARK7 
functions (Mitsumoto et al. 2001; Kinumi et al. 2004; Meulener et al. 2006; Hulleman et 
al. 2007; Blackinton et al. 2009). So far, about 28 mutations are found in this gene 
(Table1.1). The effects of most of these sequence alterations in PARK7 are not clear but 
the L166P seems to be a dramatic point mutation, which affects PARK7 function 
(Bonifati et al. 2003). L166 is located in the middle of α­helix 8 (α8) and the mutation 
from leucine to proline seems to cause a break in the α­helix, which results in abrogation 
of the dimer formation, unstable and degradation of the protein (Miller et al. 2003; Moore 





Figure 1.2 Structure of PARK7 Protein  
The crystal structure of human PARK7 (PDB 1P5F) was used to generate this dimer, 
which represents the biologically active unit. The two subunits are colored in cyan and 
magenta. Residues of the active site catalytic triad (Glu18, Cys106, His126) are shown as 
sticks. The location of the PD mutation that disrupts dimerization (L166P) is indicated by 




Table 1.1 Genetic Variation of PARK7 
Mutation Population Effects Reference 
Ex1­5del Dutch Loss of protein (Bonifati et al. 2003) 
Ex1­5dup Dutch Unknown (Macedo et al. 2009) 
Ex2del Chinese Unknown (Guo et al. 2010) 
Ex5del Serbian Unknown (Djarmati et al. 2004) 
Ex5­7del Northern Italian Altered transcript (Hedrich et al. 2004) 
c.­122_­107del South African Promoter activity (Keyser et al. 2009) 
Leu10Pro Chinese Unknown (Guo et al. 2010) 
Met26Ile Ashkenazi Jewish Decreased stability (Abou­Sleiman et al. 2003) 
Ala39Ser Chinese Destabilized PINK1 (Tang et al. 2006) 
Glu64Asp Turkish Unknown (Hering et al. 2004) 
IVS4+8_9insA Southern Italy polymorphism (Tarantino et al. 2009) 
Arg98Gln Global Polymorphism (Hedrich et al. 2004) 
Ala104Thr Latino Unknown (Hague et al. 2003) 
IVS5+2_12del Russian Altered transcript (Hague et al. 2003) 
Asp149Ala Afro Caribbean Unknown (Abou­Sleiman et al. 2003) 
Pro158del Dutch Unknown (Macedo et al. 2009) 
Thr160 
(g.33808C>A) 
American Unknown (Pankratz et al. 2006) 
Glu163Lys Italian Altered activity (Annesi et al. 2005) 
Leu166Pro Italian Protein instability (Bonifati et al. 2003) 
Ala171Ser Global Unknown (Clark et al. 2004) 




Figure 1.3 Cysteine Oxidation and A
PARK7 contains three cysteine residues at amino acid numbers 46, 54, and 106 (C46, 
C54, and C106). C106 is sequentially oxidized with SOH, SO
C46 and C54 are oxidized. Graph modified from 
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the inhibition effect of anti­PARK7 antiserum is decreased when using zona­free eggs, 
which suggests that PARK7 works to enable binding of sperm to the egg surface and 
penetrating of the egg surface (Klinefelter et al. 2002). Since its sensitivity and 
correlation with fertility, PARK7 is proposed as a sperm fertility biomarker (Klinefelter 
2008). In addition, a recent study unveils the expression and localization of PARK7 in 
efferent ducts, which conduct sperm from the rete testis to the epididymis. The 
epididymis is the place where the sperm acquire the mobility and ability to fertilize an 
egg (Trepos­Pouplard et al. 2010). In their study, they also found the promoter region of 
PARK7 contains estrogen response elements, which together implicate its role in sperm 
maturation and sex hormones regulation (Trepos­Pouplard et al. 2010).   
1.5.3 Park7 and Its RNA Binding Capacity 
RNA­binding proteins play an important role in the post­transcriptional control of 
gene expression. The activity of this family of proteins is mediated through specific 
recognition of sequences and structural elements within the mRNA transcripts. In 1993, a 
RNA binding complex includes a RNA­binding subunit (s), and a regulatory subunit(s) 
(RS) were identified in FTO­2B rat hepatoma cells (Nachaliel et al. 1993). Later, this RS 
was cloned and characterized identical to human PARK7 gene (Hod et al. 1999). This 
study also showed that the purified recombinant RS had the capacity to inhibit RNA 
binding complex activity (Hod et al. 1999). However, the RNA binding capacity of 
PARK7 has not been stated until recently (van der Brug et al. 2008). Though lacking of 
classical RNA binding motifs, PARK7 can bind to GG/CC­rich sequences and dissociate 
under conditions of oxidative stress (van der Brug et al. 2008). The mRNA binding 
partners of PARK7 were involved in but not limited to cell metabolism, mitochondrial 
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transcripts and cell survival components both in vitro and in vivo (van der Brug et al. 
2008). The RNA binding capacity provides an explanation of the multifunction of 
PARK7.  
1.5.4 Park7 and Parkinson ’s disease 
Parkinson's disease (PD) is a progressive neurodegenerative disease affecting more 
than 1 million individuals in the United States. Approximately 0.3% of the general 
population and 3% of the population above 65 years have PD (Shaikh & Verma 2011). 
Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of PD. 
Park7 had been investigated to exhibit the functions in maintaining mitochondrial 
homeostasis and protecting neurons from oxidative stress. 
1.5.4.1 Role of Park7 in Mitochondrial Homeostasis  
PARK7 is located both in the cytoplasm and nucleus (Nagakubo et al. 1997) and a 
portion of PARK7 has been shown to be located in the mitochondria (Canet­Aviles et al. 
2004; Shendelman et al. 2004; Zhang et al. 2005; Hayashi et al. 2009). It has been 
reported that some parts of PARK7 are translocated into mitochondria after cells has been 
subjected to oxidative stress, to protect cells from oxidative stress­induced cell death (Li 
et al. 2005; Junn et al. 2009). The oxidation of C106 with SO2H and the N­terminal 12 
amino acids are necessary for the mitochondrial translocation of PARK7 (Canet­Aviles et 
al. 2004; Maita et al. 2013). The localization of PARK7 in mitochondria is controversial. 
Zhang et al. reported that PARK7 is located in the mitochondrial matrix and inner 
membrane space (Zhang et al. 2005), while Canet­Aviles et al. reported that PARK7 is 
located in the outer membrane but not inside of mitochondrial outer membrane (Canet­
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Aviles et al. 2004). Recently, the localization of PARK7 in outer mitochondrial 
membrane is supported by the identification of a PARK7 binding partner Bcl­XL, a 
typical Bcl­2 family protein that primarily localized in the outer mitochondrial membrane 
(Ren et al. 2011). The Bcl­2 family proteins are involved in PD pathogenesis and the Bcl­
XL is required for mouse substantial nigra development. The Bcl­XL inhibits 
dopaminergic neuronal death induced by MPTP in the substantia nigra pars compacta 
(Savitt et al. 2005; Dietz et al. 2008), thus it has a protective role in PD. In response to 
ultraviolet B irradiation (an oxidative agent), the mitochondrial distribution of Park7 
increases, which leads to the more binding capacity to Bcl­XL and further to prevent Bcl­
XL degradation (Ren et al. 2011).  
Moreover, loss function of Park7 results in several mitochondrial abnormalities. 
Significantly more fragmented mitochondria are reported in Park7 knockout mice and 
cells (Irrcher et al. 2010). Loss of Park7 causes decreased mitochondrial transmembrane 
potential and increased mitochondrial permeability transition pore opening, which can be 
restored by treatment of antioxidant molecules (Giaime et al. 2012). Reduced activity 
level and reduced amount of mitochondrial complex I have been reported in PD patients. 
PARK7 is colocalized with mitochondrial complex I and directly bounded to NDUFA4 
[NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4] and ND1 (NADH 
dehydrogenase subunit 1), which are nuclear and mitochondrial DNA­encoding subunits 
of mitochondrial complex I respectively (Hayashi et al. 2009). Knockdown of Park7 in 
vitro causes reduced activity of mitochondrial complex I and delivery of Park7 partially 
restored its activity (Hayashi et al. 2009). Since the pathogenic Park7 mutants such as 
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L166P and M26I are localized in mitochondria as monomers, the dimer formation is 
necessary for PARK7 to elicit its function in mitochondrial (Maita et al. 2013).  
Since Park7 sequence contains no consensus mitochondrial targeting signals, the precise 
mechanism by which Park7 is translocated into mitochondria is still not known. However, 
the mitochondrial Hsp70 has the capacity to direct the import of nuclear­encoded proteins 
into mitochondria (Li et al. 2005; De Mena et al. 2009), therefore it has been proposed 
that the binding of PARK7 to chaperones such as the Hsp70, CHIP, and mitochondrial 
Hsp70 / Grp 75 may contribute to the translocation of PARK7 to mitochondria.   
Regulation of autophagy and especially the autophagic degradation of mitochondria is 
an essential tool to maintain mitochondrial function and cellular homeostasis. Autophagy 
is a process that is involved in cell degradation of unnecessary or dysfunctional cellular 
components to provide sufficient ATP to ensure the functionality of vital cellular 
processes such as transcription and protein synthesis during periods of energy limitation 
(Vasseur et al. 2009; Macintosh & Ryan 2013). Recent studies provide evidence for a 
potential role of Park7 in regulation of autophagy. The association of Park7 with 
autophagy varies. Park7 silencing results in both up­regulation (Irrcher et al. 2010; 
Thomas et al. 2011) and down­regulation of autophagy (Gonzalez­Polo et al. 2009; 
Vasseur et al. 2009; Krebiehl et al. 2010). It has been reported that Park7 acts in parallel 
to the Pink1 / Parkin to control mitochondrial function and autophagy (Thomas et al. 
2011). Future studies on the precise mechanism of autophagy induction by Park7 will be 




1.5.4.2 Role of PARK7 in Anti­oxidative Stress  
Park7 plays an important role in protecting neurons and somatic cells from oxidative 
stress. Park7 has several isoforms with different isoelectric points (pI). It quenches 
reactive oxygen species (ROS) by converting from pI 6.2 to the more acidic form pI 5.8 
in mammalian cell lines. This pI shift is caused by the oxidation of cysteine residues in 
PARK7 (Figure 1.3.) (Mitsumoto & Nakagawa 2001; Mitsumoto et al. 2001). Post­
mortem studies of brain samples taken from sporadic Parkinson’s disease patients found 
that the acidic isoforms of PARK7 are more abundant in PD brains as compared to 
controls.  
The anti­oxidative stress function of Park7 is confirmed both in vitro and in vivo. In 
the presence of H2O2, the cell viability of Park7 knockout primary cortical neurons is 
increased when transfected with wild­type Park7 and further improves upon over­
expression of Park7, suggesting a gene dosage effect (Kim et al. 2005b). Transient 
knockout Park7 in SH­SY5Y neuroblastoma cells results in less resistant to 1­methyl­4­
phenyl­1,2,3,6­tetrahydropyrindine (MPTP), a neurotoxin leading to the pathology most 
similar to PD, and H2O2 treatment (Taira et al. 2004). Conversely, stable over­expression 
of Park7 in H9C2 cardiomyocytes effectively attenuates ROS generation, enhances the 
cellular antioxidant capacity and prevents ischemia/reperfusion­induced oxidative stress 
(Yu et al. 2013). In addition to the in vitro studies, several Park7 knockout mice lines 
were established to study the consequences of Park7 deficiency in vivo. Under basal 
conditions, Park7 knockout mice are viable, fertile, and show no gross anatomical or 
neuronal abnormalities (Kim et al. 2005b; Yamaguchi & Shen 2007). However, when 
exposing to MPTP, Park7 deficient mice show increased striatal denervation and 
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dopaminergic neuron loss. Adenoviral vector delivery of Park7 restores all these 
phenotypes (Kim et al. 2005b) and over­expression of Park7 resists the MPTP induced 
striatal damage. Similar to Park7 knockout mice, Park7 knockdown zebrafish and 
Drosophila melanogaster flies are specifically sensitized to lethal oxidative stress 
(Menzies et al. 2005; Bretaud et al. 2007). Taken together, all these evidences suggested 
the anti­oxidative stress and cell protective function of Park7. 
The mechanism on how Park7 exerts its cell protective function has been extensively 
studied. In addition to maintaining mitochondrial homeostasis and oxidizing itself to a 
more acidic form, Park7 has chaperone activities and it can also regulate anti­oxidative 
gene induction, and signaling pathways against oxidative stress.  
1.5.4.3 Chaperone Activity of PARK7 
Structural similarities to Hsp31 (heat shock proteins 31) suggests that PARK7 may 
function as a chaperone, and the presence of a hydrophobic patch, which is a 
characteristic of chaperone proteins, in the PARK7 dimer complex supports to this notion 
(Lee et al. 2003). Subsequent evidence of its chaperone activity has been demonstrated 
by quantification of the suppression of heat­induced aggregation of citrate synthase (CS) 
and glutathione S­transferase (GST), two well characterized protein chaperone assays in 
vitro (Shendelman et al. 2004). The chaperone activity of PARK7 is in a redox­
dependent manner (Shendelman et al. 2004) and the oxidation of C106 to SO2H form is 
required for this activity (Zhou et al. 2006). A recent study also showed that the 
abrogation of chaperone activity of PARK7 by L166P mutation could be restored by 
BAG1 (Bcl­2 associated athanogene1), an anti­apoptotic foldase stimulating co­
24 
 
chaperone (Deeg et al. 2010). The aggregation of α­synuclein, a 140 residue presynaptic 
protein, is believed to be a critical factor in the development of Parkinson’s disease and it 
has been suggested that oligomeric forms of α­synuclein might be toxic (Zhou et al. 
2006). Under an oxidative condition, the chaperone activity of PARK7 inhibits the 
aggregation of α­synuclein, (Shendelman et al. 2004), suggesting an alternative 
mechanism on how PARK7 is involved in PD pathogenesis.  
1.5.4.4 Role of Park7 in Transcriptional Regulation 
Park7 acts as a coactivator or a corepressor through binding to proteins to regulate 
transcriptional activities. Several studies have reported the regulation of Park7 on 
androgen receptor (AR) function. The androgen receptor is a member of the nuclear 
receptor superfamily and plays a role as a ligand­dependent transcription factor. After a 
ligand binds to the AR, the AR translocates into the nucleus and binds to the androgen­
responsive element (ARE) and the androgen­activating genes. These AR binding partners 
affect development, growth, and regulation of male reproductive functions (Heinlein & 
Chang 2002). Park7 modulates androgen receptor activities in a highly cell­type­specific 
manner. The first identified PARK7 interacting protein is PIASxα (protein inhibitor of 
activated STAT), also known as androgen receptor­interacting protein (Takahashi et al. 
2001). PARK7 bounds to the AR­binding region of PIASxα to abolish the suppression of 
AR transcription activity by PIASxα in CV1 monkey kidney cells and the TM4 mouse 
testis sertoli cell line but not in human HepG2 hepatoma cells. In mouse Cos1 cells, 
PARK7 is found to bind to DJBP (DJ­1 binding protein) to reverse the suppression of 
DJBP on AR transactivation activity in a testosterone­dependent manner (Niki et al. 
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2003). Surprisingly, in human neuroblastoma SK­N­BE(2)C, Park7 is reported to inhibit 
AR­dependent gene activation by approximately 50% (Jeong et al. 2006). In 2007, a 
direct interaction between PARK7 and AR was reported in prostate cancer cells (LNCaP 
and LAPC4 cell lines) and this study also showed PARK7 functions as a positive 
regulator of AR signaling (Tillman et al. 2007).  
The regulation of the transcriptional activity of the tyrosine hydroxylase (TH) gene by 
androgen receptor leads to the studies on the modulation of Park7 on TH activity (Jeong 
et al. 2006). The characteristics of Parkinson disease are the selective loss of 
dopaminergic neurons and the decrease of striatal dopamine levels. Dopamine is 
synthesized from tyrosine by two enzymes; tyrosine hydroxylase (TH) and L­DOPA 
decarboxylase (DDC). After synthesis, dopamine is transported into synaptic vesicles by 
vesicular monoamine transporter 2 (VMAT2). Tyrosine hydroxylase catalyzes the first 
and rate­limiting step of dopamine synthesis. Park7 positively regulates human TH gene 
expression by sequestering the transcriptional repressor PSF (polypyrimidine tract­
binding protein­associated splicing factor) from the human TH gene promoter (Zhong et 
al. 2006). Park7 suppresses PSF activity by inhibiting the sumoylation of PSF and 
preventing its sumoylation­dependent recruitment of histone deacetylase 1(Zhong et al. 
2006). However, this up­regulation of TH is only observed in human, the Park7 knockout 
mice do not exhibit reduced TH expression or decreased dopamine production due to the 
lacking of PSF­recognition sequence in the mouse TH gene (Ishikawa et al. 2010). 
Recently, the nuclear receptor related protein 1 (NURR1) is reported to mediate Park7 
induced TH activation via the ERK1 pathway (Lu et al. 2012). The TH up­regulation by 
Park7 can be abolished when NURR1 is silenced. Conversely, the up­regulation of 
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NURR1 as a result of over­expression of Park7 increases TH activity (Lu et al. 2012). In 
addition, a recent study reported that Park7 regulates dopamine synthesis by stimulating 
VMAT2 activity in the synapse through directly binding to VMAT2 and modulating the 
transactivation of the VMAT2 gene. The cysteine 106 is necessary for the stimulating 
activity of Park7 toward VMAT2 (Ishikawa et al. 2012).  
Park7 is an important regulator of anti­oxidative gene induction. Park7 is reported to 
stabilize Nrf2 (nuclear factor erythroid 2­related factor) by preventing its association with 
the inhibitor protein, Keap1 and further preventing the subsequent ubiquitination of Nrf2 
(Clements et al. 2006). Upon exposure to oxidative stress, Nrf2 translocates to the 
nucleus, which allows transcriptional activation of various antioxidant enzymes, such as 
NQO1 [NAD(P)H quinone oxidoreductase 1], Hmox-1, and enzymes that generate 
antioxidant molecules, such as glutathione. Therefore, Park7 acts as a positive regulator 
of Nrf2­driven antioxidant protection (Clements et al. 2006). Furthermore, Park7 protects 
rat dopaminergic cells upon oxidative damage by mediating the induction of glutamate 
cysteine ligase, the rate­limiting enzyme of glutathione biosynthesis (Zhou & Freed 
2005). In addition, knockdown or L166P mutant of Park7 in NIH3T3 cells reduces the 
expression of the extracellular superoxide dismutase (SOD3), leading to the increase of 
ROS in cells (Nishinaga et al. 2005)  
1.5.4.5 Role of Park7 on Signal Transduction 
As introduced above (see section 1.5.4.2), Park7 quenches reactive oxygen species 
(ROS) by converting itself to a more acidic form to protect cells from oxidative stress. 
Notably, the ROS are not only cytotoxic molecules; they are produced in cells in minute 
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amounts to facilitate signal transduction pathways (Hattori et al. 2009). The ASK1 
signaling pathway is one of the pathways that can be activated by ROS (Hattori et al. 
2009). Apoptosis signal­regulating kinase 1 (ASK1) is mitogen­activated protein kinase­
kinase­kinase 5 (MAP3 K5) and it can activate c­Jun N­terminal kinase (JNK) and p38 
mitogen­activated protein kinases (Hattori et al. 2009). Activation of these pathways 
induces cellular responses such as apoptosis, differentiation, cell survival, and also 
produces inflammatory cytokines (Hayakawa et al. 2012). PARK7 co­
immunoprecipitates with ASK1 upon H2O2 exposure and this binding occurs after ASK1 
dissociation with Trx1 (thioredoxin 1), an ASK1 inhibitor. Herein it has been proposed 
that Park7 replaces Trx1 under acute oxidative stress, providing a second safeguard 
suppressing ASK1­mediated apoptosis (Gorner et al. 2007). This result is further 
confirmed by another group, which demonstrated that after H2O2 treatment, Park7 is 
incorporated into the ASK1 complexes and forms mixed disulfide bonds to suppress 
ASK1 function (Waak et al. 2009). Furthermore, PARK7 has been identified to bind to 
Daxx, a death domain­associated protein. Through this binding, PARK7 sequesters Daxx 
in the nucleus, which prevents Daxx from binding to and activating its effector kinase 
ASK1 (Junn et al. 2005). This process is reversed by the MPTP mediated down­
regulation of Park7 (Karunakaran et al. 2007), which induces the translocation of Daxx 
from nucleus to cytoplasm and results in the death of dopaminergic neurons. Through 
suppression of ASK1 activity, Park7 negatively regulates the stress­activated p38 MAPK 
and JNK pathways. In addition, Park7 has been shown to physically interacts with 
MAPK/extracellular signal­regulated kinase kinase kinase 1 (MEKK1) and inhibits 
MEKK1 activation, resulting in the suppression of MEKK1­mediated cell death (Mo et al. 
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2008). Considering that MEKK1 is an MAP3K that participates in the JNK signaling 
cascade, the inhibition of MEKK1 activation by Park7 may also be an important 
mechanism in the progression of PD (Mo et al. 2008). Pathogenic mutants of PARK7 do 
not have this activity. 
Park7 has been identified to be involved in ERK pathway since 1997 when it was 
first defined as a Ras­pathway interactor during oncogenic transformation (Nagakubo et 
al. 1997). The ERK pathway is the main cell­progression pathway starting from Ras, 
followed by Raf, Mek, and ERK. A recent study showed that dopamine­exposure led to 
the up­regulation of Park7, which in turn to protect cells from dopamine toxicity and 
reduce intracellular ROS (Lev et al. 2009). Inhibition of ERK 1, 2 phosphorylation 
abolishes dopamine induced up­regulation of Park7, suggesting the up­regulation of 
Park7 is mediated by the MAP kinases pathway through the activation of ERK 1, 2 (Lev 
et al. 2009). Moreover, combined deletion of ERK and Park7 in Drosophila enhances the 
developmental defects during eye and wing development caused by ERK deletion, 
providing evidence for an important role for the interaction between Park7 and ERK 
related signaling during evolution (Aron et al. 2010). In addition, it has been shown that 
Park7 protects dopaminergic neurons against rotenone­induced apoptosis by enhancing 
ERK­dependent mitophagy (Gao et al. 2012).  
Since reactive oxygen species (ROS) has also been implicated to induce programmed 
cell death or necrosis (Hancock et al. 2001), the involvement of JNK and ERK pathway 
makes Park7 an important regulator in cancer development.  
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1.5.5 Park7 and Cancer  
Park7 has been shown to regulate a variety of cancers’ development. Both breast 
cancer and pancreatic cancer patients have elevated levels of circulating Park7, and thus 
Park7 is proposed as the biomarker for these two cancers (Pucci­Minafra et al. 2008; He 
et al. 2011). Park7 stabilizes Nrf2 (nuclear factor erythroid­drived 2­like2) to up­regulate 
the expression of antioxidant / protective enzymes, which confers a consequent survival 
benefit to the lung carcinomas (Clements et al. 2006). PARK7 is associated with prostate 
cancer by directly binding to androgen receptor to promote the progression of prostate 
cancer to androgen independence (Tillman et al. 2007). In addition, elevated levels of 
Park7 have been detected in astrocytomas (Miyajima et al. 2010), leukemias (Liu et al. 
2008), and renal cell carcinomas (Eltoweissy et al. 2011). In addition to the involvement 
of Park7 in JNK and ERK pathways, Park7 can also modulate cell survival through 
regulation of p53, NF­κB and the PI3K/AKT pathway. 
p53 is a tumor suppressor and plays roles in induction of senescence and apoptosis of 
cells (Smith et al. 2003). Park7 regulates p53 transcriptional activity in many ways. 
Topors is a ring finger protein binding to both topoisomerase I and p53 in vitro and in 
vivo. Transcription activity of p53 is found to be abrogated by Topors concomitant with 
sumoylation of p53 in a dose­dependent manner, and PARK7 restores the repressed 
activity of p53 by releasing the sumoylated form of p53 (Shinbo et al. 2005). 
Sumoylation of PARK7 itself is necessary for PARK7 to localize from the cytoplasm to 
the nucleus (Shinbo et al. 2006), and PARK7 is a negative regulator for sumoylation (Fan 
et al. 2008a). Interestingly, increased levels of p53 and Bax (a transcriptional target of 
p53 and an inducer for apoptosis) are found in Park7 knockout zebrafish, suggesting 
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Park7 may act as a negative regulator of p53 (Bretaud et al. 2007). This result is 
supported by another group which demonstrated Park7 decreases Bax expression by 
repressing p53 transcriptional activity (Fan et al. 2008b). A recent study showed that 
PARK7 bounds to the DNA­binding region of p53 in a manner dependent on the 
oxidation of C106. PARK7 suppresses the expression of p53 target genes through 
preventing promoter recognition of p53 in a DNA­binding affinity dependent manner 
(Kato et al. 2013). 
The identification of Cezanne, a known deubiquitination enzyme that inhibits NF­κB 
activity, as a PARK7 binding partner leads to the investigation of Park7 in NF­κB 
signaling (McNally et al. 2011). The amino terminus of PARK7 is sufficient to mediate 
this interaction, and this interaction between Cezanne and PARK7 is enhanced by 
oxidation of the C106 residue of PARK7. (McNally et al. 2011). Park7 and Cezanne 
shRNA are found to reciprocally regulate interleukin 8 (IL-8) and intercellular adhesion 
molecule 1 (ICAM-1), whose transcription are mediated by NF­κB, and both of them are 
shown to be positively associated in human cancer (Dong et al. 2005; Rubie et al. 2007; 
Chavey et al. 2008; Singh & Lokeshwar 2009). This result indicated the roles of Park7 
and Cezanne in NF­κB mediated transcription (McNally et al. 2011). The link between 
Park7 and NF­κB is confirmed with the discovery of decreased nuclear p65 expression in 
the presence of Park7 shRNA, suggesting Park7 acts as a positive regulator of NF­κB 
signaling (McNally et al. 2011). 
Park7 is shown to suppress the phosphatase activity of PTEN (Phosphatase with 
tensin homology), one of the most frequently mutated tumor suppressor genes in human 
cancers (Guldberg et al. 1997). PTEN is a negative regulator of the phosphatidylinositol 
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3' kinase (PI3K)/AKT pathway (Kim et al. 2005a), which is an important pathway 
regulating the signaling of multiple biological processes such as apoptosis, metabolism, 
cell proliferation and cell growth (Morgensztern & McLeod 2005). The activation of 
PI3K is initiated by the binding of the transmembrane tyrosine kinase linked receptors 
(Hennessy et al. 2005). The activated PI3K phosphorylates phospholipid 
phosphatidylinositol­4, 5­bisphosphate (PIP2) to phosphatidylinositol­3, 4, 5­
trisphosphate (PIP3), which creates a lipid­binding site on the cell membrane for the 
recruitment of serine/threonine kinase AKT (protein kinase B). AKT is phosphorylated 
and activated by 3’­Phoshphoinositide­dependent protein kinase 1(PDK1). PTEN 
phosphatase activity catalyzes the reverse reaction of PIP3 back to PIP2, resulting in less 
activated AKT (Maehama & Dixon 1998) (see Figure 1.4 in section 1.6.1).  
The suppression of Pten phosphatase activity by Park7 is supported by several gain­
of­function experiments. In Drosophila, Park7 rescues the reduced eye size caused by the 
over­expression of Pten (Kim et al. 2005a). This result is further confirmed in 
mammalian cells by observation of the increased cell survival in Park7 transfected Pten 
(+/­) cells, but not in Pten (­/­) cells. In NIH­3T3 cells line, over­expression of Park7 
reduces by 40 to 50% apoptosis in response to treatment with UV irradiation, sorbitol, or 
TNF­α. A decrease in phosphorylation of AKT is seen in Park7 siRNA treated Pten (+/−) 
immortalized mouse embryonic fibroblasts, but not in Pten (­/­) cells, suggesting the 
function of Park7 requires the presence of Pten (Kim et al. 2005a). In primary breast 
cancer samples, Park7 expression correlates negatively with PTEN immunoreactivity and 
positively with AKT hyper­phosphorylation (Kim et al. 2005a). Since the 
phosphorylation levels of PTEN at Ser380, Thr382, Thr383 and Ser385 are equal in 
32 
 
Park7 transfected NIH3T3 cells (Kim et al. 2009), the inhibition of PTEN phosphatase 
activity by Park7 is not affected by phosphorylation of PTEN. The detailed mechanism 
on how PARK7 inhibits PTEN phosphatase activity is still remaining unclear. But studies 
have proposed that PARK7 can directly bind to PTEN to change its conformation to form 
a disulfide bond between C71 and C124 of PTEN upon oxidative stress and this form of 
PTEN was considered to be inactive (Lee et al. 2002; Kwon et al. 2004; Kim et al. 2009). 
It also has proposed that the interaction of PARK7 to PTEN may accelerate the oxidation 
of PTEN, thus rendering the PTEN function inactive (Kim et al. 2009).  
The inhibition of PTEN function by Park7 makes it as a positive regulator in the 
PI3K/AKT pathway. AKT signaling inactivates several proapoptotic factors including the 
proapoptotic protein (BAD) (Gu et al. 2004) , procaspase­9 (Cheng et al. 2006) and 
Forkhead (FKHR) transcription factors (Abid et al. 2004), and it also activates 
transcription factors that up­regulate anti­apoptotic genes, including the cyclic­AMP 
response element binding protein (CREB) (Perkinton et al. 2002) and IκB kinase (IKK) 
(Gustin et al. 2004). AKT­mediated activation of mTOR (the mammalian target of 
rapamycin, also known as FRAP1) is important in stimulating cell proliferation (Wendel 
et al. 2004). mTOR is a serine/threonine kinase that serves as a molecular sensor 
regulating protein synthesis on the basis of the availability of nutrients. It also has been 
shown as an important mediator in regulating skeletal muscle hypertrophy (Glass 2003b) 




1.6 Muscle Hypertrophy Pathways 
The skeletal muscle growth during postnatal development reflects the balance 
between overall rates of protein synthesis and rates of protein degradation. Two major 
signaling pathways control the protein accretion: the PI3K/AKT pathway, acting as a 
positive regulator; and the myostatin­Smad2/3 pathway, acting as a negative regulator. 
These two pathways are described in this section to provide the detailed mechanism on 
how Park7 induced myotube hypertrophy. 
1.6.1 PI3K/AKT Pathway 
The PI3K/AKT pathway has been extensively studied and well characterized due to 
its positive regulation on muscle growth (Bodine et al. 2001; Rommel et al. 2001; Glass 
2003a; Stitt et al. 2004; Latres et al. 2005; Wilson & Rotwein 2007; Glass 2010; 
Schiaffino et al. 2013). In live animals, the increases in muscle load stimulate the 
expression of insulin­like growth factor 1(IGF1) (DeVol et al. 1990). The role of IGF1 on 
muscle growth has been supported by a variety of evidences. Addition of the IGF1 into 
culture medium induces hypertrophy in C2C12 myotubes through enhanced activation of 
AKT (Rommel et al. 2001). Muscle­specific over­expression of IGF1 causes muscle 
hypertrophy (Musaro et al. 2001), and conversely, muscle­specific inactivation of the 
IGF1 receptors impair muscle growth due to the reduced muscle fiber number and size 
(Mavalli et al. 2010). In mammals, IGF1 induces phosphorylation of the IGF1 receptor, a 
tyrosine kinase that directly activates the insulin receptor substrate (IRS) (Bohni et al. 
1999) and PI3K (Leevers et al. 1996). The detailed description on how PI3K activates 
AKT was described in section 1.5.5. It has also been well demonstrated that the 
activation of AKT is sufficient to induce hypertrophy. Over­expression of activated AKT 
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in muscle fibers results in significantly larger fiber size (Bodine et al. 2001; Pallafacchina 
et al. 2002). Transgenic mice expressing a constitutively active form of Akt in muscle 
exhibits rapid skeletal muscle hypertrophy (Lai et al. 2004). Conversely, genetic 
depletion of Akt in mice leads to smaller body size and shorter life span (Chen et al. 
2001). AKT stimulates protein synthesis by activating mammalian target of rapamycin 
(mTOR) and the downstream effectors of mTOR. The essential role of mTOR in muscle 
growth has been well established. Loss of mTOR in skeletal muscle leads to premature 
death and severe myopathy (Risson et al. 2009). Inhibition of mTOR by rapamycin 
blocks the adaptive hypertrophy in adult animals (Bodine et al. 2001) and suppresses 
muscle growth during postnatal development (Bodine 2006) and muscle regeneration 
(Pallafacchina et al. 2002).  
The activated mTOR further phosphorylates and activates p70S6 kinase (p70S6K) as 
well as releases the inhibitory effects of phosphorylated, heat and acid stable (PHAS)­
1⁄eukaryotic translation initiation factor 4E­binding (eIF4E­binding) protein 1 (4E­BP1) 
to promote protein synthesis. The activated p70S6K up­regulates the translational rates of 
mRNA in the ribosome and thus increases the total protein synthesis rates (Hornberger et 
al. 2007). The 4E­BP1, on the other hand, is a negative regulator of the protein initiation 
factor eIF4E. The activation of mTOR leads to hyperphosphorylation of 4E­BPs, 
resulting in dissociation of the 4E­BPs from eIF4E (Le Bacquer et al. 2007). Increased 
phosphorylation of eIF4E as well as its over­expression is associated with the stimulation 




In addition to the mTOR pathway, the glycogen synthase kinase 3 beta (GSK3β) is a 
distinct substrate of AKT that can also modulate hypertrophy [for reviews see (Glass 
2005)]. GSK3β is a ubiquitously expressed constitutively active serine/threonine kinase 
that phosphorylates cellular substrates, and thereby regulates a wide variety of cellular 
functions, including development, metabolism, gene transcription, and protein translation 
(Hardt & Sadoshima 2002). GSK3β is a negative regulator in myotube hypertrophy. 
Phosphorylation of AKT inhibits GSK3β activity (Cross et al. 1995). Profound myotube 
hypertrophy is observed in the dominant negative form of GSK3β expressed myotubes 
(Rommel et al. 2001). GSK3β inhibits cardiac hypertrophy both in vivo and in vitro 
through blockage of protein translation initiated by the eIF2B protein (Hardt & 
Sadoshima 2002). Furthermore, deficiency of GSK3β protein results in enhanced 
myotube formation and muscle­specific gene expression in both mouse embryonic 
fibroblasts and C2C12 myoblasts depending on the transcriptional regulator nuclear 
factor of activated T­cells c3 (NFATc3) (van der Velden et al. 2008).  
PTEN negatively regulates AKT activity (see section 1.5.5). Thus the inhibition of 
PTEN phosphatase activity by PARK7 positively regulates PI3K/AKT pathway, and in 
turn to modulate the activities of the downstream targets of AKT to enhance protein 
synthesis (Figure 1.4.).  
  
 
Figure 1.4 Effects of PARK7 in PI3K/AKT P
Factors that are inhibitory of protein synthesis are indicated in red and stimulatory factors 
are in blue. The activation of PI3K is initiated by the binding of IGF1 to its receptors. 
The activated PI3K phosphorylates phospholipid phosphatidylinositol
(PIP2) to phosphatidylinositol
site on the cell membrane for the recruitment of serine/threonine kinase AKT (prot
kinase B). AKT is phosphorylated and activated by 3’
protein kinase 1(PDK1). PTEN catalyzes the reverse reaction of PIP3 back to PIP2, 
resulting in less activated AKT. PARK7 inhibits PTEN phosphatase activity and 
positively regulates AKT activity. Activated AKT phosphorylates mTOR and GSK3
increase protein synthesis and thus leads to hypertrophy. Graph modified from 
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1.6.2 Myostatin­Smad2/3 pathway 
The myostatin­Smad2/3 pathway is described here since the callipyge sheep share 
several similar characteristics with myostatin mutant animals and the myostatin­Smad2/3 
pathway interferes with the Akt­mTOR pathway (Trendelenburg et al. 2009). 
Understanding the myostatin pathway helps to build the whole picture on the regulation 
of muscle growth.  
Myostatin, also known as growth/differentiation factor 8 (GDF­8), is a member of the 
transforming growth factor β (TGFβ) super family. Myostatin is produced by skeletal 
muscle and acts as a negative regulator of muscle growth (McPherron & Lee 1997b). 
Several animal models, including mice, cattle, dogs and sheep, demonstrate the increased 
muscle mass as a result of a variety of mutations in the myostatin gene (McPherron & 
Lee 1997a; Girgenrath et al. 2005; McCroskery et al. 2005; Clop et al. 2006; Mosher et 
al. 2007). Muscle growth due to a myostatin mutation results in both hyperplasia and 
hypertrophy with 40% more fibers in each muscle as well as a 20 to 40% increase in fiber 
diameters in cattle (Kambadur et al. 1997; McPherron & Lee 1997a; Lee 2004). In 
addition to the hypertrophy, the myostatin knockout mice exhibit a larger proportion of 
fast, glycolytic fibers as well as a decrease in adiposity. These characteristics are similar 
to the callipyge phenotype (Pankratz et al. 2006). Purified myostatin inhibits protein 
synthesis and reduces myotube size when added to differentiated myotubes in culture 
further proves its negative effects in muscle growth (Taylor et al. 2001). 
The myostatin signal initiates from the interaction and activation of a heterodimeric 
receptor complex with serine­threonine kinase activity. These receptor complexes are 
composed of a type II receptor, ACVR2 or ACVR2B, and a type I receptor, ALK4 or 
38 
 
ALK5 (Rebbapragada et al. 2003). The binding of myostatin to these receptor complexes 
results in the phosphorylation and the activation of the transcriptional factors, Smad2 and 
Smad3, which translocate to the nucleus upon phosphorylation to form heterodimers with 
Smad4 [for reviews see (Lee 2004)]. The detailed mechanism on how these complexes 
inhibit muscle growth is still unclear but many studies show that it interacts with the 
AKT/mTOR pathway [for reviews see (Welle 2009)]. Myostatin reduces Akt 
phosphorylation both in human and mouse C2C12 myotubes (Trendelenburg et al. 2009). 
Blockage of mTOR increases myostatin­induced phosphorylation of Smad2 and 
facilitates myostatin’s inhibition of muscle differentiation (Trendelenburg et al. 2009). 
The muscle fiber atrophy induced by Smad2/3 activation is prevented by the presence of 
constitutively active Akt. Conversely, constitutively active Smad3 is also found to 
suppress mTOR activation (Sartori et al. 2009). The addition of IGF1 does not block 
Smad2/3 transcriptional activity but nevertheless it can promote myotube hypertrophy 
when myostatin levels are high (Sartori et al. 2009). The precise cross­talk between these 
two pathways is still under study.  
In addition, transcriptomic and proteomic analyses in quadriceps muscles in 
myostatin­null mice show elevated levels of PARK7 and phosphorylation of AKT (Chelh 
et al. 2009). This result is further proved by the same group in double­muscled cattle 
showing higher PARK7 expression in double­muscled fetuses compared to normal 
controls (Chelh et al. 2011). Since up­regulated PARK7 was reported in callipyge sheep 
as well (Fleming­Waddell et al. 2009), the combined results here suggest that PARK7 
may be involved in the intersection of myostatin and PI3K/AKT pathway, and thus 




Callipyge sheep is a unique model to study muscle growth since a small nucleotide 
mutation leads to the profound muscle hypertrophy in live animals. Understanding the 
genes network in callipyge muscle hypertrophy will enrich the notions on muscle 
metabolism, muscle fiber type switch, and muscular protein synthesis. Since DLK1 and / 
or RTL1 are examined as the primary causative genes, the identification of the secondary 
transcriptional responses genes becomes the research goals in several studies including 
the present one. In addition to the demonstration of callipyge phenotype and callipyge 
genes regulation, this literature review detailed described the function of PARK7, which 
is identified in previous study as a potential secondary response to DLK1 signaling , that 
may stimulate protein synthesis in muscles. PARK7 is a multi­functional protein and is 
involved in diverse biological processes. PARK7 occupies a pivotal position in cellular 
biology with the loss of function leads to the Parkinson’s disease and the gain of function 
results in the unregulated cell survival in human cancers. PARK7 acts through interaction 
with RNA and partner proteins to modulate the transcriptional activities and signaling 
pathways. The regulation of Park7 in muscle is explored in the present dissertation to 




CHAPTER 2.  ASSAY VALIDATION 
2.1 Introduction 
Callipyge sheep have extreme muscling in their loin and hindquarters as a result of a 
genetic mutation located in the DLK1-DIO3 imprinted gene cluster (Freking et al. 2002; 
Smit et al. 2003) This mutation up­regulates the expression of nearby genes through cis 
and these genes in turn to further alter the gene network in hypertrophied muscles 
(Charlier et al. 2001a; Bidwell et al. 2004; Murphy et al. 2006; Perkins et al. 2006; 
Fleming­Waddell et al. 2007). Several recent studies have been conducted to profile gene 
expression in callipyge sheep in order to understand the signals and pathways leading to 
the increased muscle mass (Fleming­Waddell et al. 2007; Vuocolo et al. 2007; Fleming­
Waddell et al. 2009). The overall aim of this dissertation is to identify the downstream 
genes that respond to DLK1 and / or RTL1 signaling and characterize their function in 
muscle growth. In order to achieve this aim, several experiments including quantitative 
PCR, western blots, ELISA, in situ ELISA, gene clone, gene transfection, and luciferase 
assays have been conducted. This chapter covers the validation of assays used in this 
thesis to provide reliable experimental methods as well as lab protocols to perform the 
complete experiments.  
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2.2 Material and Methods 
2.2.1 PARK7 Plasmid Construct 
Full length PARK7 cDNA was first synthesized by reverse transcriptional PCR from 
total sheep RNA extraction using the following primers: F: 5’ 
CACCATGGCTTCAAAAAGAGCTCTAGT 3’ and R: 5’ 
ATCTTTAAGAACCAGCGG 3’. (CACC sequence was added into 5’ end of forward 
primer to construct directional TOPO cloning vector). Primers were designed based on 
the sequence from Bos taurus (GenBank accession number, NM_001015572). The PCR 
product was cloned into pENTR/SD/D­TOPO vector as instructed by manufacturer (Life 
Technologies, Grand Island, NY USA). NotI and AscI enzymes were used to cut out the 
whole vector in order to identify the insertion. The insertion was confirmed by 
sequencing using T7_ZL primer (5’ GTAAAACGACGGCCAG 3’). To create an 
expression clone construct, the LR Recombination Reaction (Life Technologies) was 
performed to recombine pENTR­PARK7/SD/D­TOPO construct with pcDNA3.2/V5­
DEST vector (Life Technologies). The pcDNA3.2/V5­DEST vector contains V5 epitope 
tag allowing detection of the recombination fusion protein by recognizing the V5 tag. To 
confirm the insertion of PARK7, the expression construct was sequenced from both 
directions using the following primers; T7_ZL F: 5’ GTAAAACGACGGCCAG 3’ and 
V5 reverse: 5’ ACCGAGGAGAGGGTTAGGGAT 3’.  
2.2.2 C2C12 Cell Culture and Cell Transfection 
C2C12 cells were cultured in Dulbecco’s modified Eagle’s medium (Life Technology) 
containing 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA USA), 100 
units of penicillin, 100 µg of streptomycin, and 0. 292 mg/ml of L­glutamine. To valid 
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the expression of pPARK7­pcDNA3.2 /V5 construct, C2C12 cells were transfected using 
FuGene 6 reagent (Roche Applied Science, Indianapolis, IN USA) according to the 
manufacturer’s instructions. pPARK7­pcDNA3.2 / V5 plasmids were transfected at a rate 
of 1 μg of plasmid DNA in 3×105 cells and seeded in 24­well plates with cover slides. 
The transfected cells were cultured in growth medium without antibiotics on the first day 
of transfection and the regular growth medium was changed to the culture afterwards.  
2.2.3  Optimizing Electroporation Condition 
In order to optimize the electroporation conditions, C2C12 cells were transfected 
using Neon TM Transfection System (Life Technologies) according to the manufacturer’s 
recommended protocol. C2C12 cells (2 × 105 for 10 µL tips and 2 × 106 for 100 µL tips) 
were electroporated with green fluorescence protein (pGFP) (3 µg for 10 µL tips and 30 
µg for 100 µL tips) construct at the indicated transfection condition (see Figure 2.3). The 
transfected cells were plated in one well of 6­well plate in the growth medium without 
antibiotics and normal medium was changed into culture afterwards. Cells were 
suspended in 2 days and count on BD Accuri™ C6 Flow Cytometry (BD Biosciences, 
San Jose, CA USA). For each individual transfection, the total number of the cells 
transfected was same. The gated cells reflect the population of cells in the restricted 
gating area in the scatter plot. The same gating area was applied to every treatment. The 
transfection efficiency was calculated by the percentage of GFP positive cells to total 
gated cells. 
2.2.4 Primary Myoblast Isolation and Culture 
Primary myoblasts were isolated from hind limb skeletal muscles at 3­5 weeks of age. 
Muscles were washed with Dulbecco’s Phosphate­Buffered Saline (DPBS), minced and 
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digested in type I collagenase and dispase B mixture (Roche Applied Science, 
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm 
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris 
and then plated on culture dishes. In 3 days, the cells together with the small debris were 
collected and digested with 0.025% trypsin for 10 minutes with agitation. Cells were 
seeded in growth media (F­10 Ham’s medium supplemented with 20 % fetal bovine 
serum, 100 units of penicillin, 100 µg of streptomycin,0. 292 mg/ml of L­glutamine, , and 
4 ng/mL basic fibroblast growth factor) on rat­tail collagen (Roche Applied Science)­
coated dishes with preplating on non­coated plates for 45 minutes to deplete fibroblasts 
as previous described (Waddell et al. 2010; Liu et al. 2012).  
2.2.5 Luciferase Assay 
Primary myoblast from Park7 (+/+) and Park7 (­/­) mice were transfected using Neon 
TM Transfection System (Life Technologies) according to the manufacturer’s 
recommended protocol. Myoblasts (2 × 105 cells) were electroporated with 3 µg of 
plasmid DNA consisting of 2.7 µg of pGL3IIB2.6 and 0.3 µg of pRL­SV40 (control) at 
three pulses of 1500 V for 10 ms. The transfected cells were plated into 96­ well plate in 
growth medium overnight and then fused into myotubes for 3 days with the indicated 
concentration (50 ng/mL, 100 ng/mL and 200 ng/mL) of long®R3 IGF1. The reporter 
assays were performed with Dual­Luciferase Reporter Assay System (Promega, Madison, 
WI USA), according to the manufacturer’s recommendations. The samples were read at 
Tecan Genios Pro (Tecan Group Ltd.) plate reader. Luciferase activity was adjusted for 
transfection efficiency by multiplying the firefly luciferase activity of a given well by the 
ratio of mean renilla luciferase activity for all wells divided by renilla luciferase activity 
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of the given well to produce units of adjusted luciferase activity. The results were 
analyzed for the genotype and IGF1 as the main effects by ANOVA using SAS 9.2 
software.  
2.2.6 Immunocytochemistry and Microscopy 
C2C12 cells were transfected as described method and cultured in a 24­well plate 
with cover slides for 48 hours. Cells were fixed in 4 % formaldehyde and permeabilized 
in 0.5 % Triton X­100. Cells were blocked in 1 % bovine serum albumin (BSA) in PBS 
for 1 hour at room temperature and stained with primary antibody with a dilution of 
1:200 for 2 hours. The primary antibodies used in this experiment were goat anti­PARK7 
antibody (Santa Cruz Biotechnology) and mouse anti­V5 antibody (Life Technology). 
Cells were then washed with PBS, and incubated with secondary antibodies with a 
dilution of 1:1000 for 1 hour. The secondary antibodies used in the experiments were 
Alexa Fluor 488­conjugated donkey anti­Goat IgG secondary antibody (Life Technology) 
and Alexa Fluor 594­conjugated donkey anti­mouse IgG secondary antibody (Life 
Technologies). Finally, cells were mounted with Prolong Gold antifade reagent with 
DAPI (Life Technologies). The IP Lab software (Scanalytics Inc., Madison, WI USA) 
and Leica DM6000 microscope were used to acquire pictures. 
2.3 Results and Discussion 
2.3.1 Validation of the pPARK7­pcDNA3.2 Construct 
Full length PARK7 cDNA was synthesis from total sheep RNA extraction using 
primers designed from Bos taurus sequence (GenBank accession number, 
NM_001015572) due to the unavailability of sheep PARK7 gene sequence. The forward 
PCR primer contained the sequence, CACC, at the 5’end of the primer, matching the 
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overhang sequence GTGG in pENTR™ TOPO® vector allowing directly cloning the 
entire gene to the entry clone vector. The full length of PARK7 open reading frame is 
570bp. In order to fuse PARK7 protein in frame with a C­terminal tag, the reverse PCR 
primer was designed without the stop codon. The PARK7 cDNA was cloned into entry 
vector first (pENTR™ TOPO®) and then subcloned into pcDNA3.2/V5­DEST vector for 
expression in mammalian cells. The illustration of PARK7 expression construct 
(pPARK7­pcDNA3.2 /V5) was shown in Figure 2.1. The human cytomegalovirus 
immediate­early (CMV) promoter drove the high­level expression of PARK7 and the 
fusion of the V5 epitope tag allows the detection using anti­V5 antibodies. The detailed 
description of this vector can be found on the website 
(http://www.lifetechnologies.com/us/en/home.html). 
In order to examine the ectopic expression of PARK7 gene in mammalian cells, 
C2C12 cells were transfected with pPARK7­pcDNA3.2 /V5 construct and detected using 
anti­PARK7 and anti­V5 antibodies (Figure 2.2). The cells stained with anti­PARK7 
antibody (green) can also be detected with anti­V5 antibody (red), suggesting the 
effectiveness of pPARK7­pcDNA3.2 /V5 construct. PARK7 was mostly localized in 
cytoplasm, however, the nucleus localization was also detected (Figure 2.2). This result 
was in consistent with previous studies which also demonstrated the nucleus, cytoplasm 
and mitochondrial localization of Park7 (Nagakubo et al. 1997; Junn et al. 2009). The 
subcellular compartmentalization of Park7 is important to its cytoprotective activity. A 
study reported that the oxidative stress drives the translocation of Park7 from cytoplasm 
to mitochondrial and nucleus whereas under basal conditions Park7 is present mostly in 
the cytoplasm and to a lesser extent in mitochondria and nucleus (Junn et al. 2009).  
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2.3.2 Optimization of Electroporation Conditions 
To accurately optimize the transfection conditions, the green fluorescence protein 
(GFP) construct was transfected into cells and counted through the flow­cytometry. The 
start condition was based on the manufacture’s instruction. A combined consideration of 
transfection efficiency and cell viability was taken to determine the best transfection 
condition. The NeonTM transfection system provides two sizes of tips that fits two 
volumes of cells, 10 µL for 2×105 (Figure 2.3) and 100 uL for 2×106 (Figure 2.4). The 
non­transfected cells were used as controls to define the gated cells area and the non­
fluorescence cells graphic area (Figure 2.3 A, B and Figure 2.4 A, B). The same gating 
areas were applied to each treatment. The condition for the 10 µL tip was first examined. 
The input pulse width and pulse number were maintained the same, however, an increase 
of voltage results in higher transfection efficiency. There are 63.6 % of GFP positive cells 
at the condition of 1800V, 10ms and 3 pulses (Figure 2.3 E and F); however, the cell 
population that counted in this treatment and the observed cell viability is much lower 
than at the condition of 1650V, 10ms and 3 pulses with 60.2 % GFP positive cells (Figure 
2.3 C and D). Therefore, the optimized condition for transfection of 2×105 cells using 10 
µL tips was at 1650 V, 10ms and 3 pulses. The conditions titrated in this study was given 
in Table 2.1A. Based on the optimized condition for 10 µL tips, the starting voltage for 
testing conditions using 100 µL tips was determined at 1500V and 1650V. Different 
input pulse width and pulse number were examined in this assay. Interestingly, the 
optimal transfection condition was still at 1650V, 10ms and 3 pulses, where 81.2 % cells 
were GFP positive (Figure 2.4 C and D). The condition of 1650V, 20ms and 2 pulses 
gave the worst transfection efficiency of 22.2% (Figure 2.4 E and F). The entire condition 
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titrated in this study was given in Table 2.1B. These results suggested that over 50 % of 
the cells can be transfected by NeonTM transfection system and the high transfection 
efficiency supported the feasibility of luciferase assay.  
2.3.3 Titration of IGF1 concentrations 
One objective of current study was to investigate the effects of PARK7 in muscle 
growth and protein accretion in response to IGF1 (see Chapter 4). Herein, the Long®R3 
IGF1, whose effects was determined to induce myotube hypertrophy (Rommel et al. 
2001), was introduced to this study. The effectiveness of IGF1 was also examined in the 
current study by observation of the myotube size. C2C12 cells were fused into myotubes 
for 6 days with the additional of indicated concentration of IGF1 for the last 4 days. 
Additional of IGF1 led to observed more and larger sizes of myotubes (Figure 2.5B and 
C) compared to no addition of IGF1 (Figure 2.5A). Here, we concluded that the 
Long®R3 IGF1 enhanced myoblast differentiation.  
PARK7 was identified as a secondary effector gene in DLK1 and RTL1 (primary 
inducers) induced muscle hypertrophy in the current study (see Chapter 3). Since the 
hypertrophied muscles in callipyge sheep have a greater proportion of fast­twitch, 
glycolytic muscle fibers and a marked reduction in mRNA levels of Myh4 was detected 
in the Dlk1knockout mice (Waddell et al. 2010), the effects of PARK7 on regulation of 
myosin heavy chain 4 (Myh4) promoter luciferase activity was examined to determine 
whether it is a component of DLK1 regulation of muscle fiber type switch. Different 
concentrations of IGF1 were titrated here to determine the optimal treatment that can 
induce significant differences between Park7 wildtype (+/+) and knockout (­/­) cells 
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(Figure 2.6). The statistical analysis suggested that in the presence of PARK7, Myh4 
luciferase activity was significantly elevated by 7% (P<0.0001). IGF1 treatments also 
increased Myh4 luciferase activity by 30 % (P<0.0001). A significant interaction effects 
was also detected (P=0.0122). Specifically, a 36 % increase was detected in the Park7 
(+/+) myotubes at IGF1 concentration of 100 ng/mL and further increase of IGF1 
concentration to 200 ng/mL does not change this magnitude. No significant differences 
were observed in other lower IGF1 concentrations (12.5, 25 and 50 ng/mL). Therefore, a 
higher concentration of IGF1 (100 ng/mL or 200 ng / mL) was used in the future 
luciferase assays to explore the effects of over­expression of Park7 on the Myh4 





Figure 2.1 Illustration of pPARK7­pcDNA3.2 Construct. 
Full length PARK7 cDNA was amplified by reverse transcriptional PCR from total sheep 
RNA extraction, first cloned to pENTR/SD/D­TOPO vector and subcloned to pcDNA3.2 
/V5­DEST vector. The CMV promoter drives the expression of PARK7 gene. The V5 
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Condition Transfection Efficiency Gated Cells 
Non-Transfection 0 % 67.2% 
1500V 10ms 3 pulse 49.5% 64.4% 
1650V 10ms 3 pulse 60.2 % 48.8% 
1800V 10ms 3pulse 63.6% 15.9% 
1950V 10ms 3pulse 52.9% 14.3% 
B 
Condition Transfection Efficiency Gated Cells 
Non-Transfection 0 % 72.3% 
1500V 10ms 3pulse 66.3% 67.7% 
1500V 30ms 1 pulse 62.3% 69.0% 
1500V 20ms 2pulse 69.4% 42.4% 
1650V 10ms 3pulse 81.2% 69.2% 
1650V 30ms 1 pulse 65.9% 42.2% 
1650V 20ms 2pulse 22.1% 17.8% 
Table 2.1 Summary of the Transfection Efficiency.  
C2C12 cells were transfected with GFP and counted through BD Accuri™ C6 Flow 
Cytometry. The total number of the cells transfected was same. The gated cells reflect the 
population of cells in the restricted gating area in the scatter plot. The same gating area 
was applied to every treatment. The transfection efficiency was calculated by the 
percentage of GFP positive cells to total gated cells. A: C2C12 cells were transfected 
with 10 µL Neon tips with 3 µg plasmids in 2 × 105 cells per tip and B: C2C12 cells were 
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CHAPTER 3. IDENTIFICATION OF GENES DIRECTLY RESPOND TO DLK1 
SIGNALING IN CALLIPYGE SHEEP 
3.1 Abstract 
Callipyge sheep are an excellent model to study genes regulation in muscle growth 
since the up-regulation of DLK1 and RTL1 results in extreme postnatal muscle 
hypertrophy. Gene expression analysis was conducted in four hypertrophied and three 
non-hypertrophied muscles to distinguish the genes that directly respond to DLK1 
signaling from the muscle specific effects of hypertrophy. The quantitative PCR results 
suggested that DLK1 expression was significantly increased in the 4 hypertrophied 
muscles but not in the 3 non-hypertrophied muscles. However, RTL1 was up-regulated in 
both hypertrophied and non-hypertrophied muscles, which reinforced DLK1 as the 
primary inducer for callipyge phenotype and also indicated that RTL1 alone is not 
sufficient to induce muscle hypertrophy. Five genes, including PARK7, DNTTIP1, 
SLC22A3, METTL21E and PDE4D, were consistently co-expressed with DLK1, and 
therefore have the potential to be the transcriptional target genes responding to DLK1 
signaling. The expression of DNTTIP1, METTL21E and PARK7 were examined for their 
effects on Myosin Heavy Chain (MYH) promoter activity using luciferase assays. The 
results showed that both PARK7 and DNTTIP1 increased MYH4 and decreased MYH7 
promoter activity, similar to the effects of DLK1. In contrast, expression of METTL21E 
increased MYH7 and decreased MYH4 luciferase activity. Treatment of myoblast and 
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myotubes with DLK1 induced a 1.6-fold and a 2-fold increase in DNTTIP1 expression. 
The expression of MYH4 also increased in DLK1-treated myotubes, however, no 
significant difference was found in PARK7 expression. This suggests that DNTTIP1 was 
a secondary effector gene responding to DLK1 signaling. 




Callipyge sheep are well known for their postnatal muscle hypertrophy that is 
prominent in loin and hind quarters (Koohmaraie et al. 1995; Jackson et al. 1997c; 
Duckett et al. 2000). The muscle mass in callipyge sheep is increased 35-40 % and 
carcass fat is decreased 6-7 % but the live weights were the same relative to normal 
lambs (Jackson et al. 1997a; Jackson et al. 1997b, c; Freking et al. 1998b). Callipyge 
lambs are born with normal muscling and hypertrophy becomes detectable at 4-6 weeks 
of age (Jackson et al. 1997a; Carpenter & Cockett 2000; Duckett et al. 2000; Lorenzen et 
al. 2000). After 5 weeks of age, an increased proportion and larger size of fast-twitch, 
glycolytic muscle fibers were found in callipyge muscles (Carpenter et al. 1996; 
Carpenter & Cockett 2000). Not all the skeletal muscles in callipyge sheep develop 
hypertrophy, the supraspinatus and infraspinatus muscles in thoracic limb are two 
muscles that do not undergo hypertrophy (Koohmaraie et al. 1995; Jackson et al. 1997b; 
Freking et al. 1998b).  
The callipyge mutation is a single base change of an A (wild-type allele) to a G 
(callipyge allele) between DLK1 (Delta-Like homolog 1) and MEG3 (Maternal Expressed 
Gene 3) genes in the DLK1-DIO3 (Deiodinase, Iodothyronine, type III) imprinted gene 
cluster (Freking et al. 2002; Smit et al. 2003). The callipyge mutation did not disrupt any 
protein coding sequence. However, several studies have shown that the highly conserved 
12 bp sequence including the mutation acts as a long-range control element to alter the 
transcription of the surrounding imprinted genes in cis. Specifically, the inheritance of a 
callipyge allele from the sire up-regulates the transcription of paternal protein-coding 
genes DLK1 and RTL1 (Retrotransposon-like 1), while the inheritance of a maternal 
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callipyge allele enhances the expression of maternal non-coding RNA including MEG3, 
MEG8 (Maternal Expressed Gene 8) and RTL1AS (RTL1 antisense)(Bidwell et al. 2001; 
Charlier et al. 2001a; Bidwell et al. 2004; Perkins et al. 2006).  
Dlk1 encodes a transmembrane protein belonging to the epidermal growth factor 
(EGF)-like repeat containing family. This family includes proteins such as the Notch 
receptors and their ligands including Delta-like (Dll1, Dll3 and Dll4) and Serrate 
(Jagged)-like (Jagged1 and Jagged2) ligands (Laborda et al. 1993; Smas 1993; Jensen et 
al. 1994a; Okamoto et al. 1998). Unlike Delta and Serrate, Dlk1 lacks the critical 
Delta/Serrate/Lag-2 (DSL) domain at its N-terminus. Therefore, Dlk1 is thought to 
interact with the Notch receptors through its EGF repeats as an antagonist and down-
regulates Notch signaling (Baladron et al. 2005; Bray et al. 2008). The Notch signaling is 
a conserved cell fate regulator and is known to inhibit myogenic regulatory transcription 
factor MyoD expression and myogenic differentiation, but enhances satellite cell 
proliferation and self-renewal (Nofziger et al. 1999; Wen et al. 2012). Several studies 
indicate that DLK1 expression can influence postnatal muscle growth. Transgenic mice 
over-expressing Dlk1 caused increased muscle mass and myofiber diameter (Davis et al. 
2004). Muscle-specific gene ablation of Dlk1 in the mouse resulted in reduced body 
weight and skeletal muscle mass due to reductions in myofiber numbers (Waddell et al. 
2010). Conversely, over-expression of Dlk1 in cell culture was shown to inhibit myoblast 
proliferation and enhanced differentiation (Waddell et al. 2010). DLK1 mRNA was up-
regulated in longissimus dorsi, gluteus medius and semimembranosus, the hypertrophied 
muscles in callipyge lambs but not up-regulated in supraspinatus, the non-hypertrophied 
muscle (Bidwell et al. 2004; Perkins et al. 2006; Fleming-Waddell et al. 2007; Fleming-
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Waddell et al. 2009). The DLK1 protein was expressed at high levels observed in the 
myofibers of callipyge longissimus dorsi and semimembranosus but was not detected in 
normal muscles (White et al. 2008). 
Similar to DLK1, the mRNA abundance of RTL1 is also increased in the calipyge 
muscles. RTL1 belongs to Ty3-Gypsy retrotransposons gene family and contains gag-pol-
like structure common to retroviruses (Charlier et al. 2001b). This highly conserved gene 
only has one single exon and encodes a full length 151 kDa protein in skeletal muscles 
(Byrne et al. 2010). In the mouse, Rtl1 is highly expressed at the late-fetal stage in both 
the fetus and placenta and the loss or over-expression of Rtl1 cause late-fetal and / or 
neonatal lethality (Sekita et al. 2008). In callipyge sheep, the up-regulation of RTL1 is not 
specific to hypertrophied muscles, a lower magnitude of induction of RTL1 in the non-
hypertrophied muscle (supraspinatus) was detected (Bidwell et al. 2004), suggesting 
RTL1 alone is not sufficient to induce muscle hypertrophy. These combined studies 
suggest that elevated DLK1 expression is the primary cause of callipyge muscle 
hypertrophy. Since the biological activity of RTL1 in muscles is not well understood, a 
synergistic effect with DLK1 has not been ruled out.  
MEG3, MEG8, and RTL1AS are all non-coding RNA that are transcribed from the 
maternal chromosome. MEG3 was recently proposed to possess tumor suppressor 
properties (Zhou et al. 2012; Balik et al. 2013). MEG8 was located in embryonic brain 
and muscles (Gu et al. 2012) but the function of MEG8 is still unclear. RTL1AS contains 
at least four microRNA that was identified for RISC-mediated degradation of RTL1 
transcripts (Seitz et al. 2003b; Davis et al. 2005).  
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Several studies were conducted to identify the downstream target genes responding to 
the over-expression of DLK1 and RTL1 in callipyge animals (Fleming-Waddell et al. 
2007; Vuocolo et al. 2007; Fleming-Waddell et al. 2009). Microarray analysis of gene 
expression in the semimembranosus identified 375 genes that were differentially 
expressed in callipyge versus normal lambs (Fleming-Waddell et al. 2009). Twenty-five 
transcripts were further verified by quantitative PCR in 2 hypertrophied muscles 
(semimembranosus and longissimus dorsi) and one non-hypertrophied muscle 
(supraspinatus). It has been assumed that among these 25 transcripts, there are direct 
targets of DLK1 signalings and tertiary responses to hypertrophy. Therefore, gene 
expression analysis using 4 hypertrophied muscles longissimus dorsi, semimembranosus, 
semitendinosus and triceps brachii and 3 non-hypertrophied muscles supraspinatus, 
infraspinatus and heart was conducted in the current study to distinguish the genes that 
directly respond to DLK1 signaling from tertiary effects of hypertrophy. These direct 
targets are defined as the physiological directly respond to DLK1 signaling rather than a 
direct binding partner of DLK1, and these genes would expect to have a similar mRNA 
expression pattern as DLK1 in all the muscles examined. Whereas the tertiary response 
genes are assumed as the genes that indirectly respond to DLK1 signaling and thus could 
have different expression levels in one or several muscles. These tertiary response genes 
could be associated with many bioactivities such as protein accretion, myofiber type and 
metabolic changes. Since the hypertrophied muscles have a fiber type proportions shift to 
a greater number of fast-twitch, glycolytic muscle fibers expressing MYH4, the MYH4 is 
an appropriate indicator of the tertiary responses. Therefore, the MYH4 luciferase reporter 
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assay was conducted to explore the potential components on DLK1 regulation of MYH4 
expression.  
3.3 Materials and Methods 
3.3.1 Sample Collection 
Matings between a ram that was heterozygous for the callipyge allele and a group of 
normal ewes were used to generate a cohort of callipyge and normal lambs. The lambs 
were genotyped to detect the callipyge SNP and sampled at 30-35 days of age following 
protocols approved by Purdue University Animal Care and Use Committee. Seven 
muscles including (longissimus dorsi, semimembranosus, semitendinosus, triceps brachi, 
supraspinatus, infraspinatus, and heart) were weighed and sampled as described 
(Fleming-Waddell et al. 2007; Fleming-Waddell et al. 2009) . Muscle RNA was isolated 
according to the methods described previously (Fleming-Waddell et al. 2007).  
3.3.2 Primary Myoblast Isolation and Culture 
Primary myoblasts were isolated from hind limb skeletal muscles of mice at 3-5 
weeks of age. Muscles were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS), 
minced and digested in type I collagenase and dispase B mixture (Roche Applied Science, 
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm 
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris 
and then plated on collagen-coated dishes. After 3 days, the cells together with the small 
debris were collected and digested with 0.025% trypsin for 10 mins with agitation. Cells 
were seeded in growth media (F-10 Ham’s medium supplemented with 20 % fetal bovine 
serum, 100 units/mL of penicillin, 100 µg/mL of streptomycin,0. 292 mg/ml of L-
glutamine, and 4 ng/mL basic fibroblast growth factor) on non-coated plates for 45 mins 
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to deplete fibroblasts as previous described (Waddell et al. 2010; Liu et al. 2012) and 
then transferred to collagen (Roche Applied Science)-coated dishes. Myoblasts were 
differentiated into myotubes after plating cells at approximately 80% confluency on 
Matrigel (BD Biosciences, San Jose, CA USA) coated plates and the addition of fusion 
media consisting of DMEM supplemented with 5 % horse serum, 100 units/mL of 
penicillin, 100 µg/mL of streptomycin, and 0. 292 mg/ml of L-glutamine. Myoblast 
cultures testing the effects of DLK1 ligand were plated on a bed of 1 mg/mL BD Matrigel 
containing 500 ng/mL of recombinant DLK1 protein [DLK1 (mouse): Fc(human), 
Adipogen International Inc., San Diego CA USA]. Cells were induced to differentiate the 
next day and fused for 2 days before mRNA isolation.  
3.3.3 Quantitative PCR Analysis 
Complimentary DNA (cDNA) synthesis for measuring RTL1 transcript abundance 
used gene-specific priming of 5 µg total RNA and Superscript III reverse transcriptase at 
50 ℃ (Life Technology). The cDNA synthesis for other transcripts used random hexamer 
priming from 5 µg RNA and MMLV reverse transcriptase. The first strand cDNA 
synthesis reaction was diluted 25-fold so that there was an equivalent of 20 ng of input 
RNA per microliter. Quantitative PCR assays were carried out in 15-µL reaction volumes 
of iQ SYBR Green Supermix with cDNA equivalent to 100 ng of input RNA. All cDNA 
samples were assayed in duplicate. Absolute quantification was used to measure gene 
expression in sheep muscle RNA. The quantitative PCR primers and the plasmid 
standards were designed and tested according to the methods described previously 
(Fleming-Waddell et al. 2009). Primer sequences were listed in Supplement Table 1. 
Cloned amplicons were used as standards to calculate a regression of threshold cycle on 
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molecule copy number to determine a log value of starting abundance for each of the 
cDNA samples based on their threshold cycle (Bidwell et al. 2004). All plasmid 
standards were diluted from either 108 to 102 or 107 to 101 molecules. Quantitative PCR 
reactions for standards were performed in triplicate. The variance analysis was performed 
using SAS 9.2 software and the MIXED procedure was used to analyze the log value of 
gene expression. Genotype was the main effect in the model and each muscle was 
analyzed individually. The random effect was defined as animal nested within genotype. 
The least squares means; standard error and difference between least squares means were 
calculated for the variance analysis.  
Relative quantification was used to measure gene expression in DLK-treated 
myoblast experiments. RNA from cultured myotubes was extracted and purified using 
Nucleo Spin RNA II columns (Machery-Nagel Inc., Easton, PA USA) with DNase I 
treatment. First strand cDNA was synthesized from RNA using random hexamer and 
oligo dT priming and MMLV (Life Technologies). Quantitative PCR measurements were 
performed using the SA Bioscience SYBR Green Supermix (QIAGEN, Valencia, CA 
USA) reagents on an iCycler Real-Time PCR Detection System (Bio-Rad Inc.). Each 
reaction was carried out in 15 µl reaction volumes of SA Bioscience SYBR Green 
Supermix with 5 pM of each primer and diluted first-strand cDNA. Primer sequences 
were listed in Supplement Table S1. Ribosomal protein large protein 38 (Rplp38) was 
used as the housekeeping gene control for ΔCT calculation [ΔCT = (CT of the target gene) 
– (average CT of housekeeping genes)]. Fold expression values were calculated using 2
-
ΔΔCT methods (Livak & Schmittgen 2001), where ΔΔCT = (ΔCT of the treatment sample) 
– (ΔCT of control treatment samples) with no added DLK1 as control treatment and 
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normalized to 1. Statistical significance was determined by Analysis of Variance 
(ANOVA) method.  
3.3.4 Plasmid Construction 
Full length DNTTIP1, METTL21E and PARK7 cDNA were amplified by reverse 
transcription PCR from total sheep RNA and directionally cloned into pENTR/SD/D-
TOPO vector (Life Technologies, Grand Island, NY USA) and then subcloned by 
recombination into the pcDNA3.2/V5-DEST expression vector (Life Technologies) 
according to the manufacturer’s recommendations. The mouse pDLK1-pCMV-SPORT 
6.1 plasmid was commercial available (cat#: MMM1013-9201636, Thermo Fisher 
Scientific Inc., PA USA). To confirm the insertion of the target genes with an intact open 
reading frame, all plasmids were sequenced from both directions. The pGWCAT-
pcDNA3.2 /V5 control plasmid was obtained from Life Technologies.  
The mouse Myh4 luciferase construct (pGL3IIB2.6) containing 2.56 kb of the promoter 
region of Myh4 was kindly provided by Dr. Swoap (Swoap 1998). The rat Myh7 
luciferase construct (p-3542β-MHCluc), containing 3.5 kb of the promoter of Myh7, was 
obtained from Dr.Hasegawa (Hasegawa et al. 1997). The pRL-SV40 plasmid expressing 
renilla luciferase was commercial available at Promega Corporation. Plasmids for 
electroporation were purified using EndoFree Plasmid Maxi Kit (QIAGEN) and 
quantified by Nanodrop spectrophotometry (Thermo Fisher Scientific Inc, Rockford, IL 
USA). 
3.3.5 Luciferase Reporter Assay 
Neon TM Transfection System (Life Technologies) was used according to the 
manufacturer’s recommended protocol. Myoblasts (2 × 105 cells) were electroporated 
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with 3 µg of plasmid DNA with three pulses 10 msec pulses of 1500V. To determine if 
these target genes could have effects on myosin gene expression, the effector experiments 
were done by co-transfection of protein coding sequence of the target genes along with 
the myosin luciferase reporter construct. The myosin luciferase reporter construct and the 
transfection control (renilla) were kept constant first, and the two different amounts of 
effector cDNA were titrated. In order to keep a constant amount of the total plasmid 
DNA, the GW-CAT was added and also used as the null control vector. A detailed 
description of the plasmid combinations were given in Supplementary Table A4. The 
electroporated cells were put into 96-well plates in growth media overnight and 
subsequently fused into myotubes for 3 days. In PARK7 luciferase experiments, the 
indicated concentrations of IGF1 (50, 100, and 200 ng / mL) (long®R3 IGF1, Sigma-
Aldrich Co, St Louis, MO USA) were added to the fusion medium 24 hours after 
differentiation and cultured for another 48 hours. The reporter assays were performed 
with Dual-Luciferase Reporter Assay System (Promega, Madison, WI USA), according 
to the manufacturer’s recommendations. The samples were read with a Tecan Genios Pro 
(Tecan Group Ltd.) plate reader. Luciferase activity was adjusted for transfection 
efficiency by multiplying the firefly luciferase activity of a given well by the ratio of 
mean renilla luciferase activity for all wells divided by renilla luciferase activity of the 
given well to produce units of adjusted luciferase activity. The results were analyzed for 
the addition of target construct as the main effect by ANOVA using SAS 9.2 software. 
The IGF1 treatment was also considered as a main effect when analyzing PARK7 




3.4.1 Phenotypic Data Analysis  
Animal birth weights and live weights were collected and statistical analysis (Figure 
3.1) showed that there were no significant differences in birth weight and live weight 
between callipyge (+/C) and normal lambs (+/+). The callipyge lambs have significantly 
heavier longissimus dorsi, semimembranosus, semitendinosus and triceps brachi, ranging 
from 23 % to 17 % more relative to normal muscles (Figure 3.1), thus these 4 muscles are 
referred to “hypertrophied muscles” in this study. No significant differences were 
detected in supraspinatus, infraspinatus, and heart; herein these are “non-hypertrophied 
muscles”. These results verified the muscle specific hypertrophy in the experimental 
samples.  
3.4.2 Muscle Specific Gene Expression 
The mRNA abundance of the 25 differentially expressed transcripts from the previous 
study (Fleming-Waddell et al. 2009) were assayed by quantitative PCR. To investigate 
the shift of myosin heavy chain isoforms in callipyge animals, the four myosin heavy 
chain genes [MYOSIN HEAVY CHAIN 4 (MYH4), MYOSIN HEAVY CHAIN 7 (MYH7), 
MYOSIN HEAVY CHAIN 2 (MYH2) and MYOSIN HEAVY CHAIN 1 (MYH1)] were also 
examined in this study. The complete set of primers for all genes analyzed by quantitative 
PCR and PCR conditions was given in supplementary Table A1 and the least square 
mean with standard errors was given in supplementary Table A2. The differential 




The expression of Ribosomal protein, large P0 (RPLP0) was used as a control gene. 
RPLP0 expression was not significantly different in the two genotypes in all the 7 
muscles (Figure 3.2), which is an indication that equivalent amounts of RNA were used 
for cDNA synthesis and for quantitative PCR. The callipyge mutation affected the genes 
expression at DLK1-DIO3 locus (Figure 3.3). Compared to normal lambs, the expression 
of DLK1 was significantly elevated in hypertrophied muscles with semimembranosus 
having the largest magnitude of increase; and triceps brachi had the smallest increase. 
There were no significant differences in supraspinatus, infraspinatus and heart (Figure 
3.3A). The expression pattern of RTL1 was different from DLK1. Normal lambs had 
extremely low RTL1 expression in longissimus dorsi , semitendinosus, triceps brachi and 
supraspinatus with average log value is 1.14, and its expression level was barely 
detectable in semimembranosus, infraspinatus and heart with average log value is less 
than 1 (Figure 3.3B). The expression of RTL1 was significantly increased in callipyge 
lambs in all the assayed muscles with an average log value for RTL1 was 4.6. The 
expression patterns of MEG3 and MEG8 were quite similar. Both of their expression 
levels were significantly elevated in the hypertrophied muscles (Figure 3.3D). The 
callipyge lambs also had a significantly elevated MEG3 expression (4-fold, P=0.0323) in 
supraspinatus. There was a trend (P=0.0678) for MEG8 to express differentially in 
supraspinatus (Figure 3.3C). The expression patterns of these imprinted genes in DLK1-
DIO3 locus were consistent with the previous reports (Bidwell et al. 2004; Perkins et al. 
2006).  
The expression of several myosin isoforms were examined as markers of the muscle 
hypertrophy response. The differential expression of myosin isoforms show the 
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established fiber type changes in callipyge muscle. Previous studies reported significant 
and strong up-regulation of muscle genes characteristic of type IIb (MYH4) and down-
regulation of genes characteristic of type IIa fibers (fast oxidative/glycolytic) (MYH2) 
and type 1 fibers (slow oxidative) (MYH7) in hypertrophied muscles (Vuocolo et al. 
2007). The present study confirmed this phenotype by examination of a 60-fold increase 
in MYH4 expression in the hypertrophied muscles (Figure 3.4A). MYH1 is the most 
abundant myosin isoform measured in the skeletal muscles and its mRNA abundance was 
significantly elevated in semimembranosus by 2.5-fold (Figure 3.4B). MYH2, which is 
characteristic of an intermediate fiber type between fast and slow fibers, was relatively 
unchanged in triceps brachi (2.5-fold) but down-regulated in other hypertrophied 
muscles with longissimus dorsi has the largest magnitude at 0.125-fold (Figure 3.4C). 
The mRNA abundance of MYH7 was only down-regulated in semimembranosus with 
0.27-fold, which is different from the previous report indicating a decreased level of 
MYH7 in longissimus dorsi (Figure 3.4D). The myosin heavy chain gene expression 
results confirmed the reported callipyge phenotype with increased fast-glycolytic and 
decreased slow-oxidative myofibers (Carpenter et al. 1996; Vuocolo et al. 2007).  
The gene expression pattern of these 25 transcripts was given in Figure 3.5. The 
variable gene expression pattern reflected the differences in response to the DLK1 
signaling. Five genes including Parkinson Protein 7 (PARK7, also known as DJ-1) 
(Figure 3.6A), Deoxynucleotidyltransferase, terminal, interacting protin 1 (DNTTIP1) 
(Figure 3.6B), Solute carrier family 22 member 3 (SLC22A3) (Figure 3.6C), protein-
lysine methyltransferase METTL21E (METTL21E) (Figure 3.6D), and cAMP specific 
phophodiesterase 4D (PDE4D) (Figure 3.6E) were specifically up-regulated in the 
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hypertrophied muscles, but not in the non-hypertrophied muscles, resembling the DLK1 
expression pattern. The change in gene expression of PARK7 in hypertrophied muscles is 
small relative to other four genes, but significantly different from normal muscles with 
semimembranosus having the biggest magnitude of 6.1-fold (Figure 3.6A). DNTTIP1 had 
the biggest magnitude of increase in longissimus dorsi with 6.8-fold and smallest increase 
in semimembranosus with 5.6-fold (Figure 3.6B). There was a substantial up-regulation 
of SLC22A3 in hypertrophied muscles with the magnitude ranging from 6.5-fold to 17.8-
fold (Figure 3.6C). The average mRNA abundance for METTL21E (Figure 3.6D) and 
PDE4D (Figure 3.6E) in hypertrophied muscles were 8.4-fold and 5-fold greater relative 
to normal lambs. In addition to these 5 transcripts, there is a muscle specific expression 
pattern for all the other assayed genes. Since these transcripts were identified from the 
microarray and quantitative PCR using longissimus dorsi and semimembranosus, the 
majority of these genes were differentially expressed in both of these two muscles. Many 
of these genes are metabolic in nature; for example, PFKM was up-regulated in 3 of the 4 
hypertrophied muscles and LPL was down-regulated in 2 of the 4 hypertrophied muscles, 
therefore they were likely to be involved in the response to the changes of MYH isoforms 
and metabolic demands in callipyge lambs.  
3.4.3 Effects of Candidate Target Genes on Myh4 and Myh7 
Promoter Activity 
The muscle specific gene expression analysis identified 5 genes, DNTTIP1, PARK7, 
METTL21E, SLC22A3 and PDE4D, whose muscle specific expression pattern is the same 
as DLK1. In order to determine if PARK7, DNTTIP1, and METTL21E could influence 
myosin isoform expression similar to what occurs in callipyge muscle, a series of 
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luciferase assays were conducted to test the effects of these candidate genes on MYH4 
and MYH7 promoter activity. The luciferase assays were conducted by co-transfection of 
the candidate gene cDNA constructs as effector plasmids together with Myh4 
(pGL3IIB2.6) or Myh7 (p-3542β-MHCluc) luciferase reporter plasmids in primary 
myoblasts. The amount of effector plasmid that was co-transfected was titrated for each 
plasmid with the addition of the null vector (pGWCAT) to maintain equal amounts of 
input DNA. After tranfection, the myoblasts were differentiated into myotubes for 3 days. 
To validate the expression of the effector protein in cells, the cells were stained with 
corresponding antibodies after transfection (DNTTIP1 in Supplementary Figure A1, 
PARK7 in Supplementary Figure A2 and METTL21E in Supplementary Figure A3). 
These results validated the expression of these constructs and also illustrated the nuclear 
localization of DNTTIP1, and the nuclear and cytoplasmic localizations of PARK7, 
METTL21E and GWCAT.  
There was a dose effect for DLK1 induced MYH4 luciferase activity. Adding DLK1 
significantly increased Myh4 luciferase activity at the high concentration (48%) (P= 
0.0012) (Figure 3.7A). The same effect was also observed in DNTTIP1 treatment with the 
high concentration (24%) of DNTTIP1 resulting in significantly elevation of MYH4 
luciferase activity (P< 0.0001) (Figure 3.7C). In this experiment, less DNA was used for 
DNTTIP1 because it was a nuclear factor. Conversely, adding METTL21E (60%) 
significantly decreased MYH4 luciferase activity (P=0.0126) by 16.5 % (Figure 3.7E). An 
opposite dose response was observed in MYH7 luciferase assay for DLK1 and DNTTIP1 
treatments. A 35 % decrease in MYH7 luciferase activity was examined by adding a high 
concentration of either DLK1 (48%) (Figure 3.7B) or DNTTIP1 (24%) (Figure 3.7C) 
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treatment. Adding METTL21E, on the other hand, significantly increased MYH7 
luciferase activity even at a low concentration (30%, P=0.0135 relative to control) 
(Figure 3.7F).  
Since PARK7 was assumed as a positive regulator in PI3K/AKT pathway which was 
initiated by the binding of IGF1 to its receptor (Kim et al. 2005a; Fleming-Waddell et al. 
2009), different concentrations of IGF1 were applied to the myotubes in order to induce a 
differential response in PARK7 treatment. Statistical analysis indicated the overall effect 
of PARK7 was significant in both MYH4 (P=0.0004) (Figure 3.8A) and MYH7 (P<0.0001) 
(Figure 3.8B) luciferase assays (P=0.0471). Specifically, with a higher concentration of 
IGF1 (100 ng/mL) treatment, adding PARK7 even at a low concentration (30%) 
significantly increased MYH4 luciferase activity (P=0.0007). There is a similar trend at 
IGF1 concentration of 200 ng/mL with 30% input of PARK7 significantly increasing 
MYH4 luciferase activity by 20% (Figure 3.8A). No significant difference was found at 
low IGF1 concentration (50 ng / mL) and no added IGF1 treatment. There is a dose effect 
for IGF1 treatment in MYH4 luciferase assay, however, the MYH7 luciferase activity was 
not affected by IGF1 treatment. A dose response for PARK7 was observed in PARK7 
induced MYH7 luciferase activity. Adding PARK7 (60%) significantly reduced MYH7 
luciferase activity regardless of IGF1 concentrations (Figure 3.8B).  
3.4.4 Effects of DLK1 on DNTTIP1 and PARK7 Expression 
The luciferase assay indicated both DNTTIP1 and PARK7 are capable of altering 
MYH4 and MYH7 gene expression, similar to DLK1. Therefore treatment of myoblast and 
myotube with DLK1 was tested to determine its effects on DNTTIP1 and PARK7 
expression. Since it had been reported that C2C12 cells over-expressing DLK1 failed to 
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proliferate (Waddell et al. 2010), the primary myoblasts were plated onto Matrigel 
containing recombinant DLK1 protein to enable DLK1 to act as a ligand for cell surface 
receptors. The mRNA abundance of DNTTIP1 was significantly increased by DLK1 
treatment in both myoblast and myotubes (Figure 3.9A). Specifically, the DLK1-treated 
myoblasts had 1.6-fold increase in DNTTIP1 expression and the DLK1-treated myotubes 
had 2-fold increase. The expression of Myh4 was very low in myoblasts and there were 
no significant differences between the control and DLK1 treatments (Figure 3.9B). 
However, the mRNA abundance of Myh4 was significantly elevated after differentiation 
with the DLK1 treated myotubes having 1.8-fold (P<0.0001) higher expression compared 
to the control myotubes. The mRNA abundance of Park7 was not significantly changed 
in the presence of DLK1 (Figure 3.9C).  
3.5 Discussion 
In food animal agriculture, there is a need to identify the mechanisms that can 
improve the efficiency of muscle growth and protein accretion. Callipyge sheep have 
improved feed efficiency with greater than 35% more muscle mass, which proves that 
much higher production efficiency is biologically possible. Therefore callipyge muscle 
hypertrophy provides a unique model for investigating the genes that are potentially rate 
limiting for muscle growth. The 25 transcripts examined in the current study were 
initially identified and validated from previous study by which their expressions were 
explored at extensive postnatal developmental series (10, 20, 30 days and 80 days) 
(Fleming-Waddell et al. 2009). Changes in gene expression during muscle hypertrophy 
can be categorized as the primary causative genes, DLK1 and RTL1, which were known 
due to the co-localization with the causative mutation and up-regulation with the 
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inheritance of the mutation in cis. The secondary effector genes have a directly 
physiological response to DLK1 and RTL1 activities, and the tertiary response genes that 
indirectly respond to DLK1 signaling or hypertrophy. This study extended the 
investigation to several muscles (longissimus dorsi, semimembranosus, semitendinosus, 
triceps brachi, supraspinatus, infraspinatus and heart). The muscle specific patterns of 
gene expression provide a comprehensive analysis to discern the secondary effectors 
response to DLK1 and RTL1 from the tertiary changes in expression due to the muscle 
hypertrophy. 
The phenotypic data analysis supported the reported callipyge phenotype that the 
callipyge lambs share the same body weight as normal lambs (Jackson et al. 1997a; 
Freking et al. 1998b), and also confirmed the well-recognized pattern of muscle 
hypertrophy that the increase of muscle mass in the pelvic limb and the torso is much 
greater than in the thoracic limbs (Jackson et al. 1997c). The gene expression analysis in 
DLK1-DIO3 locus showed the established pattern for induction of muscle hypertrophy in 
callipyge lambs. There was high level of expression of DLK1 and RTL1 in the callipyge 
lambs. DLK1 was only up-regulated in hypertrophied muscles but the up-regulation of 
RTL1 was also detected in the 3 non-hypertrophied muscles. The expression levels of 
MEG3 and MEG8 were increased in supraspinatus. These combined evidence together 
suggested that RTL1 alone is insufficient to induce muscle hypertrophy and reinforce that 
DLK1 is the primary inducer of muscle hypertrophy. However, since the biological 
activity of RTL1 is not well understood, it is still possible that RTL1 acts in concert with 
DLK1 to co-regulate the callipyge phenotype.  
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Analysis of several myosin isoforms showed the up-regulation of the fast twitch 
glycolytic myosin isoform (MYH4) in all hypertrophied muscles and the down-regulation 
of the fast twitch mixed oxidative and glycolytic myosin isoform (MYH2) in 
hypertrophied musclses except triceps brachi. The changes in muscle fiber type are 
indicative for metabolism, which have been directly associated with elevated postnatal 
expression of the DLK1 protein in muscle fibers (White et al. 2008). A decrease in slow 
twitch oxidative MYH7 was only detected in the semimembranosus but not in other 
hypertrophied muscles, which is inconsistent with previous observation of decreases in 
MYH7 expression and smaller oxidative myofibers in longissimus dorsi (bCarpenter et al. 
1996; Carpenter & Cockett 2000; Vuocolo et al. 2007; White et al. 2008). The 
discrepancy is possibly due to the younger animals used in the current study. The 
decreased level of MYH7 may not be evident in these animals.  
Among the 25 examined transcripts, five genes, DNTTIP1, PARK7, PDE4D, 
SLC22A3, and METTL21E, were up-regulated specifically in hypertrophied muscles, 
resembling DLK1 expression pattern in 7 assayed muscles and thus these genes were 
considered as the secondary targets in response to DLK1 and RTL1 signaling. Further 
luciferase experiments demonstrated Park7 and DNTTIP1 positively regulate MYH4 and 
negatively influence MYH7 luciferase activity similar to the effects of DLK1. However, 
only the expression of DNTTIP1 was increased in DLK1 treated cells. These combined 
results indicated that DNTTIP1 is a direct transcriptional response to DLK1 signaling. 
DNTTIP1 (deoxynucleotidyl transferase interacting protein 1), is a transcriptional 
factor that negatively regulates the activity of terminal deoxynucleotidyltransferase (TdT), 
which is a DNA polymerase that synthesized the N-region of B and T-cell receptor genes, 
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independent of a DNA template. (Yamashita et al. 2001). DNTTIP1 is ubiquitously 
expressed and exclusively localized in the nucleus and it has a helix-turn-helix and AT-
hook-like motif and preferentially binds to AT-rich regions of double-stranded DNA 
(Yamashita et al. 2001; Kubota et al. 2007). Notably, the promoter region of Myh4 gene 
contains two AT-rich motifs (Takeda et al. 1992) which suggested that DNTTIP1 may 
bind to Myh4 promoter region to active its transcription. Moreover, DNTTIP1 is reported 
to interact with HDAC1 and HDAC2 during M phase (Bantscheff et al. 2011). The 
HDACs usually down-regulate transcriptional activity by deacetylating histones (Segre & 
Chiocca 2011). The interaction with HDACs may facilitate DNTTIP1 to regulate gene 
expression in muscles. The function of DNTTIP1 in muscle growth is unclear. But the up-
regulation of DNTTIP1 was reported in longissimus dorsi and semimembranosus in 
callipyge lamb from two previous studies (Fleming-Waddell et al. 2007; Fleming-
Waddell et al. 2009). The current study confirmed its up-regulation in longissimus dorsi 
and semimembranosus, and also revealed its increased levels in semitendinosus and 
triceps brachi, along with the regulation of myosin gene expression and the response to 
the DLK1 treatment. Taken together, DNTTIP1 could be a seconday effector in response 
to DLK1 and it may involve in the differential expression of MYH genes and regulation 
of other genes in callipyge lambs.  
Since PARK7 was not up-regulated in DLK1-treated cells, it may not act as a direct 
transcriptional response to DLK1 signaling. However, due to its increased expression in 
hypertrophied muscles and the regulation of MYH4 and MYH7 luciferase activity, it may 
have a physiological role in response to the DLK1-induced muscle hypertrophy. PARK7 
encodes a ubiquitously expressed, highly conserved protein that was originally identified 
76 
 
as an oncogene that transforms NIH3T3 cells in cooperation with the activated ras gene 
(Nagakubo et al. 1997). PARK7 has been associated with diverse biological processes 
including oxidative stress response, transcriptional regulation and cell survival 
(Takahashi et al. 2001; Tillman et al. 2007; McNally et al. 2011). The PI3K/AKT 
pathway is known for its positive regulation on muscle growth, and the binding of IGF1 
to its receptor initiates this pathway. PARK7 was identified to positively regulate 
PI3K/AKT pathway by suppressing the phosphatase activity of PTEN in mouse 
fibroblasts (Kim et al. 2005a). Thus the up-regulation of PARK7 may lead to the 
enhanced activity and prolonged sustained activity of PI3K/AKT pathway and in turn to 
elevate the response of the downstream elements in PI3K/AKT pathway to increase 
protein synthesis and muscle mass. Moreover, a recent study demonstrated that over-
expression of constitutively active AKT resulted in the hypertrophy of glycolytic 
myofibers not oxidative myobfiers (Izumiya et al. 2008). This study was supported by 
identification a regulatory cascade that regulate AKT activation to drive the metabolic 
and contractile specification of fast-twitch muscle fibers (Meng et al. 2013). Therefore, 
the significantly higher Myh4 luciferase activity induced by adding PARK7 could be 
expected as enhanced activation of AKT. Interestingly, in addition to callipyge animals, 
double muscle cattle, in which the expression of Park7 gene was also elevated, had an 
increased proportion of white fast-twitch glycolytic fibers as well (Chelh et al. 2011).  
Although different from DLK1, METTL21E up-regulated MYH7 and down-
regulated MYH4 luciferase activity, it may still have a physiological role in callipyge 
muscle hypertrophy since it consistently up-regulated in hypertrophied muscles similar to 
DLK1. METTL21E has nuclear localization, but it mostly accumulated in perinuclear 
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cytoplasm (Supplementary Figure S3). Herein, it may not act as a direct transcriptional 
response to DLK1. The results from luciferase assay suggested METTL21E may not 
regulate the myosin heavy chain gene expression, but it may be involved in other 
biological activities since its multiple function. The METTL21E, known as protein-lysine 
methyltransferase METTL21E in Bos taurus, encodes a methyltransferase domain similar 
to members of the S-adenosylmethionine (SAM) -dependent methyltransferase family 
(Marchler-Bauer et al. 2007). This family of methyltransferases catalyzes the transfer of a 
methyl group (CH3) from a donor, generally S-adenosyl-L-methionine (AdoMet), to 
various acceptor molecules (Martin & McMillan 2002; Schubert et al. 2003). In human, 
there is no METTL21E, but the bovine METTL21E gene shares 51 % similarity to human 
METTL21C. Due to the species specificity, the function of METTL21E is not well 
defined. However, thousands substrates of SAM-dependent methyltransferases has been 
identified. These substrates included nucleic acids for regulation of gene expression, 
DNA repair or protection against restriction enzymes, proteins for repair or control of 
signal transduction pathways, hormones and neurotransmitters, and biosynthetic 
intermediates to produce secondary metabolites (Schubert et al. 2003). These 
bioactivities of the substrates may indicate the diverse functional role of METTL21E in 
the metabolic changes during the callipyge muscle development. 
Both PDE4D and SLC22A3 have increased expression only in hypertrophied 
muscles, which implied they may play roles in DLK1-induced muscle hypertrophy. The 
luciferase analysis was not done for PDE4D in this study due to the expression of 
numerous alternatively spliced transcripts that dictate subcellular localization and the 
specific cAMP pools that are affected (Richter et al. 2005). PDE4D is a member of 
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Phosphodiesterases (PDEs), which catalyze the hydrolysis of cyclic nucleotides cAMP 
into the inactive substrate 5’-AMP. The cAMP signaling is important for muscle 
hypertrophy and metabolism (Berdeaux & Stewart 2012). The β2-adrenergic receptors 
(β2-ARs) as cAMP inducers in skeletal muscle draw the majority of attention since its 
main target are β-agonists. The phenotype observed in callipyge hypertrophy is very 
similar to muscle growth induced by the β-agonists agent, which includes increased 
muscle mass and decreased adiposity (Kretchmar et al. 1990; Pringle et al. 1993). It has 
shown that the activation of PDE4D is an important feedback regulation contributing to 
the transient nature of the β2-ARs response and represents a major adaptive mechanism 
required for physiological β2-ARs signaling (Liu et al. 2000). Though the callipyge lambs 
do not respond to β-agonist supplementation with additional muscle hypertrophy 
(Koohmaraie et al. 1996), the up-regulation of PDE4D in hypertrophied muscles may be 
associated with a stronger response to the physiological levels of adrenaline in young 
growing lambs. The nature of SLC22A3 is an organic cation transporter and SLC22A3 
knockout mice did not show overt phenotypic abnormalities indicating it was not 
essential for physiological functions (Zwart et al. 2001). Therefore, it is unlikely a direct 
transcriptional response to DLK1. Herein, it was also excluded from the luciferase study. 
SLC22A3 / OCT3 (Solute carrier 22A3 / Organic cation transporter 3) mediates the 
uptake of many important endogenous amines and basic drugs in a variety of tissues 
(Chen et al. 2013). Studies have shown that in excretory organs, such as kidney and liver, 
SLC22A3 facilitated the uptake of organic cations across the basolateral membrane into 
the cell (Ahmadimoghaddam et al. 2012; Ahmadimoghaddam et al. 2013). Though it had 
been already reported that SLC22A3 expressed in skeletal muscle (Lee et al. 2009), the 
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up-regulation of SLC22A3 in hypertrophied muscles was firstly discovered in our lab. It 
is assumed that the high-levels of SLC22A3 may enhance the up-take of amines including 
amino acids and biogenic amines to stimulate muscle growth in callipyge lambs. Further 
studies will be needed to explore its function in muscle development.  
In summary, the present study extended the knowledge on the genes regulation in 
callipyge lamb. This study provided additional support that RTL1 alone was not sufficient 
to induce muscle hypertrophy, examined the up-regulation of DNTTIP1, PARK7, 
SLC22A3, PDE4D and METTL21E in hypertrophied muscles, proposed the regulation of 
DNTTIP1 and PARK7 on myosin gene expression and identified DNTTIP1 as a 
secondary effector gene responding to DLK1 signaling. The present study also assumed 
the possible mechanisms on how these genes influence muscle mass in callipyge lambs. 
The callipyge sheep is a valuable model in livestock since its increased muscle growth 
and higher feed efficiency. Identification of the genes and the signaling that cause the 
callipyge phenotype will enrich the understanding of the postnatal muscle growth in all 
meat animal species, and will help to solve the world’s poverty problem by producing 
higher protein accretion.  
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Figure 3.1 Muscle Hypertrophy in Callipyge Lambs.  
There were no differences in the birth weights (BW) and live weights (LW) between 
callipyge (+/C) and normal lambs (+/+). Callipyge lambs had significantly heavier 
longissimus dorsi (LD), semimembranosus (SM), semitendinosus (ST) and triceps 
brachii (TB) muscles. There were no differences in muscle weights for the supraspinatus 
(SS), infraspinatus (IS) and heart (HT). Significant differences are indicated by (*; P < 


























































Figure 3.2 Transcript Abundance of RPLP0 in 7 Muscles.  
Least square means and standard errors for log transcript abundance in 100 ng of total 
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and 
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles, 
SS, IS and HT are non-hypertrophied muscles. RPLP0 was used as a control to confirm 
equivalent RNA input into cDNA synthesis and qPCR assays, and no significant 






















































































































Figure 3.3 mRNA Abundance of Genes From the DLK1-DIO3 Locus.  
Least square means and standard errors for log transcript abundance in 100 ng of total 
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and 
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles, 
SS, IS and HT are non-hypertrophied muscles. Samples are from 30 – 35 days of age 
lamb. DLK1 shown in (A), RTL1 in (B), MEG8 in (C) and MEG3 in (D). Significant 
differences are indicated by (*; P < 0.05, or **; P < 0.01) between callipyge and normal 

































































































































Figure 3.4 mRNA Abundance of Myosin Heavy Chain Genes.  
Least square means and standard errors for log transcript abundance in 100 ng of total 
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and 
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles, 
SS, IS and HT are non-hypertrophied muscles. Samples are from 30 – 35 days of age 
lamb. MYH4 shown in (A), MYH1 in (B), MYH2 in (C) and MYH7 in (D). Significant 
differences are indicated by (*; P < 0.05, or **; P < 0.01) between callipyge and normal 





Figure 3.5 Hierarchal Clustering of Candidate Gene Expression Pattern in 7 Muscles.  
Columns for the seven muscles were fixed and rows representing gene expression were 
subject to clustering. The fold change of transcript abundance for the ratio of callipyge to 
normal was transformed to log2 .  The magnitude of the fold change is represented by red 
if gene expression was higher in callipyge than normal or blue if expression was lower in 
callipyge than normal muscle. Significant differences are indicated by (*; P < 0.05, or **; 

















































































































































Figure 3.6 Transcript Abundance of the Candidate Target Genes in 7 Muscles.  
Least square means and standard errors for log transcript abundance in 100 ng of total 
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and 
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles, 
SS, IS and HT are non-hypertrophied muscles. PAKR7  (A), DNTTIP1 (B), SLC22A3  (C), 
METTL21E  (D), and PDE4D in (E) are up-regulated in hypertrophied muscles but not in 
non-hypertrophied muscles. Significant differences are indicated by (*; P < 0.05, or **; P 






Figure 3.7 Effects of DLK1, DNTTIP1 and METTL21E on Myosin Promoter Activity.  
Increased Myh4 and decreased Myh7 luciferase activity was examined in DLK1 (A: 
Myh4; B: Myh7) and DNTTIP1 (C: Myh4; D:Myh7) over-expressed myotubes. Over-
expression of METTL21E decreased Myh4 (E) and increased Myh7 (F) luciferase activity. 
Primary myoblasts were transfected with different compositions (indicated by percentage 
in graph) of effector constructs together with Myh4 or Myh7 luciferase plasmids. The 
pRL-SV40 plasmid was constantly transfected into cells as a transfection efficiency 
control. The transfected cells were put into 96-well plates in growth media overnight and 
fused into myotubes for 3 days.  Luciferase activity was adjusted for transfection 
efficiency by multiplying the firefly luciferase activity of a given well by the ratio of 
mean renilla luciferase activity for all wells divided by renilla luciferase activity of the 
given well to produce units of adjusted luciferase activity. Differing lower case letters 
























































































































































Figure 3.8 Effect of Park7 on Myosin Promoter Activity.  
(A) Increased PARK7  input (30 % and 60 %) significantly elevated Myh4 luciferase 
activity at high concentrations of IGF1 (100 ng / mL and 200 ng / mL). (B) Adding 
PARK7  (30% and 60%) significantly decreased Myh7 luciferase activity regardless of 
IGF1 concentration. Primary myoblasts were transfected with different compositions of 
effector constructs pPARK7-pcDNA3.2  and pGWCAT- pcDNA3.2 (control) plasmids 
together with Myh4 or Myh7 luciferase plasmids.The pRL-SV40 plasmid was constantly 
transfected into cells as a transfection efficiency control. The transfected cells were put 
into 96-well plates in growth media overnight and fused into myotubes for 3 days. IGF1 
was added to the culture 24h after differentiation at the indicated concentration. Different 
composition of the effector gene in the transfected plasmid complex was indicated as 
percentage.  Luciferase activity was adjusted for transfection efficiency by multiplying 
the firefly luciferase activity of a given well by the ratio of mean renilla luciferase 
activity for all wells divided by renilla luciferase activity of the given well to produce 
units of adjusted luciferase activity. Differing lower case letters indicate significance (P < 
0.05) within each IGF1 treatment.  
  
A
IGF1 Concentration (ng / mL)


























IGF1 Concentration (ng / mL)








































Figure 3.9 Transcript Abundance of DNTTIP 1, Myh4 and Park7 in DLK1 Treated 
Myoblast and Myotubes.  
Primary myoblasts cultured on Matrigel (Control) or Matrigel plus recombinant DLK1 
protein (Dlk1) for 24 hours and induced to differentiation for 48 hours. (A) DNTTIP 1 
expression was increased in DLK1 treatment in both myoblast and myotubes. (B) The 
mRNA abundance of Myh4 was highly elevated in DLK1-treated myotubes but not in 
myoblast. (C) No significant difference was observed in the expression of Park7. 
Differing lower case letters indicate significance (P<0.05) between control and Dlk1 














































































CHAPTER 4. PARK7 EXPRESSION INFLUENCES MYOTUBE SIZE AND 
MYOSIN EXPRESSION IN MUSCLE 
4.1 Summary 
Callipyge sheep exhibit postnatal muscle hypertrophy due to the up-regulation of 
DLK1 and/or RTL1. The up-regulation of PARK7 was identified in hypertrophied muscles 
by microarray analysis and further validated by quantitative PCR. The expression of 
PARK7 in hypertrophied muscle of callipyge lambs was confirmed to be up-regulated at 
the protein level. PARK7 was identified to positively regulate PI3K/AKT pathway by 
suppressing the phosphatase activity of PTEN in mouse fibroblasts. The purpose of this 
study was to investigate the effects of PARK7 in muscle growth and protein accretion in 
response to IGF1. Primary myoblasts isolated from Park7 (+/+) and Park7 (-/-) mice 
were used to examine the effect of differential expression of Park7. The Park7 (+/+) 
myotubes had significantly larger diameters and more total sacomeric myosin expression 
than Park7 (-/-) myotubes. IGF1 treatment increased the mRNA abundance of Myh4, 
Myh7 and Myh8 between 20-40% in Park7 (+/+) myotubes relative to Park7 (-/-). The 
level of AKT phosphorylation was increased in Park7 (+/+) myotubes and this increase 
was substantially elevated in Park7 (+/+) myotubes at all levels of IGF1 supplementation. 
After removal of IGF1, the Park7 (+/+) myotubes maintained about higher signal 
intensity through 3 hours. PARK7 positively regulates the PI3K/AKT pathway by 
inhibition of PTEN phosphatase activity in skeletal muscle. The activity of PARK7 in 
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muscle can increase protein synthesis and result in myotube hypertrophy. These results 
support the hypothesis that elevated expression of PARK7 in callipyge muscle would 
increase levels of AKT activity to cause hypertrophy in response to the normal IGF1 
signaling in rapidly growing lambs and PARK7 could be a key regulator in protein 
accretion and muscle growth. 
Keywords 




Callipyge sheep exhibit postnatal muscle hypertrophy, with higher rates of protein 
accretion and lower rates of fat deposition compared to wild type sheep (Jackson et al. 
1997b; Freking et al. 1998a). The muscle hypertrophy phenotype is most prominent in 
the loin and hind-quarters at 4-6 weeks of age due to increased muscle fiber diameter, 
while the muscle fiber number remains unchanged (Carpenter et al. 1996; Jackson et al. 
1997c; Duckett et al. 2000).After 5 weeks of age, fiber type proportions shift to a greater 
number of fast-twitch, glycolytic muscle fibers at the expense of oxidative fibers in 
callipyge muscles (Carpenter et al. 1996; Carpenter & Cockett 2000). The callipyge 
mutation is a single nucleotide polymorphism in the DLK1-DIO3 imprinted gene cluster 
(Freking et al. 2002; Smit et al. 2003) that causes up-regulation of Delta-like 1 (DLK1) 
and Retrotransposon-like 1 (RTL1) in hypertrophied muscles (Charlier et al. 2001a; 
Bidwell et al. 2004; Murphy et al. 2006; Perkins et al. 2006; Fleming-Waddell et al. 
2007). Transgenic mice over-expressing Dlk1 exhibited increased muscle mass and 
myofiber diameter (Davis et al. 2004). Muscle-specific gene ablation of Dlk1 in the 
mouse resulted in reduced body weight and skeletal muscle mass due to reductions in 
myofiber numbers (Waddell et al. 2010). Conversely, over-expression of Dlk1 in culture 
was shown to inhibit myoblast proliferation and enhance myotube differentiation 
(Waddell et al. 2010). The expression of DLK1 has a clear role for inducing muscle 
hypertrophy although the biological activity of RTL1 is not well understood and a 
synergistic effect with DLK1 has not been ruled out in the callipyge phenotype.  
Microarray analysis of gene expression identified 199 genes that were differentially 
expressed in semimembranosus muscle of callipyge and normal lambs (Fleming-Waddell 
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et al. 2009). Twenty-five transcripts were further verified by quantitative PCR in two 
hypertrophied muscles (semimembranosus and longissimus dorsi) and one non-
hypertrophied muscle (supraspinatus). Parkinson Protein 7 (PARK7; also known as DJ-1) 
expression was consistently up-regulated in hypertrophied muscles.  
PARK7 encodes a ubiquitously expressed, highly conserved protein that has been 
shown to be involved in diverse biological processes including oxidative stress response, 
transcriptional regulation and cell survival modulation. A mutation causing a loss of 
function of PARK7 was found to be responsible for a recessive early-onset form of 
Parkinson’s disease (Bonifati et al. 2003). PARK7 protects neurons and somatic cells 
from oxidative stress by oxidizing itself to a more acidic form (Mitsumoto & Nakagawa 
2001). PARK7 could modulate transcription through interaction with proteins. PARK7 
enhances the NF-κB pathway by binding to Cezanne (McNally et al. 2011), restores 
androgen receptor transcription activity by bound to PIAS1 (protein inhibitor of activated 
STAT,1) (Takahashi et al. 2001), and up-regulates human tyrosine hydroxylase gene 
expression by interaction and inhibition of PSF (Splicing factor proline/glutamine-rich; 
also known as Polypyrimidine tract-binding protein-associated splicing factor) (Zhong et 
al. 2006). In addition, PARK7 could mediate cell survival signaling pathways. Park7 was 
originally identified as an oncogene that transforms NIH3T3 cells in cooperation with the 
activated Ras gene (Nagakubo et al. 1997). Later, substantial studies have shown that 
PARK7 is involved in the progression of many cancers including lung cancer (Clements 
et al. 2006), breast cancer (Pucci-Minafra et al. 2008), pancreatic cancer (He et al. 2011), 
astrocytomas (Miyajima et al. 2010), leukemias (Liu et al. 2008), and renal cell 
carcinomas (Eltoweissy et al. 2011). The mechanism of how PARK7 is involved in 
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cancer development is complex and studies have shown that PARK7 could bind to 
Topors/p53BP3, p53 (Shinbo et al. 2005; Fan et al. 2008b), DAXX (death domain-
associated protein), ASK1 (Apoptosis signal-regulating kinase 1) (Junn et al. 2005; 
Karunakaran et al. 2007) and PTEN (Phosphatase with tensin homology) (Kim et al. 
2005a) to regulate cell cycle progression.  
PARK7 was shown to suppress the phosphatase activity of PTEN which is a negative 
regulator of the phosphatidylinositol 3' kinase (PI3K)/AKT pathway (Kim et al. 2005a). 
The activated PI3K phosphorylates phospholipid phosphatidylinositol-4, 5-bisphosphate 
(PIP2) to phosphatidylinositol-3, 4, 5-trisphosphate (PIP3), which creates a lipid-binding 
site on the cell membrane for the serine/threonine kinase AKT (v-akt murine thymoma 
viral oncogene homolog 1 /protein kinase B). AKT is activated by phosphorylation of 3’-
Phoshphoinositide-dependent protein kinase 1(PDK1) (Latres et al. 2005). PTEN 
phosphatase activity catalyzes the reverse reaction of PIP3 back to PIP2 resulting in less 
activated AKT (Maehama & Dixon 1998). PARK7 acts to suppress PTEN phosphatase 
activity and, therefore, can modulate levels of AKT activity (Kim et al. 2005a). The 
phosphorylation of AKT activates several pathways to regulate cell proliferation 
(Sandirasegarane & Kester 2001), cell survival (Lawlor & Rotwein 2000) and protein 
synthesis (Rommel et al. 1999).  
The PI3K/AKT pathway is known for its positive regulation on muscle growth 
(Bodine et al. 2001; Rommel et al. 2001). The binding of insulin-like growth factor 1 
(IGF1) to its receptor initiates this pathway and activates AKT. The role of IGF1 for 
stimulating muscle growth had been well established. Addition of IGF1 into culture 
medium induced hypertrophy in C2C12 myotubes through enhanced activation of AKT 
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(Rommel et al. 2001). Muscle-specific over-expression of Igf1caused muscle 
hypertrophy in mice (Musaro et al. 2001) and conversely muscle-specific inactivation of 
the Igf1 receptor impaired muscle growth due to reduced muscle fiber number and size 
(Mavalli et al. 2010). It also had been well demonstrated that the activation of AKT is 
sufficient to induce hypertrophy. Over-expression of activated Akt in muscle fibers results 
in significantly larger fiber size (Bodine et al. 2001; Pallafacchina et al. 2002). 
Transgenic mice expressing a constitutively active form of Akt in muscle exhibit rapid 
skeletal muscle hypertrophy (Lai et al. 2004). Conversely, genetic depletion of Akt in 
mice leads to a smaller body size and shorter life span (Chen et al. 2001).  
Though extensively studied, the role of PARK7 in muscle growth had not been 
reported until recently. Transcriptomic and proteomic analyses in quadriceps muscles in 
myostatin-null mice, which exhibit a muscle hyperplasia phenotype, found elevated 
levels of PARK7 and phosphorylation of AKT (Chelh et al. 2009). Further work by the 
same group in double-muscled cattle also showed higher PARK7 expression in double-
muscled fetuses compared to normal controls (Chelh et al. 2011). In food animal 
agriculture, there is a need to identify genes that can increase muscle growth and protein 
accretion. The identification of elevated expression of PARK7 in hypermuscular animals 
suggests PARK7 could play a functional role in muscle growth and could be a rate-
limiting gene in protein accretion. Differential expression of PARK7 was examined in 
this study using Park7 (+/+) and Park7 (-/-) mouse models to investigate the effects of 
Park7 in muscle growth and protein accretion in response to IGF1. Here the elevation of 
PARK7 was proposed as part of the physiological mechanism for the induced muscle 
hypertrophy in callipyge lambs.  
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4.3 Materials and Methods 
4.3.1 Mice and Animal Care 
Mice with the Park7 locus inactivated by gene targeting [Park (-/-)] are available 
from JAX mice® (Strain 006577, Jackson Laboratories, Bar Harbor, ME). The initial 
Park7 (-/-) mouse was back crossed with C57BL6 to produce Park7 (+/+) (+/-) and (-/-) 
mice. Twenty females with 4 Park7 (+/+), 12 (+/-) and 4 (-/-) animals and twenty-five 
males with 4 Park7 (+/+), 11 (+/-) and 10 (-/-) were examined to analyze the live animal 
growth. The carcass and internal organ weights were measured on a total of 18 males (4 
Park7 (+/+), 6 (+/-) and 8 (-/-) animals) and 16 females (4 Park7 (+/+), 8 (+/-) and 4 (-/-) 
animals). Mice maintenance and experimental use were performed according to protocols 
approved by the Purdue Animal Care and Use Committee.  
4.3.2 RNA Isolation and Quantitative PCR Analysis 
RNA from cultured cells was extracted and purified using Nucleo Spin RNA II 
columns (Machery-Nagel Inc., Easton, PA USA). First strand cDNA was synthesized 
from RNA using random hexamer and oligo dT priming and moloney murine leukemia 
virus reverse transcriptase (MMLV, Life Technologies) were used to produce random 
primed cDNA. Quantitative PCR measurements were performed using the SA Bioscience 
SYBR Green Supermix (QIAGEN, Valencia, CA USA) reagents on an iCycler Real-
Time PCR Detection System (Bio-Rad Inc., Hercules, CA USA). Each reaction was 
carried out in 15 µl reaction volumes of SA Bioscience SYBR Green Supermix with 5 
pM of each primer and diluted first-strand cDNA. All cDNA samples were measured in 
duplicate. Ribosomal protein large protein 38 (Rplp38) was used as the housekeeping 
gene control for ΔCT calculation [ΔCT = (CT of the target gene) – (average CT of 
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housekeeping genes)]. Primer sequences were listed in Additional file 3. Fold expression 
values were calculated using 2-ΔΔCT methods(Livak & Schmittgen 2001), where ΔΔCT = 
(ΔCT of the treatment sample) – (ΔCT of control treatment samples) with no added IGF1 
as control treatment and normalized to 1. Statistical significance was determined by 
ANOVA.  
4.3.3 Primary Myoblast Isolation and Culture 
Primary myoblasts were isolated from hind limb skeletal muscles at 3-5 weeks of age. 
Muscles were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS), minced and 
digested in type I collagenase and dispase B mixture (Roche Applied Science, 
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm 
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris 
and then plated on culture dishes. In 3 days, the cells together with the small debris were 
collected and digested with 0.025% trypsin for 10 minutes with agitation. Cells were 
seeded in growth media (F-10 Ham’s medium supplemented with 20 % fetal bovine 
serum, 100 units of penicillin, 100 µg of streptomycin,0. 292 mg/ml of L-glutamine, , and 
4 ng/mL basic fibroblast growth factor) on rat-tail collagen (Roche Applied Science)-
coated dishes with preplating on non-coated plates for 45 minutes to deplete fibroblasts 
as previous described (Waddell et al. 2010; Liu et al. 2012). Myoblasts were 
differentiated into myotubes after plating cells at approximately 80% confluency on 
Matrigel (BD Biosciences, San Jose, CA USA) coated plates and the addition of fusion 
media consisting of DMEM supplemented with 5 % horse serum, 100 units of penicillin, 
100 µg of streptomycin, and 0. 292 mg/ml of L-glutamine. Long®R3 IGF1 (Sigma-
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Aldrich Co, St Louis, MO USA) was added to the fusion medium for 15 minutes at 3 
days after differentiation. Cells were collected for analysis of protein expression.  
4.3.4 Protein Extraction and Western Blots Analysis  
Semimembranosus and supraspinatus muscles were extracted from 4 callipyge and 4 
normal lambs at 30-35 days. Samples were frozen immediately after dissection and 
homogenized in RIPA buffer [50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 10 % 
TritonX100, 0.5 % Deoxycholate, 0.1 % SDS and 1 × complete protease inhibitor (Roche 
Applied Science)]. Samples were centrifuged at 10,000 × g for 10 minutes at 4 ℃. The 
supernatant was transferred into ultracentrifuge tubes and centrifuged at 50,000 × g for 15 
minutes at 4 ℃.  
Proteins were quantified by BCA assay (Thermo Fisher Scientific Inc, Rockford, IL 
USA) per manufacturer’s recommendation. A total of 60 µg of protein from each muscle 
sample was diluted in SDS loading buffer, denatured by heating for 5 minutes in boiling 
water and loaded in the 6 %-18 % gradient SDS-PAGE gel. The gel was transferred to 
PVDF membrane by semi-dry transfer using 20 % methanol, 40 mM glycine, 0.15 % 
ethanolamine, 0.2% SDS at 180 mA for 1h 45 min. PVDF membrane was blocked 
overnight with agitation in 5% sodium caseinate in PBS with 0.1 % Tween 20. 
Antibodies used for blotting were goat polyclonal anti-Park7 (sc-27006, Santa Cruz 
Biotechnology, Santa Cruz, CA USA), anti-DLK1 (provided by Dr. Ross L. Tellam, 
CSIRO), and secondary antibodies were rabbit anti-goat antibody conjugated HRP or 
goat anti-rabbit conjugated HRP respectively. The blots were incubated in primary 
antibody 2 hours at room temperature with a dilution of 1:1000. After washing 3 times 
with DPBS, the blots were incubated with secondary antibody with dilution of 1:20000. 
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Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) was used 
to detect HRP on immunoblots. The blots were visualized using Gel Logic 2200 PRO 
(Carestream Molecular Imaging System) with exposure times of 2-6 minutes. Carestream 
Molecular Imaging Software was used to quantify the chemiluminescent signal intensity.  
4.3.5 Analysis of Myotube Differentiation and Size 
Primary myotubes were fixed in 4 % formaldehyde and permeabilized in 0.5 % Triton 
X-100. Cells were blocked in 1 % bovine serum albumin (BSA) in PBS for 1 hour at 
room temperature and stained with 1:1000 anti-myosin heavy chain antibody (MF20, 
Developmental Studies Hybridoma Bank, Iowa City, Iowa USA) for 2 hours. Cells were 
washed in PBS, and then incubated in 1:1000 Alexa Fluor 594-conjugated donkey anti-
mouse IgG secondary antibody (Life Technologies) for 1 hour. Finally, cells were 
mounted with Prolong Gold antifade reagent with DAPI (Life Technologies). The IP Lab 
software (Scanalytics Inc., Madison, WI USA) and Leica DM6000 microscope were used 
to acquire pictures. 
The fusion index was defined as the ratio of nuclei within the myotubes (>2 nuclei) to 
the total number of nuclei. The average number of nuclei per myotube was determined by 
counting over 500 nuclei from randomly chosen MHC-positive cells. Myotube diameters 
were measured at 5 points along the entire tube. A total of 150 counts were examined for 
each genotype in the experiment. 
4.3.6 In situ ELISA Quantification of Myosin Expression 
Primary myoblasts were put into Matrigel coated-96-well plate at a high density. The 
myoblasts were fused into myotubes for 3 days in fusion media with different 
concentration (12.5, 25, 50, 100 and 200 ng / mL) of IGF1. The mature myotubes were 
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fixed in 4 % formaldehyde in PBS for 5 minutes at room temperature, washed 3 times 
with PBS and permeabilized with 0.5 % Triton×100 for 5 minutes. After washing 3 times 
with PBS, the cells were blocked for 1 hour in 1 % BSA in PBS. Cells were incubated 
with anti-myosin heavy chain antibody (MF20, Developmental Studies Hybridoma Bank) 
diluted in 0.1 % BSA overnight at 4 ℃, and washed 5 times in PBS. Secondary antibody 
(Donkey anti-mouse IgG, Life Technologies) were diluted in 0.1 % BSA and filtered 
through 0.2 µM filters. Cells were incubated in secondary antibody for 1 hour and 
washed 5 times with PBS. 
The fluorescence signals were read on Tecan Genios Pro (Tecan Group Ltd., 
Morrisville, NC USA) plate reader and results were analyzed using SAS 9.2 software and 
ANOVA procedure with IGF1 and genotype as main effects.  
4.3.7 AKT Phosphorylation in Primary Myotubes 
Cultured primary myoblasts or myotubes were used to examine AKT phosphorylation. 
Different concentrations of IGF1 were added into culture for 15 minutes to induce 
phosphorylation of AKT. For the PTEN inhibitor experiment, different concentrations (0, 
100 nM and 800 nM) of VO-OHpic trihydrate (Sigma-Aldrich) were added into culture 
and incubated with myotubes for 15 minutes after removal of IGF1. For testing sustained 
activity of phosphorylation of AKT, IGF1 was removed 15 minutes after incubation with 
myotubes. The cells were incubated in normal differentiation conditions and cell lysis 
was collected at the indicated time points (0, 45, 90, 180, 360, 720 minutes). Cells 
attached to plates were rinsed with ice-cold DPBS, and scraped on ice in cell lysis buffer 
(50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM sodium fluoride, 1 % Triton 100, 1 X phos-
stop (Roche Applied Science) and 1 × complete protease inhibitor cocktail ). Cells were 
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collected in 1.5 mL microcentrifuge tubes, rotated for 45 minutes, and centrifuged at 
12,000 × g for 10 minutes at 4 ℃ to remove insoluble debris.  
A total of 45 µg protein from each cell sample was diluted in SDS loading buffer, and 
loaded in the 6 %-18 % gradient SDS-PAGE gel. The gel electrophoresis and transfer to 
PVDF membranes were the same as described above. The PVDF membranes were 
blocked in 5 % non-fat milk in Tris-Buffered Saline (TBS) with 0.1 % Tween 20 for 3 
hours. Antibodies used for blotting were rabbit polyclonal anti-AKT (Cat #: 4685, Cell 
Signaling Technology, Danvers, MA USA), anti-phospho-AKT (Ser473) (Cat #: 4695 
Cell Signaling Technology), anti-PTEN (Cat #: 9188 Cell Signaling Technology). The 
primary antibody was incubated at 4 ℃ overnight at a dilution of 1:1000. The goat anti-
rabbit conjugated HRP was used as secondary antibody and was incubated for 1 hour at 
4 ℃ at a dilution of 1:20000. The visualization of blots was the same as described above. 
4.4 Results 
4.4.1 Up-regulation of PARK7 in Hypertrophied Muscle of 
Callipyge Lambs  
Semimembranosus and supraspinatus muscle samples were collected from 4 
callipyge and 4 normal lambs at 30-35 days of age when muscle hypertrophy is 
detectable by muscle mass. The semimembranosus from the pelvic limb undergoes the 
largest magnitude of hypertrophy and supraspinatus from the thoracic limb does not 
become hypertrophied (Koohmaraie et al. 1995; Jackson et al. 1997b). Western blots 
(Figure 4.1A) showed that PARK7 protein expression was elevated about 3-fold 
(P=0.027; Figure 4.1B) in the semimembranosus of callipyge animals (+/C) but not in 
supraspinatus. Elevated levels of DLK1 protein were also confirmed in the callipyge 
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semimembranosus. No detectable DLK1 expression was found in the muscles of normal 
animals and non-hypertrophied muscles, along with a reduced PARK7 expression in 
these same animals and tissues.  
4.4.2 Effects of Park7 Genotype on Myosin Heavy Chain 
Gene Expression  
The initial Park7 (-/-) mouse was obtained from Jackson Laboratory and back crossed 
with C57BL6 mice to generate Park7 (+/+), (+/-) and (-/-) littermate mice. Live animal 
body weights were monitored and collected from 3 – 6 weeks of age. Mice were 
euthanized at 6 weeks and carcass (muscle and skeleton) weight and internal organs 
weights were collected. The phenotypic data from male and female mice was analyzed 
separately to account for gender differences. No significant differences were found 
between genotypes for analysis of live weight by age, carcass weight by live weight, or 
organ weight by live weight analysis in males or females (Figure B.1 and Table B1).  
The expression of PARK7 protein in the vastus lateralis muscle was examined to 
verify the loss of expression in Park7 (-/-) mice (Figure 4.2). The results showed that the 
expression of PARK7 was easily detectable in the muscles in Park7 (+/+) and Park7 (+/-) 
animals, with lower expression in heterozygotes (+/-). No PARK7 protein was detectable 
in Park7 (-/-) muscles.  
Primary myoblasts were isolated from Park7 (+/+) and Park7 (-/-) animals and fused 
into myotubes in order to model the effect of Park7 levels on growth and myosin 
expression. The relative sizes of myotubes were determined after 72hours of 
differentiation in fusion media (Figure 4.3A). The fusion index was calculated to 
determine the proportion of myoblasts that fused into myotubes, and myotube diameters 
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were measured to estimate relative myotube size. There were no differences (p=0.4103) 
in the fusion index between the Park7 (-/-) and (+/+) cultures (Figure 4.3B). Park7 (+/+) 
myotubes were significantly larger (1.6-fold; p<0.0001) than Park7 (-/-) myotubes 
(Figure 4.3C). These results indicated that Park7 activity can influence myotube growth 
through a hypertrophy mechanism. An in vitro ELISA assay was performed to detect 
total sarcomeric myosin protein accretion to test the hypertrophy mechanism. IGF1 
treatments were included due to its well-established role in regulating muscle 
hypertrophy (Bodine et al. 2001; Rommel et al. 2001). Statistical analysis (Figure 4.4) 
indicated the overall effect of genotype was significant (p=0.0471) with the Park7 (+/+) 
myotubes having about 10% higher myosin expression than Park7 (-/-) myotubes, 
regardless of IGF1 treatment. All IGF1 treatments had a significant effect compared to no 
added IGF1 (p=0.0015), with 34 % higher myosin expression in IGF1 treated myotubes. 
However, the genotype by IGF1 interaction effect was not significant (p=0.5208).  
Quantitative PCR was used to detect the effect of Park7 genotype on Myh4, Myh7, 
Myh8 and Myh3 expression in IGF1 treated mature myotubes (Figure 4.5). The mRNA 
abundance of Myh4 was 40 % greater (p=0.0032) in Park7 (+/+) myotubes, relative to 
Park7 (-/-) myotubes. The addition of IGF1 in culture induced significantly higher Myh4 
expression with 1.6-fold increase at 10 ng / mL, 1.9-fold increase at 25 ng / mL and 1.3-
fold increase at 50 ng / mL of IGF1 respectively. The Myh7 and Myh8 genes had similar 
expression patterns as Myh4. The mRNA abundance of Myh7 and Myh8 were increased 
20 % (p=0.0018) and 30 % (p=0.0001) respectively in Park7 (+/+) myotubes. IGF1 also 
stimulated Myh7 and Myh8 mRNA expression, but only at the lower concentration (10 ng 
/ mL) with 23 % increase in Myh7 and 10 % increase in Myh8 respectively, relative to the 
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treatment without IGF1. At the high concentration of IGF1 (50 ng / mL), Myh7 
expression dropped 12 % and Myh8 expression dropped 16 % compared to the treatment 
without IGF1. Myh3 was the only isoform measured that showed no genotype effect or 
IGF1 effect. There was no significant genotype by IGF1 interactions for the four myosin 
isoforms.  
4.4.3 Effect of Park7 Genotype on Phosphorylation Level of 
AKT (S473)  
In order to explore the mechanism of Park7 regulation on myotube size and myosin 
gene expression, a series of experiments were conducted to assess the activation of AKT 
by phosphorylation at S473 in presence or absence of Park7. It has been demonstrated 
that PARK7 can suppress PTEN phosphatase activity, which would have the effect of 
increasing receptor tyrosine kinase signaling through AKT (Kim et al. 2005a). IGF1 was 
used to test the effect of Park7 genotype on the phosphorylation of AKT. The level of 
phosphorylation of AKT was elevated in Park7 (+/+) myotubes relative to Park7 (-/-) in 
5% horse serum differentiation media without added IGF1 (Figure 4.6). The 
phosphorylation of AKT was substantially elevated in Park7 (+/+) myotubes at all levels 
of added IGF1. To investigate if the activity of PARK7 could be mimicked by inhibition 
of PTEN function, VO-OHpic trihydrate, a known effective PTEN inhibitor (Rosivatz et 
al. 2006) was introduced into this study. Myotubes were first treated with IGF1 (5 ng / 
mL) for 15 minutes to induce increased phosphorylation of AKT. Different 
concentrations of VO-OHpic trihydrate was then added for an additional 15 minutes  
after removing IGF1. The addition of VO-OHpic trihydrate at 800 nM increased the level 
of AKT phosphorylation in Park7 (-/-) myotubes and eliminated the differences between 
105 
 
the two Park7 genotypes (Figure 4.7A). There were no detectable differences in PTEN 
protein levels (Figure 4.7A) or RNA expression (Figure 4.7B, p= 0.6057). This indicates 
that PARK7 inhibits the activity of PTEN but not its expression levels. 
Since increased phosphorylation of AKT was found in Park7 (+/+) myotubes, the 
timing and duration of the elevated phospho-AKT was tested. Myotubes were treated 
with IGF1 for 15 minutes and protein was collected at several time points up to 12 hours. 
Western blots showed increased phosphorylation of AKT in Park7 (+/+) myotubes 
(Figure 4.8A). Quantitative analysis of relative signal intensity based on the ratio of 
phospho-AKT to total AKT indicated a 2-fold higher level of P-AKT in Park7 (+/+) 
myotubes relative to Park7 (-/-) myotubes with no added IGF1 (Figure 4.8B). The level 
of AKT phosphorylation in Park7 (+/+) myotubes reached its maximum at 45 minutes at 
3.4-fold higher signal intensity than Park7 (-/-) myotubes after removal of IGF1. Park7 (-
/-) myotubes had maximum phosphorylation at 90 minutes and the decreases in 
phosphorylation over time were similar with Park7 (+/+) myotubes, generally 
maintaining approximately 20% higher signal intensity through 12 hours.  
4.5 Discussion  
Overall, the present results indicate that differential expression of Park7 altered the 
response to IGF1 signaling through inhibition of PTEN, and further affected myotube 
growth and protein accretion. A previous study showed elevated PARK7 expression in 
callipyge sheep at the transcriptional level (Fleming-Waddell et al. 2009). These western 
blot results confirmed the increased expression of PARK7 in hypertrophied muscles at 
the protein level.  
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The Park7 (-/-) mice lack obvious developmental abnormalities and no significant 
difference was found between Park7 (+/+) and (-/-) animals in vivo when we compared 
body weight, carcass weight and internal organ weight. These results were consistent 
with others findings, which indicated no significant differences in body weights between 
the two genotypes from birth to 12 months (Chandran et al. 2008). Skeletal muscle 
growth in live animals is stimulated by different hormones such as IGF1, androgens and 
β-adrenergic agonists to initiate multiple signaling pathways to regulate growth. 
Therefore, the loss of Park7 functions in Park7 (-/-) mice may be compensated by other 
hormones and signaling pathways in vivo. Furthermore, the viability of Park7 (-/-) mice 
suggests that Park7 is not essential for animal growth. An in vitro cell culture model was 
introduced to this study to investigate the effects of differential expression of Park7 in 
myogenesis. The in vitro comparison of myotube size showed Park7 (+/+) myotubes had 
a bigger size and higher myosin expression, but no significant change in the fusion index, 
which indicates Park7 causes myotube hypertrophy (increased myofiber diameter), not 
hyperplasia (increased myofiber number). This result also supports the idea that PARK7 
is part of the physiological mechanism for the induced muscle hypertrophy in callipyge 
lambs. 
The PI3K/ AKT pathway is one of the primary targets of IGF1 signaling and has been 
well characterized for its positive regulation on muscle growth (Bodine et al. 2001; 
Rommel et al. 2001). The postnatal muscle mass and myofiber size generally reflects 
protein accretion. AKT stimulates protein synthesis by activating mammalian target of 
rapamycin (mTOR) and its downstream effectors. This study showed that the Park7 (+/+) 
myotubes had a higher increase of phosphorylation of AKT compared to Park7 (-/-) after 
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IGF1 stimulation, which induced significantly more total sarcomeric protein accretion. 
Notably, this increase of protein accretion reached saturation at IGF1 concentrations of 
25 ng / mL and above. Higher levels of Myh4, Myh7 and Myh8 mRNA expression were 
also observed in Park7 (-/-) myotubes. Myosin transcription as well as translation was 
elevated. Myh3, also known as embryonic myosin heavy chain 3, was the only myosin 
gene assayed that was not affected by the Park7 genotype. Muscle contractile 
characteristics partially depend on the expression of myosin heavy chain isoforms. The 
hypertrophied muscles in callipyge sheep have an increased size of fast twitch glycolytic 
myofibers along with increased MYH4 expression and a decreased frequency of oxidative 
fibers (Carpenter et al. 1996; Carpenter & Cockett 2000). Over-expression of 
constitutively active Akt had been reported to promote myofiber growth with no effect on 
fiber specification in regenerating skeletal muscle (Pallafacchina et al. 2002). The use of 
a doxycycline-inducible Akt transgene in mice resulted in the hypertrophy of glycolytic 
myofibers, but not oxidative myofibers (Izumiya et al. 2008). A recent study supported 
this result by identifying a regulatory cascade of AKT activation to drive the metabolic 
and contractile specification of fast-twitch muscle fibers (Meng et al. 2013). Similarly, 
the results presented here are congruent with the up-regulation of Myh4 and the enhanced 
activation of AKT in the presence of Park7. Interestingly, double-muscled cattle, in 
which the expression of Park7 gene is also elevated, have an increased proportion of fast-
twitch glycolytic fibers as well (Stavaux et al. 1994). 
The difference of phosphorylation of AKT in Park7 (+/+) and Park7 (-/-) myotubes 
was eliminated when treated with higher concentrations of PTEN inhibitor, but the total 
amount of PTEN had not been changed, suggesting PARK7 acts through inhibition of 
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PTEN phosphatase activity, not total PTEN expression. This result was consistent with 
the findings of Kim et al. (Kim et al. 2005a; Kim et al. 2009). In their studies, they also 
examined the phosphorylation level of PTEN at Ser380, Thr382, Thr383 and Ser385 in 
Park7 transfected NIH3T3 cells, but no change was detected; indicating the inhibition of 
PTEN phosphatase activity by PARK7 is not affected by phosphorylation of PTEN. The 
detailed mechanism on how PARK7 inhibits PTEN phosphatase activity remains unclear. 
Some studies have proposed that PARK7 can directly bind to PTEN to confer an inactive 
conformation by forming a disulfide bond between cys71and cys124 of PTEN upon 
oxidative stress (Lee et al. 2002; Kwon et al. 2004; Kim et al. 2009). It has also been 
speculated that the interaction of PARK7 to PTEN may accelerate the oxidation of PTEN, 
thus inactivating the PTEN function (Kim et al. 2009). Further analysis will be necessary 
to determine how PARK7 inhibits PTEN function in muscle.  
In live animals, skeletal muscle responds to the natural IGF1 stimulation to grow. 
With the increased level of PARK7, the AKT phosphorylation in callipyge animals 
would be expected to be higher relative to normal lambs with natural IGF1 stimulation, 
thus causing increased muscle mass. However, the steady state level of AKT 
phosphorylation would be difficult to determine in the live lambs since IGF1 stimulation 
of individual in animals would be variable. Stress responses associated with 
transportation and slaughter could rapidly alter levels of AKT phosphorylation. However, 
this cell culture study provides evidence that PARK7 activity in muscle may be part of 





In summary, the present study provided a novel insight into the function of PARK7 in 
the regulation of skeletal muscle growth. The effect of PARK7 in muscle growth can 
contribute to increased protein synthesis and result in myotube hypertrophy. Since 
PARK7 can positively regulate the PI3K/AKT pathway by inhibition of PTEN 
phosphatase activity, elevated expression of PARK7 in the muscles of callipyge lambs 
would lead to increased muscle growth in response to the normal IGF1 signaling present 
in young growing lambs. DLK1 and PARK7 expression were both up-regulated in 
hypertrophied muscle. Since DLK1 is one of the causative genes for the callipyge 
phenotype due to the inheritance of the mutation, PARK7 could be considered a 
downstream response to DLK1 signaling. These results support the hypothesis that 
elevated expression of PARK7 is part of the physiological mechanism for the induced 
muscle hypertrophy in callipyge lambs. In addition to the callipyge animals, the up-
regulation of PARK7 in double muscled cattle also suggests the essential role of PARK7 
in regulating muscle mass. These combined results indicated that PARK7 is a key 
modulator of PI3K/AKT pathway controlling muscle growth and protein accretion. 
Identifying methods to increase the expression of PARK7 in muscle could provide a 
mechanism to increase livestock muscle growth and production efficiency or prevent the 
loss of muscle mass due to disease or aging.  
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Figure 4.1 PARK7 Protein 
A: There were higher levels of PARK7 and DLK1 proteins in the semimembranosus (SM)
of callipyge lambs (+/C) relative to normal lambs (+/+), but no difference in PARK7 or 
DLK1 protein levels in the supraspinatus (SS). B: Quantitative analysis of PARK7 
protein expression was significantly higher in the SM of callipyge lambs. α
the control for protein loading. Data shown are mean signal intensity ± SE. The p
for comparisons between genotypes for each muscle is given. 
 
 
Figure 4.2 PARK7 Protein
PARK7 protein expression was not detectable in vastus lateralis in Park7 (
Tubulin was used as a control to show equal protein loading. 
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Figure 4.3 Comparison of Myotube Size B
A: Primary myoblasts were induced to differentiate for 72 hours and stained with an 
antibody for total myosin heavy chain (red: MF20) and DNA (blue
significant differences were detected between the two genotypes for fusion index. C: The 
distribution of myotube diameters were significantly larger (P<.0001) for 
1.70±0.24) than Park7 (-/
 
etween Park7 (+/+) and Park7 
: DAPI). B: No 









Figure 4.4 Detection of Total Sarcomere Myosin Expression in Myotubes by ELISA.  
There were significant effects for genotype and IGF1 treatment, but no significant 
interaction. The Park7 (+/+) myotubes had significantly more total sarcomere myosin 
expression than Park7 (-/-) myotubes and IGF1 induced significant higher sarcomere 
myosin expression at all concentrations. 
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Figure 4.5 Detection of Myosin Heavy Chain Isoform mRNA Levels in Myotubes by 
Quantitative PCR.  
Primary myoblasts were isolated from 2 animals for each genotype. IGF1 was added to 
the culture 24hours after differentiation at the indicated concentration. A: Myh4 (Myosin 
Heavy Chain, Type IIB) expression; B: Myh7 (Myosin Heavy Chain, Type I) expression; 
C: Myh8 (Myosin Heavy Chain, perinatal) expression; D: Myh3 expression (Myosin 
Heavy Chain, embryonic). Myh4, Myh7 and Myh8 had significantly higher expression in 
Park7 (+/+) myotubes, however, no significant differences were detected for Myh3. The 
mean fold change value was calculated using the 2 –ΔΔCt method with Rplp38 as the 
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Figure 4.8 Sustained Activity of AKT Phosphorylation (S473) in Park7 (+/+) and Park7 
(-/-) Myotubes After IGF1 Stimulation.  
Mature myotubes were stimulated with IGF1 (12.5 ng / mL) for 15 minutes. Total protein 
was extracted at the indicated time after removal of IGF1. A: Western blot analysis 
showed a higher level of AKT phosphorylation in Park7 (+/+) relative to Park7 (-/-) 
myotubes. B: Analysis of the signal intensity for the P-AKT/total AKT showed the Park7 
(+/+) myotubes had higher AKT phosphorylation without added IGF1 and had a 3.4 fold 
higher level of P-AKT than Park7 (-/-) myotubes at 45 minutes after IGF1 treatment. The 
decline in AKT phosphorylation was similar between the genotypes after 90 minutes with 





CHAPTER 5. IMPLICATION AND FUTURE DIRECTIONS 
In the meat animal industry, there is always a need to identify genes that can increase 
meat production. The callipyge sheep is an ideal model to screen these genes due to its 
muscle hypertrophy phenotype. Functional genomics experiments, such as microarrays, 
facilitate to narrow the candidate genes from a pool of genes to a certain number. The 
follow-up experiments after functional genomics are essentially required to validate the 
expression of candidate genes in multiple muscles, and to determine the true molecular 
mechanisms on how these candidate genes regulate protein accretion and muscle growth. 
The work presented in this dissertation contains two themes. One is to identify the 
potential downstream effector genes that respond to the up-regulation of DLK1 and / or 
RTL1 in hypertrophied muscles, and the other one is to explore the functional role of 
PARK7, one of the candidate genes from the first study, in muscle growth and 
development. These two studies provide insights on the potential genes network in 
callipyge sheep and demonstrate how PARK7 could alter myotube size and myosin gene 
expression. However, there are other working hypotheses developed from this work and 
these should be tested in the future. This chapter covers these hypotheses from the two 
studies in this thesis.
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5.1 Possible Physiological Roles of Effector Genes in Callipyge Sheep 
The first study (Chapter 3) identified PARK7, DNTTIP1, SLC22A3, METTL21E and 
PDE4D as the potential secondary effector genes in responding to DLK1 (primary 
inducer) signaling and also indicated PARK7 and DNTTIP1 could be the components in 
the signaling of DLK1 induced up-regulation of Myh4 (see Chapter 3). Though the 
current thesis only explores the function of PARK7 in muscle growth (see Chapter 4), 
specific studies on the regulations of other genes should be performed in the future in 
order to understand the gene regulation in callipyge muscles. Here are some clues that 
may facilitate future studies. 
DNTTIP1 encodes TdT interacting factor 1 (TdIF1), which was first identified as a 
protein that directly binds to terminal deoxynucleotidyltransferase (TdT), and negatively 
regulates TdT activity. There are few studies on DNTTIP1 in muscle growth. A recent 
study revealed that DNTTIP1 preferentially binds to the sequence 5′-GNTGCATG-3′ 
following an AT-tract, through its helix-turn-helix and AT-hook motifs (Kubota et al. 
2013). Since the increased MYH4 luciferase activity was reported in Chapter 3, the 
sequence analysis on MYH4 promoter region was conducted. However, no positive 
results were found. Nevertheless, the three DNA-binding regions of DNTTIP1 [within 
residues 1–75, an AT-hook domain between residues 159–173, and a predicted helix-
turn-helix (HTH) region between residues 184–243] (Kubota et al. 2007) makes it with 
strong DNA-binding capacity. Herein, we cannot exclude the possibility that DNTTIP1 
may bind to other DNA sequence to regulate MYH4 transcriptional activity. Identification 
of the binding sequences of DNTTIP1 may be the first step to study its regulatory 
function. Moreover, DNTTIP1 is reported to interact with HDAC1 and HDAC2 during 
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the M phase (Bantscheff et al. 2011). The HDACs usually repress transcriptional activity 
by deacetylating histones (Segre & Chiocca 2011). HDAC1 and HDAC2 interact with 
many transcriptional factors, including Rb binding protein-1, Sp1, and ZEB1(Kao et al. 
2000; Aghdassi et al. 2012) in order to regulate gene transcription. They are subjected to 
various post-translational modifications, such as phosphorylation, ubiquitination, and 
SUMOylation (Segre & Chiocca 2011). Based on the multiple function of the HDAC 
complex, the other option for future studies is to start with the interaction with HDACs 
and examine the regulatory role of this complex on gene expression during myogenisis.  
SLC22A3 / OCT3 (Solute carrier 22A3 / Organic cation transporter 3) mediates the 
uptake of many important endogenous amines and basic drugs in a variety of tissues 
(Chen et al. 2013). Transported endogenous substrates of human OCTs include: 
monoamine neurotransmitters, neuromodulators, and other compounds such as choline, 
creatinine, and guanidine [for reviews, see (Nies et al. 2011)]. Therefore, the studies on 
SLC22A3 could start with the examination of the substrates of SLC22A3 in muscles, and 
the inhibitors of SLC22A3 can be used here. Furthermore, it is postulated that SLC22A3 
has a role in the overall regulation of neurotransmission and maintenance of homeostasis 
within the central nervous system (Wu et al. 1998; Zwart et al. 2001). Since the muscle 
activity is controlled by the motor neuron, the other study could be conducted on the 
regulation of SLC22A3 in neuron function in muscle.  
The functions of METTL21E and PDE4D in muscles have not been characterized. 
METTL21E, also known as protein-lysine methyltransferase METTL21E in Bos taurus, 
shares 51 % similarity to human METTL21C whose protein family is consisted of other 9 
proteins (Cloutier et al. 2013). Methyltransferases catalyze the transfer of a methyl group 
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(CH3) from a donor, generally S-adenosyl-L-methionine (AdoMet), to various acceptor 
molecules, such as proteins, DNA, RNA, lipids, and small metabolites (Martin & 
McMillan 2002; Schubert et al. 2003). The function of METTL21E can be determined by 
identifying its acceptors in muscles. Furthermore, a recent study has shown that human 
METTL22 family of proteins could interact with molecular chaperones to regulate their 
activities. This study also determined the modification sites of these chaperones (Cloutier 
et al. 2013). Notably, PARK7 has been suggested to have the chaperone activity due to 
the structural similarities to Hsp31 (see Chapter 1). Therefore, the other starting point of 
the future study is to examine whether METTL21E could modify the activity of PARK7, 
and in turn to regulate other genes expression. The affinity purification coupled to mass 
spectrometry method could be used in this study. The phosphodiesterases (PDEs) are 
enzymes that catalyze the hydrolysis of cyclic nucleotides (cAMP and cGMP). Using 
isoform-specific PDE inhibitors, the function of PDE4D has been proved to be essential 
for signaling of β2-adrenergic receptor (β2-AR), which is responsible for both the skeletal 
muscle hypertrophy and anti-atrophy effects of the β-adrenergic agonist (Hinkle et al. 
2002; Xiang et al. 2005; Bruss et al. 2008). Therefore, future studies could be conducted 
to determine the effects of PDE4D in response of β-adrenergic agonist stimulation in 
muscles. Since most of PDE4D knockout mice died within four weeks of age, the 
muscle-specific knockout model could be helpful here (Jin et al. 1999).   
5.2 PARK7 as a Muscle Growth Regulator 
The second study (Chapter 4) characterized a positive role of PARK7 in regulating 
muscle growth. PARK7 is a molecule that occupies a pivotal position in cellular biology, 
because a loss or gain of its function drives abnormal cellular responses. This loss or gain 
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may lead either to cell death (loss of function in neurodegenerative disease) or 
unregulated cell survival (gain of function in cancer), respectively (see Chapter1). In the 
present thesis, we used the loss-of-function model to determine that the presence of 
PARK7 alters the myotube size and myosin gene expression in vitro. However, there is no 
obvious phenotype observed in vivo, which could be a result of the multiple hormone 
stimulation, such as IGF1, androgens and β-adrenergic agonists. These different hormone 
stimulations initiate multiple signaling pathways to regulate growth. Therefore, the loss 
of Park7 functions in Park7 (-/-) mice may be compensated by other hormones and 
signaling pathways in vivo. Since the gain-of-function and loss-of-function in PARK7 
leads to different cellular responses, the over-expression model will be needed to further 
determine the role of PARK7 in muscle growth. Furthermore, the expression of PARK7 
was highly elevated in hypertrophied muscles. Thus the gain-of-function model is more 
appropriate to mimic the effects of PARK7 in muscle hypertrophy. 
Opposite from muscle hypertrophy, which defines as the increase in muscle mass due 
to overall rates of protein synthesis exceed rates of protein degradation, the muscle 
atrophy means the decrease in muscle mass and fiber size when protein degradation rates 
exceed protein synthesis. Muscle atrophy results from aging, starvation, cancer, diabetes, 
bed rest, loss of neural input (denervation, motor neuron disease), or catabolic hormonal 
stimulation (corticosteroids). To better understand the role of PARK7 in muscle growth 
and development, characterization its function in muscle atrophy will be necessary.  
Increased levels of Park7 were identified in sporadic inclusion-body myositis (s-
IBM), which is a progressive muscle disease associated with aging and is manifested by 
pronounced muscle weakness and wasting (Terracciano et al. 2008). PARK7 is highly 
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oxidized and increased in the mitochondria in s-IBM muscle fibers (Terracciano et al. 
2008). A detailed description on the effects of PARK7 on maintaining mitochondrial 
homeostasis was given in Chapter 1. Though not fully understood, Park7 was reported to 
act in parallel with the Pink1 and Parkin to positively control mitochondrial homeostasis 
and autophagy (Thomas et al. 2011). The autophagy-lysosome system is one of the major 
proteolytic pathways in the cells that are coordinately activated in atrophying, and is 
crucial for atrophying [for reviews, see (Sandri 2010)]. For example, myofiber atrophy 
induced in vivo by over-expression of constitutively active FoxO3 requires autophagy. 
Conversely, knocking down the critical autophagy gene, LC3, by RNAi partially prevents 
FoxO3-mediated muscle loss (Mammucari et al. 2007). Therefore, future studies should 
address underlying molecular mechanisms on how PARK7 affects atrophy through 
modulating autophagy. In addition to the cell autophagy, the positive regulation of 
PARK7 in NF-κB signaling (see Chapter 1) also implies its role in muscle atrophy, since 
NF-κB signaling is known to induce muscle atrophy [for review, see (Peterson et al. 
2011)]. The identification of Cezanne, a known deubiquitination enzyme that inhibits 
NF-κB activity, as one of the PARK7 binding partners provides a clue to how PARK7 is 
involved in the NF-κB pathway. However, detailed working machinery on how 
Cezanne/PARK7 complex exert its effects as well as identification of other NF-κB targets 
regulated by PARK7 will be needed in future study. 
5.3 Conclusions 
The two studies presented in this dissertation provide insights on the genes regulation 
in callipyge muscle hypertrophy. This chapter describes a few of the common hypothesis 
and possible pathways arising from these two studies that may contribute to understand 
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the altered muscle growth in callipyge sheep. The data presented here requires extensive 
further studies, and undoubtedly new future technologies will facilitate these studies in 
order to be more precise and efforts-saving. Since several of the DLK1 downstream 
genes play roles in human cancers, better understanding the signals in DLK1-induced 
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Appendix A Gene Expression Data for 7-muscle Experiment 
Table A. 1 Quantitative PCR Primer Sequences and Amplification Conditions 
Gene 
Symbol Gene Title Primer Sequence 
Anneal 
Temp 
DLK1 Delta-Like 1 homolog (Drosophila) F5’-GGTTACTTCAAATGGCGTCAA-3’ 58˚C 
R5’-GGATTCCGCACAAACAACTC-3’ 
RTL1 Retrotransposon-like , Paternally expressed gene 11 F5'-AGGAACACCGCTGTGGAGGTAGAA-3' 55˚C 
R5'-ACAGCAGAGGCAGCCAAGCA-3' 
APOD Apolipoprotein D F5’-TCTTGCTTTGCTTTTCCCCTATACC-3’ 55˚C 
R5’-AGCTTGCCTTGGGTTCTTCTCC-3’ 
LPL Lipoprotein Lipase F5’-TCACGTATGAAGCCCCACAT-3’ 55˚C 
R5’-AAGGAGTGTTCCGGCACCA-3’ 
PDE7A cAMP Specific Phosphodiesterase, 7A F 5'-GGAGGTCGGCCGTGAGAGAT-3' 55˚C 
R 5'-TTCGTCAAAGGGAGGGACGAGAA-3' 
PARK7 Parkinson disease (autosomal recessive, early onset) 7 F5’-CGAGTCCGCTGCTGTGA-3’ 51˚C 
R5’-TGACTTCCGTTCATCATTTTGT-3’ 
DNTTIP Deoxynucleotidyltransferase, Terminal, Interacting  F 5'-ATGGCCTACCTTCTCATTGA-3' 49˚C 
Protein 1 R 5'-TGTACTTCCGCATCTTCTCA-3' 
BHLHB3 Basic Helix-Loop-Helix domain containing, class B3 F5’-ATGTAAGGGGTGAGACACAACAGT-3’ 54˚C 
R5’-CAAACAGTAGCAACAGCAGCAG-3’ 
METTL21E Similar to SAM dependent methyltransferase family F 5’-GCCCTTGTTCTGTGCTATT-3’ 50˚C 








Symbol Gene Title Primer Sequence 
Anneal 
Temp 
PFKM Phosphofructokinase, Muscle F 5’-GAGCCCAACTCCATTTGACA-3’ 50˚C 
 R 5’-CTTACGCATCCCCAGAACAC-3’ 
RSPRY1 Ring Finger and SPRY Domain Containing 1 F 5’-CTTCCTTCCCCACCGTTTC-3’ 50˚C 
R 5’-AATCCAGCACCCCAACAAGT-3’ 
PDE4D cAMP Specific Phosphodiesterase 4D F5’-TAAACAGTACAAAGGGGACACT-3’ 50˚C 
R5’-CTGTAAGAGAGGCTAAGAAACC-3’ 
HDAC9 Histone Deacetylase 9 F5'-CCTTTTCACTGGTTCCAGGTAG-3' 55˚C 
R5'-GGCTGAGCAGGCTTTTGTATAAT-3' 
RPLPO Ribosomal Protein , Large, P0 F 5’-CAACCCTGAAGTGCTTGACAT-3’ 50˚C 
R 5’-AGGCAGATGGATGGATCAGCCA-3’ 
CDO1 Cysteine Dioxygenase Type 1 F5’- AAGGTCCAGCGAAGTTCC-3’ 52˚C 
R5’- CAGGGGCTCTAGGCTAACA-3’ 
MAPK6 Mitogen Activated Protein Kinase 6 F5’-TCAAAGTCAGTAAGCCGAGAA-3’ 52˚C 
R5’-AACAGTCCTCCCCACCAC-3’ 
SLC22A3 Similar to Solute Carrier Family 22 member 3 F5’-TGAACAAAGGGAGAATGTAGGTA-3’ 52˚C 
R5’-GCCTTAAAGCACATCAGCAT-3’ 
TXNIP Thioredoxin Interacting Protein F5’-ATGTTGCCATGAGAAACCAGAA-3’ 52˚C 
R5’-TAAGGCGGAGAGTGACTGACC-3’ 
KCNN3 Potassium Intermediate/Small Conductance Calcium- F5’-CGGGAAACGTGGCTAATCTACA-3’ 55˚C 
Activated Channel, family N3 R5’-GTGTTGGCTTGGTCACTCAGCT-3’ 
 








Symbol Gene Title Primer Sequence 
Anneal 
Temp 
COQ10A Coenzyme Q10 homolog A F 5’-GCTGTGCGGTCATCTCT-3’  50˚C 
R 5’-ATTTCAGGTAGGCAAGGTTA-3’  
IDH2 Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial F5’-CTGGACGCGTGGCCTAGAACA-3’ 59˚C 
R5’-TTGCTGAGGCCGTGGATGC-3’ 
FCGRT Fc Fragment of IgG, Receptor, Transporter, alpha F5’-TCGTCATCGGCTTATTCCT-3’ 52˚C 
R5’-GATGATCGGCAGTTGCTG-3’ 
AKR1C4 Aldo-keto Reductases 1C4 F5’-GGATCCCAACTATCATCAGA-3’ 48˚C 
R5’-GGTTTGCTTGTGCTTTTT-3’ 
MEG8 Maternal Expressed Gene 3, GTL2 variant D F 5'-CACTGAAAAGCACGTGCCTTCT-3' 54˚C 
R 5'-GATTTAGCATCTGCCATGGACAA-3' 
CABC1 Chaperone, ABC1 Activity of bc1 Complex Homolog  F5’-GAGCTGAGCAGTGCCAACAAGTA-3’ 57˚C 
(S. pombe) R5’-TAGGAGGCGGCAGTTCTCTG-3’ 
MEG3 Maternal Expressed gene 8 F5'-GCATAGACGAGGCGGTCAGTAAATG-3' 55˚C 
R5'-CGGAGCGCTGTGGGAGAATAA-3' 
MYH7 Myosin, Heavy Chain Type I, Skeletal Muscle, adult F 5'-AAGAACCTGCTGCGGCTG-3' 57˚C 
R 5'-CCAAGATGTGGCACGGCT-3' 




adult R 5'-CCCATAGCATCAGGACACGA-3' 
MYH4 Myosin, Heavy Chain Type IIB, Skeletal Muscle,  F 5'-AAATGCAAGTGCTATCCCAGAG-3' 54˚C 








Symbol  Gene Title Primer Sequence 
Anneal 
Temp 
MYH1 Myosin, Heavy Chain Type IIX, Skeletal Muscle,  F 5'-GGAGGAACAATCCAATGTCAAC-3' 52˚C 
adult R 5'-GTCACTTTTTAGCATTTGGATGAGTTA-3'  
Myh4 Myosin, Heavy Chain Type IIB, Skeletal Muscle,  F 5'- AGTCCCAGGTCAACAAGCTG-3' 55˚C 
(Mouse) adult R 5'-TTTCTCCTGTCACCTCTCAACA-3'  
DNTTIP1 Deoxynucleotidyltransferase, Terminal,  F 5'-ATGGCCTACCTTCTCATTGA-3' 49˚C 
(Mouse) Interacting Protein 1 R 5'-TGTACTTCCGCATCTTCTCA-3'   
Park7  Parkinson disease  F 5'-AGGTCCTACGGCTCTGTTG-3' 55˚C 
(Mouse) (autosomal recessive, early onset) 7 R 5'-CACAATGGCTAGTGCAAACTCA-3'  
Rplp38 Ribosomal protein large protein 38 F 5'-GAAGGATGCCAAGTCTGTCAA-3' 55˚C 






Table A. 2 Quantitative Analysis of Gene Expression 
Gene Genotype LD SM ST TB SS IS HT 
DLK1 +/C 4.800 ± 0.065 5.002 ± 0.135 4.782 ± 0.261 4.181 ± 0.130 4.086 ± 0.165 3.749 ± 0.182 3.552 ± 0.163 
+/+ 3.695 ± 0.056 3.813 ± 0.117 3.672 ± 0.226 3.528 ± 0.112 3.944 ± 0.143 3.566 ± 0.158 3.416 ± 0.141 
RTL1 +/C 5.359 ± 0.167 5.475 ± 0.095 5.215 ± 0.143 4.909 ± 0.059 4.556 ± 0.382 4.390 ± 0.308 2.466 ± 0.133 
+/+ 1.130 ± 0.145 1.000 ± 0.082 1.015 ± 0.124 1.023 ± 0.051 1.403 ± 0.331 1.000 ± 0.267 1.000 ± 0.094 
APOD +/C 5.994 ± 0.103 6.129 ± 0.070 5.908 ± 0.176 5.806 ± 0.179 5.272 ± 0.132 5.503 ± 0.132 4.442 ± 0.171 
+/+ 5.522 ± 0.089 5.649 ± 0.061 5.312 ± 0.152 5.115 ± 0.155 5.130 ± 0.114 5.234 ± 0.114 4.272 ± 0.148 
LPL +/C 4.988 ± 0.080 5.080 ± 0.059 5.065 ± 0.234 5.610 ± 0.110 5.643 ± 0.163 5.748 ± 0.145 6.285 ± 0.098 
+/+ 5.312 ± 0.069 5.522 ± 0.051 5.071 ± 0.202 5.718 ± 0.095 5.907 ± 0.141 5.860 ± 0.128 6.182 ± 0.085 
PDE7A +/C 5.012 ± 0.126 5.004 ± 0.145 5.052 ± 0.112 5.014 ± 0.147 4.565 ± 0.105 4.876 ± 0.147 4.943 ± 0.093 
+/+ 4.581 ± 0.109 4.700 ± 0.126 4.630 ± 0.097 4.691 ± 0.128 4.527 ± 0.091 4.884 ± 0.127 4.912 ± 0.081 
RPLPO(GSP) +/C 6.999 ± 0.144 6.953 ± 0.094 7.111 ± 0.188 6.997 ± 0.109 6.952 ± 0.095 7.164 ± 0.126 6.868 ± 0.081 
+/+ 6.994 ± 0.125 6.980 ± 0.081 6.742 ± 0.163 6.892 ± 0.095 6.841 ± 0.083 6.965 ± 0.109 6.793 ± 0.071 
PARK7 +/C 6.534 ± 0.095 6.671 ± 0.059 6.443 ± 0.084 6.389 ± 0.058 6.145 ± 0.103 6.191 ± 0.056 5.951 ± 0.055 
+/+ 6.047 ± 0.082 6.051 ± 0.051 5.900 ± 0.072 5.992 ± 0.050 5.954 ± 0.089 6.104 ± 0.048 5.877 ± 0.048 
DNTTIP +/C 5.547 ± 0.095 5.587 ± 0.078 5.473 ± 0.060 5.311 ± 0.127 4.669 ± 0.086 4.837 ± 0.087 4.735 ± 0.037 
+/+ 4.866 ± 0.082 5.027 ± 0.068 4.857 ± 0.052 4.721 ± 0.110 4.456 ± 0.086 4.602 ± 0.076 4.660 ± 0.032 
DEC2 +/C 4.772 ± 0.041 4.810 ± 0.047 4.828 ± 0.114 4.908 ± 0.070 5.001 ± 0.065 5.039 ± 0.099 4.853 ± 0.081 
+/+ 4.830 ± 0.036 4.927 ± 0.040 4.758 ± 0.098 4.994 ± 0.061 5.018 ± 0.056 4.994 ± 0.086 4.832 ± 0.070 
LOC513822 +/C 5.537 ± 0.101 5.706 ± 0.097 5.868 ± 0.106 5.768 ± 0.086 5.196 ± 0.184 5.407 ± 0.093 4.549 ± 0.166 
+/+ 4.708 ± 0.088 4.860 ± 0.084 4.925 ± 0.092 5.022 ± 0.074 4.995 ± 0.159 5.153 ± 0.080 4.442 ± 0.144 
PFKM +/C 6.259 ± 0.039 6.267 ± 0.025 6.182 ± 0.037 6.157 ± 0.096 5.584 ± 0.091 5.725 ± 0.159 5.504 ± 0.085 
+/+ 5.955 ± 0.034 6.024 ± 0.022 5.846 ± 0.032 5.864 ± 0.083 5.322 ± 0.079 5.564 ± 0.138 5.416 ± 0.074 
RSPRY1 +/C 4.489 ± 0.030 4.492 ± 0.040 4.490 ± 0.087 4.477 ± 0.029 4.394 ± 0.083 4.427 ± 0.032 4.421 ± 0.082 
+/+ 4.263 ± 0.026 4.293 ± 0.035 4.083 ± 0.075 4.230 ± 0.025 4.151 ± 0.072 4.300 ± 0.028 4.336 ± 0.071 
PDE4A +/C 5.941 ± 0.085 5.998 ± 0.114 5.861 ± 0.076 5.739 ± 0.073 5.611 ± 0.122 5.552 ± 0.120 4.769 ± 0.061 
+/+ 5.454 ± 0.073 5.501 ± 0.098 5.263 ± 0.066 5.272 ± 0.063 5.283 ± 0.106 5.349 ± 0.104 4.785 ± 0.053 
HDAC9 +/C 3.959 ± 0.076 3.889 ± 0.065 3.704 ± 0.134 4.131 ± 0.069 4.278 ± 0.089 4.327 ± 0.071 4.555 ± 0.060 





Gene Genotype LD SM ST TB SS IS HT 
RPLPO(RP) +/C 6.821 ± 0.048 6.763 ± 0.038 6.740 ± 0.067 6.768 ± 0.048 6.928 ± 0.067 6.784 ± 0.040 6.687 ± 0.062 
+/+ 6.838 ± 0.042 6.809 ± 0.033 6.643 ± 0.058 6.663 ± 0.042 6.779 ± 0.058 6.716 ± 0.035 6.660 ± 0.053 
CDO1 +/C 4.024 ± 0.201 3.943 ± 0.175 3.856 ± 0.288 4.111 ± 0.232 4.058 ± 0.156 4.211 ± 0.147 4.117 ± 0.097 
+/+ 4.307 ± 0.174 4.260 ± 0.151 3.723 ± 0.249 4.127 ± 0.201 4.126 ± 0.135 4.242 ± 0.128 3.930 ± 0.084 
MAPK6 +/C 5.739 ± 0.057 5.884 ± 0.087 5.939 ± 0.134 6.046 ± 0.059 5.413 ± 0.106 5.886 ± 0.099 5.365 ± 0.142 
+/+ 5.453 ± 0.049 5.550 ± 0.075 5.602 ± 0.116 5.730 ± 0.051 5.283 ± 0.092 5.738 ± 0.086 5.183 ± 0.123 
SLC22A3 +/C 3.454 ± 0.152 3.710 ± 0.183 3.320 ± 0.255 3.773 ± 0.189 3.517 ± 0.283 3.845 ± 0.165 4.129 ± 0.145 
+/+ 2.242 ± 0.132 2.459 ± 0.159 2.412 ± 0.211 2.961 ± 0.163 2.906 ± 0.245 3.404 ± 0.143 4.065 ± 0.125 
TXNIP +/C 6.054 ± 0.073 6.102 ± 0.078 6.107 ± 0.166 6.339 ± 0.061 6.083 ± 0.098 6.328 ± 0.054 6.564 ± 0.056 
+/+ 5.942 ± 0.064 6.042 ± 0.068 5.803 ± 0.144 6.061 ± 0.053 5.962 ± 0.085 6.232 ± 0.047 6.481 ± 0.049 
KCNN3 +/C 5.145 ± 0.076 5.207 ± 0.042 5.092 ± 0.131 5.126 ± 0.049 4.637 ± 0.143 5.011 ± 0.141 4.020 ± 0.074 
+/+ 4.400 ± 0.066 4.419 ± 0.036 4.454 ± 0.114 4.459 ± 0.043 4.111 ± 0.123 4.523 ± 0.122 3.956 ± 0.064 
CAST +/C 5.419 ± 0.028 5.454 ± 0.061 5.388 ± 0.065 5.481 ± 0.072 5.282 ± 0.099 5.486 ± 0.053 6.059 ± 0.059 
+/+ 5.076 ± 0.025 5.152 ± 0.053 5.171 ± 0.056 5.273 ± 0.062 5.158 ± 0.085 5.405 ± 0.046 6.025 ± 0.051 
COQ10A +/C 5.891 ± 0.117 5.886 ± 0.098 5.871 ± 0.220 5.699 ± 0.190 5.541 ± 0.134 5.823 ± 0.152 5.931 ± 0.166 
+/+ 5.723 ± 0.102 5.752 ± 0.085 5.539 ± 0.191 5.766 ± 0.164 5.406 ± 0.116 5.713 ± 0.131 5.823 ± 0.144 
IDH2 +/C 5.276 ± 0.050 5.392 ± 0.058 5.359 ± 0.134 5.763 ± 0.055 5.681 ± 0.103 5.878 ± 0.035 6.170 ± 0.080 
+/+ 5.483 ± 0.043 5.546 ± 0.050 5.319 ± 0.116 5.710 ± 0.048 5.677 ± 0.189 5.823 ± 0.030 6.095 ± 0.069 
FCGRT +/C 5.192 ± 0.080 5.255 ± 0.088 5.461 ± 0.166 5.704 ± 0.032 5.415 ± 0.086 5.754 ± 0.095 5.461 ± 0.122 
+/+ 5.243 ± 0.070 5.284 ± 0.076 5.184 ± 0.144 5.487 ± 0.027 5.282 ± 0.074 5.599 ± 0.083 5.320 ± 0.106 
AKR1C4 +/C 4.586 ± 0.115 4.238 ± 0.127 4.662 ± 0.173 5.011 ± 0.146 4.922 ± 0.165 5.230 ± 0.083 3.852 ± 0.156 
+/+ 5.404 ± 0.099 5.313 ± 0.110 5.181 ± 0.150 5.457 ± 0.127 5.154 ± 0.143 5.421 ± 0.072 3.902 ± 0.135 
MEG8 +/C 3.849 ± 0.096 3.851 ± 0.157 3.760 ± 0.188 3.060 ± 0.150 2.798 ± 0.140 2.942 ± 0.212 2.626 ± 0.162 
+/+ 2.708 ± 0.083 2.622 ± 0.136 2.813 ± 0.162 2.382 ± 0.130 2.367 ± 0.121 2.562 ± 0.183 2.560 ± 0.140 
CABC1 +/C 6.198 ± 0.081 5.906 ± 0.041 7.466 ± 0.082 7.778 ± 0.024 5.691 ± 0.134 7.385 ± 0.051 
+/+ 6.297 ± 0.071 6.055 ± 0.035 7.433 ± 0.071 7.731 ± 0.021 5.596 ± 0.116 7.375 ± 0.044 
GTL2 +/C 7.039 ± 0.217 6.917 ± 0.189 7.241 ± 0.168 6.626 ± 0.138 5.721 ± 0.157 6.472 ± 0.157 6.080 ± 0.147 





Gene Genotype LD SM ST TB SS IS HT 
MYH7 +/C 6.703 ± 0.037 6.605 ± 0.046 6.516 ± 0.188 7.079 ± 0.054 7.280 ± 0.122 7.409 ± 0.101 7.435 ± 0.095 
+/+ 6.791 ± 0.032 6.765 ± 0.040 6.616 ± 0.163 7.089 ± 0.047 7.242 ± 0.105 7.372 ± 0.088 7.317 ± 0.082 
MYH2 +/C 6.086 ± 0.065 6.139 ± 0.082 6.335 ± 0.094 6.515 ± 0.104 6.574 ± 0.082 6.903 ± 0.125 3.573 ± 0.259 
+/+ 6.891 ± 0.056 6.776 ± 0.071 6.781 ± 0.081 6.766 ± 0.090 6.608 ± 0.071 6.767 ± 0.108 3.011 ± 0.224 
MYH4 +/C 4.153 ± 0.294 4.825 ± 0.238 5.869 ± 0.275 4.072 ± 0.132 2.856 ± 0.235 3.470 ± 0.291 1.749 ± 0.115 
+/+ 2.287 ± 0.255 2.867 ± 0.206 4.162 ± 0.238 2.641 ± 0.115 2.223 ± 0.203 2.546 ± 0.252 1.554 ± 0.099 
MYH1 +/C 7.661 ± 0.082 7.703 ± 0.059 7.657 ± 0.116 7.662 ± 0.080 7.225 ± 0.092 7.356 ± 0.302 4.411 ± 0.208 





Table A. 3 Analysis of Variance of Genotype Effects in qPCR Analysis 
Gene LD SM ST TB SS IS HT 
DLK1 0.0001 0.0012 0.0235 0.0125 0.5434 0.4831 0.5571 
DNTTIP 0.0028 0.0029 0.0006 0.0169 0.1566 0.0982 0.1847 
PARK7 0.0118 0.0005 0.0045 0.0035 0.2206 0.2897 0.3602 
METTL21E 0.0016 0.0012 0.0011 0.0012 0.4466 0.0932 0.6473 
MEG8 0.0003 0.0020 0.0124 0.0189 0.0678 0.2325 0.7686 
SLC22A3 0.0018 0.0036 0.0434 0.0226 0.1639 0.0994 0.7540 
PDE4D 0.0074 0.0211 0.0019 0.0048 0.0982 0.2560 0.8451 
APOD 0.0178 0.0036 0.0506 0.0328 0.4498 0.1834 0.4861 
PFKM 0.0019 0.0008 0.0010 0.0701 0.0818 0.4799 0.4684 
AKR1C4 0.0030 0.0014 0.0731 0.0697 0.3350 0.1425 0.8169 
CAST 0.0003 0.0137 0.0519 0.0805 0.3872 0.3024 0.6741 
MEG3 0.0041 0.0020 0.0034 0.0126 0.0323 0.1546 0.7535 
RTL1 0.0000 0.0000 0.0000 0.0000 0.0016 0.0004 0.0009 
KCNN3 0.0007 0.0000 0.0144 0.0002 0.0385 0.0480 0.5429 
RSPRY1 0.0024 0.0135 0.0167 0.0013 0.0770 0.0302 0.4678 
MAPK6 0.0123 0.0330 0.1158 0.0095 0.3987 0.3080 0.3781 
IDH2 0.0255 0.1006 0.8324 0.4994 0.9745 0.2903 0.5130 
LPL 0.0283 0.0024 0.9841 0.4894 0.2742 0.5850 0.4634 
PDE7A 0.0485 0.1745 0.0355 0.1584 0.7970 0.9658 0.8107 
HDAC9 0.1051 0.0068 0.3997 0.5484 0.6852 0.9960 0.9624 
TXNIP 0.2998 0.5872 0.2247 0.0186 0.3938 0.2387 0.3156 
COQ10A 0.3275 0.3465 0.3057 0.8007 0.4794 0.6064 0.6433 
CDO1 0.3359 0.2290 0.7413 0.9613 0.7566 0.8806 0.2066 
DEC2 0.3383 0.1143 0.6624 0.4019 0.8514 0.7466 0.8565 
FCGRT 0.6453 0.8115 0.2612 0.0035 0.2923 0.2756 0.4206 
CABC1 0.4002 0.0401 0.7727 0.1930 0.6174 0.9025 
MYH7 0.1355 0.0450 0.7061 0.8885 0.8260 0.7920 0.3918 
MYH2 0.0002 0.0021 0.0158 0.1293 0.7686 0.4483 0.1617 
MYH4 0.0049 0.0016 0.0054 0.0004 0.0971 0.0615 0.2534 
MYH1 0.0505 0.0263 0.5915 0.0538 0.2841 0.5889 0.0254 
RPLP0(RP) 0.8046 0.3995 0.3222 0.1635 0.1548 0.2511 0.7559 








Gene % (µg) 
Null Plasmids 
(GW-CAT) % (µg) 
MYH4 or MYH7 
Plasmids % (µg) 
Transfection 
Control 
PARK7 0% (0 µg) 60% (1.8 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
PARK7 30% (0.9 µg) 30% (0.9 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
PARK7 60% (1.8 µg) 0% (0 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
METTL21E 0% (0 µg) 60% (1.8 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
METTL21E 30% (0.9 µg) 30% (0.9 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
METTL21E 60% (1.8 µg) 0% (0 µg) 30% (0.9 µg) pRL-TK, 10 %, 
(0.3 µg) 
DLK1 0% (0 µg) 48% (1.44 µg) 50% (1.5 µg) pRL-SV40, 2 %, 
(0.06 µg) 
DLK1 24% (0.72 µg) 24% (0.72 µg) 50% (1.5 µg) pRL-SV40, 2 %, 
(0.06 µg) 
DLK1 48% (1.44 µg) 0% (0 µg) 50% (1.5 µg) pRL-SV40, 2 %, 
(0.06 µg) 
DNTTIP1 0% (0 µg) 48% (1.44 µg) 50% (1.5 µg) pRL-SV40, 2 %, 
(0.06 µg) 
DNTTIP1 12% (0.36 µg) 36% (1.08 µg) 50% (1.5 µg) pRL-SV40, 2 %, 
(0.06 µg) 









































































































































ct (A to C) o
anti-GW-CA









Appendix B Park7 (-/-) Mice Phenotypic Analysis 
 
 
Figure B. 1 Analysis on Live Body Weight by Age in Park7 (+/+), (+/-) and (-/-) Mice. 
Twenty females with 4 Park7 (+/+), 12 (+/-) and 4 (-/-) animals and twenty-five males 
with 4 Park7 (+/+), 11 (+/-) and 10 (-/-) were examined to analyze the live animal growth. 
Animals live body weights were collected from 3 weeks to 6 weeks old. Live body 
weights were regressed on age. Equations were given for each genotype. There were no 
genotype effect on the slopes and intercepts of any regression lines in both male and 
female. 
  
(+/+) y = 2.97x + 0.15
(+/-) y = 2.88x + 0.82





























(-/-) y = 4.18x - 2.96
(+/-) y = 4.06x - 2.13


































Table B. 1 Analysis on Carcass Weights and Internal Organs Weights in Park7 (+/+), (+/-) 
and (-/-) Mice 
 



















+/+  y=0.6396lw-4.2095 
+/-  y=0.0191lw+7.0533 +/-  y=0.6389lw-4.7451 








+/+  y=0.0025lw+0.0504 
+/-  y=0.0017lw+0.0722 +/-   y=0.005lw+0.00550 








+/+  y=0.0737lw-0.4577 
+/-  y=-0.0094lw+1.0736 +/-   y=0.0744lw-0.5963 










+/+   y=0.0144lw-0.0370 
+/-  y=0.0176lw-0.1177 +/-    y=0.0159lw-0.0749 





Table B. 2 Quantitative PCR Primers. 
Gene 
name Forward primer (5’-3’) Reverse primer (5’-3’) 
Myh7 AGTCCCAGGTCAACAAGCTG TTCCACCTAAAGGGCTGTTG 
Myh3 CGCAGAATCGCAAGTCAATA ATATCTTCTGCCCTGCACCA 
Myh8 AGTCCCAGGTCAACAAGCTG CCTCCTGTGCTTTCCTTCAG 
Myh4 AGTCCCAGGTCAACAAGCTG TTTCTCCTGTCACCTCTCAACA 
Pten CCTTTTGAAGACCATAACCCACC GAATTGCTGCAACATGATTGTCA 
Rplp38 






Appendix C Lab Protocols 




 Collagen-Coated Plates 
Product: Collage (rat tail), 10 mg/ bottle, 3 bottles/box. Cat#: 11179179001  
1. Mix collagen in the bottle from the manufacturer with the filtered 0.2 % acetic 
acid. 1 bottle of collagen (10 mg) is good for 100 mL 0.2 % acetic acid. 
2. Add 4-5 mL collagen to a 10cm plate and let it sit for 1 hour to 2 hour in 
incubator. 
3. Aspirate off liquid or collect the collagen to reuse and allow drying in laminar 
flow hood for 8 hours (overnight) (or O/N). Plates can be stored indefinitely at 
4 . 
 Collagenase / Dispase Solution 
Product: Collagenas / Dispase Mix (Roche) 500 mg. Cat#: 11097113001 
1. Add 10 mL H2O (cell culture) to make a final concentration of 50 mg/mL, filter 
and divide into 10 tubes. 
2. For each tube, add 9 mL DPBS to make the working concentration of 5 mg/mL. 
 Ham’s Complete Medium 
1. Growth Medium 
Ham’s F-10 medium (500 mL / bottle) with 20 % FBS, 1X PSG and 4 ng/mL 
bFGF 
2. Differentiation Medium  
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DMEM (500mL / bottle) with 5 % Horse Serum and 1X PSG. 
 Procedure  
1. Limb muscle collection. Before removing the skin and fascia, liberally spray the 
entire mouse with 70 % ethanol. 
2. Peel the skin and fascia from abdomen to the leg to expose the underlying 
muscles. Dissect both hind limbs and place in a sterile 60 mm plate with DPBS. 
(Remove all the fat from muscle). 
 
The following work should be done in the hood. 
3. Transfer all the muscles to a clean 60 mm plate and wash with DPBS twice. 
4. Transfer all the muscles to an empty 60 mm plate and suck off DPBS left on the 
muscles. 
5. Mulch the tissue into smooth pulp using scissors.  
6. Add 5 mL Collagenase / Dispase solution and mix well. 
7. Incubate at 37 oC for 15min, then pipet up and down to homogenize the pulp and 
incubate for another 15 min and mix well to get smooth pulp. 
8. Add 5 mL Ham’s complete medium to stop the digestion and transfer all the pulp 
into a 15 mL sterile tube. 
9. Wash the plate with 5 mL DPBS and transfer the DPBS into the same tube. 
10.  Briefly spin down the tube (150 g*30s) and filter the supernatant through 100 
µM filter (Partec Cell Trics cat.log: 04-004-2328) into another 15 mL tube. Add 
10 mL Ham’s complete medium to the debris, mix and put them into a non-coated 
plate labeled as “Debris”. 
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11. Spin down the filtered supernatant at 450 g*5 min, aspirate the supernatant, add 
10 mL Ham’s complete medium, mix the pellet and transfer all the medium into 
a 10 cm coated plate labeled as “Pellets”. 
12. Add 5 ml Ham’s complete medium every day. 
In 3 days 
13. Collect both the debris and pellet into different tubes and spin down all the tubes 
at 450 g * 5min. 
14. Aspirate off the supernatants and wash with 5 mL DPBS. Spin down at 450 g * 
5min again and aspirate the supernatant. 
15. Dilute trypsin with DPBS (1:7) and add 5 mL diluted trypsin into each tube. 
16. Incubate all the tubes in the 37  water bath for 10 mins. (Gently mix the tube 
every 2 mins). 
17. Add 5 mL Ham’s complete medium to stop digestion. Pipet up and down for 
several times to make sure the cells is mixed well. 
18. Filter the cell mix through 100 uM filters into a new 15 mL tube. Spin down at 
450 g * 5min, aspirate off the supernatants, put 10 mL Ham’s medium and put 
them into 10 cm non-coated plate. (Fibroblasts will adhere to the plate and 
myoblasts will remain in suspension). 
19. After 45 min to 1 hour, transfer the medium into the coated plates. Pre-plate 
procedure is critical to get rid of the fibroblast. And this procedure should be 
repeated 3-4 times until the myoblasts are relatively clean. Extension of the pre-









1. Make the desired amount of growth medium without antibiotics.  
For MyhIIB and MyhI luciferase assay, 400 µL (4 replicates) of the growth 
medium for each treatment is aliquoted into 1.5mL tubes. 
2. Thaw the plasmids that are needed to be transfected. 
3. Calculate the number of cells, amount of plasmids and resuspension buffer as 
needed. Usually, 2-3 µg plasmids is enough for 2 × 105 cells in one 10 µL tip and 
keep in mind that the volume of plasmids should not exceed 10 % of the total 
volume.  
For MyhIIB and MyhI luciferase assay, 3 µg of plasmids complex is transfected 
into 2 × 105 cells and the transfected cells are plated into 4 wells of 96-well plate 
(4 replates).  
 Plasmids Composition (For MyhIIB and MyhI luciferase assay) 
Make sure that the concentration of each plasmid is around 2 µg / µL, so that the 
volume of 3 µg of total plasmids does not exceed 10 % of the entire transfection 
system (10 µL).  
The plasmid compositions are indicated in Table A3.5  
 Cell Preparation and Transfection Procedures 
1. Resuspend cells with DPBS and count the cells. 
2. Put desired number of cells into 1.5 mL tubes and spin down at 450 g * 5 min. 
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3. Resuspend the cells in resuspension buffer R and put the plasmids complex into 
the cells. 
For MyhIIB and MyhI luciferase assay, ~12 µL resuspension buffer R is added to 
2 × 105 suspended cells in each tube and the calculated amount of plasmids 
complex are then added into the cell system.  
4. Take the cells, growth medium tubes, transfection tips, Neon Tube and 
Electrolytic Buffer to Dr.Kuang’s lab. 
For MyhIIB and MyhI luciferase assay, the prepared 400 µL medium (without 
antibiotics) tubes will be needed to take along. 
5. Turn on the Neon device and fill the Neon Tube with 3 mL Electrolytic Buffer. 
6. Insert the Neon Tube into the Neon Pipette Station until you hear a click sound. 
7. Press the push-button on the Neon Pipette to the first stop and immerse the Neon 
Tip into the cell-DNA mixture. Slowly release the push-button on the pipette to 
aspirate the cell-DNA mixture into the Neon Tip.  
8. Insert the Neon Pipette with the sample vertically into the Neon Tube placed in 
the Neon Pipette Station until you hear a click sound. 
9. Select the appropriate electroporation protocol and press “Start” on the 
touchscreen. 
The transfection condition for primary myoblast is at 1500 V, 10 ms and 3 pulses. 
For C2C12 cells is at 1650 V, 10 ms and 3 pulse. 
10. The touchscreen displays “Complete” to indicate that electroporation is complete. 
The tips can be reused for a couple of times if the cell-DNA mixture is the same. 
Put the transfected cells in the medium without antibiotics.  
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For MyhIIB and MyhI luciferase assay, put the transfected cells into the prepared 
400 µL medium. 
11. After finishing all the transfecitons, take off the tip, turn off the Neon device and 
clean the hood. Take everything back to the lab and spread the cells into 
appropriate plates. 
For MyhIIB and MyhI luciferase assay, spread the transfected cells into 96-well 
plates with each well 100 µL cell-medium. Usually, 4 or 8 replicates (wells) for 









Luciferase buffer are made by mixing 1 vial of Dual-Glo luciferase buffer to 1 vial of 
luciferase substrate (lyophilized). This reagent usually made when we get the product 
and aliquot the mixing buffer into small tubes.  
Stop & Glo reagent should be made just before use. Stop & Glo Substrate: Stop & 
Glo buffer = 1:100. 
 Procedure 
1. Calculate the luciferase buffer with substrate and Stop & Glow reagent needed in 
the experiments (50 µL for each reagent in each well).  
Equal amount of DPBS is used to mix the luciferase buffer, therefore the volume 
of the mixed luciferase buffer added to each well is 100 µL (50 µL luciferase 
buffer : 50 µL DPBS). Turn on the Tecan plate reader and computer in Lilly 3-
204 at least 20 mins in advance.  
2. Thaw the luciferase buffer with substrate and Stop & Glo buffer (Put back the 
left reagent into freezer). 
3. Take the 96-well plate out of incubator and wash 1*PBS.  
4. Put 100 µL mixed luciferase buffer into each well. 
5. Gently shake for 2 mins and during this time, prepare the Stop & Glow buffer by 
adding 1/50 amount of substrate to the calculated desired amount of Stop & 
Glow buffer.  
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6. Take the plate along with gloves, repeater and repeater tips to Lilly 3-204 to 
measure luminescence in Tecan plate reader. (Software: Magellan; Program 
name: Hui luciferase with 100ms measurement and 15ms shake time).  
7. After measuring the firefly luciferase luminescence, add 50 uL Stop & Glow 
Reagent into each well and measure the renilla luminescence (Program name: 
Hui renilla with 100ms measurement, 15ms shake time and 600ms settlement 
time). 
8. Copy the data into excel file and save it in the flash drive. 









Base solution: A 50 X stock is prepared at 1.25 M NaOH, 10 mM EDTA, which 
should be around pH=12. The concentration of 1 X working stock should be 25 mM 
NaOH, 0.2 mM EDTA. 
Neutralization solution: A 50 X stock is prepared at 2 M Tris-HCl, pH=5.0.The 
concentration of 1 X working stock should be 40 mM Tris-HCl pH=5.0. 
 Procedure: 
1. After weaning the mouse, put a small piece of ear into 1.5 mL tube. 
2. Add 75 µL of base solution (1 X working stock) to each sample. 
3. Place tubes at 95  in the heating block (In Dr.Lossie’s lab, the heating block 
should be powered on 30 mins in advance) for 30 mins. 
4. Cool the tubes to room temperature. 
5. Add 75 µL neutralization solution (1 X working stock) and vortex. 









 Master Mix for Park7  
5 X Green Flexi Buffer (Promega): 3 µL  
MgCl2: 2 µL;  
DMSO: 1 µL 
F Primer (20 pmol / µL): 0.6 µL; 
R Primer (20 pmol / µL): 0.6 µL 
R Primer (20 pmol / µL): 0.6 µL 
dNTPs (25 mM): 0.4 µL  
Go Taq (Promega): 0.08 µL 
H2O: 5.62 µL;  
DNA: 1 µL 









1. The amount of protein that can be absorbed by the plate needed to be titrated. 
Both the primary and secondary antibody need to be titrated.  
2.  Put the equal amount and volume of protein into 96-well Maxisorb plate.  
In the present study, 100 µL of protein (20 µg/100 µL) are added into each well. 
3. Incubate at 4  with rotation for 5 hours. 
4. Add 200 µL blocking buffer (3 % BSA) into each well and incubate at 4  
overnight.  
5. Wash briefly and add 150 µL primary antibody diluted in 0.1 % BSA in each well. 
Incubate the plate at room temperature for 2 hours.  
6. Wash with PBS / Tween for 3 times and add 150 µL secondary HRP diluted in 
0.1 % BSA into each well. Incubate at room temperature for 45 mins. 
7. Wash with PBS / Tween 3 times and wash with PBS 3 times. 
8. Make OPD tablets. Put 1 gold tablet and 1 silver tablet into 20 mL H2O.  
9. Put 200 µL OPD solutions into each well, wait for 30-45 mins and read it in 











4 % formaldehyde in PBS; 0.5 % Triton 100 (Dilute 10 % Triton with H2O); 1 % BSA 
solution (Dilute 3 % BSA with PBS); and 0.1 % BSA solution (Dilute 1 % BSA with 
PBS) 
 Procedure: 
The concentrations of primary and secondary antibody are needed to be titrated. In the 
present study, 1/500 for MF20 and 1/500 for Donkey anti-Mouse 594 are used. 
1. Aspirate growth medium from 96-well plate and gently wash with DPBS twice. 
2. Put 100 µL of 4 % formaldehyde and incubate for 5 mins. 
3. Wash 3 times with DPBS, put 0.5 % Triton100 and incubate for 5 min. 
4. Wash 3 times with DPBS, add 150 µL blocking buffer (1 % BSA) and incubate 
for 5 hours. 
5. Wash briefly with DPBS and add 100 µL primary antibody diluted in 0.1 % BSA 
and incubate at 4  overnight with rotation.  
6. Wash 5 times with DPBS and add secondary antibody diluted in 0.1 % BSA and 
incubate at RT for 45 mins. 
7.  Wash 5 times with DPBS and take the plate to LiLLY 3-204 (Tecan plate reader) 
to measure the fluorescence.   
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 Preparation  
RIPA buffer (Working Solution) 
50 mM Tris HCl; 150 mM NaCl; 2 mM EDTA; 1 % Triton X 100; 0.5 % 
Deoxycholate; 0.1 % SDS; 50 mM NaF, 1X Protease inhibitor and 1X Phosphatase 
inhibitor. 
 Procedure 
1. Remove culture medium and rinse the cells with ice-cold DPBS twice. 
2. Add the RIPA buffer to the plate and incubate the plate on ice for 10 mins with 
rotation. 
3. Scrape cells from the plate and collect cell lysate into 1.5mL tubes. 
4. Votex tubes and rotate the protein tubes in cold-box for 45 mins to 1 hour. 
5. Centrifuge tubes at 12000 X g for 15 mins at 4 ℃.  
6. Transfer supernatant to a new tube for further analysis. 
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